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Malaria is caused by members of the apicomplexan parasite genus Plasmodium. Of 
the four species that infect humans, P. falciparum is associated with the most 
severe forms of the disease. P. falciparum has a complicated life cycle involving two 
hosts. The disease in humans is associated with the red blood cell (RBC) cycle. 
Merozoites invade a RBC, replicate asexually within it, and cause the RBC to 
rupture releasing daughter merozoites into the blood stream to repeat the cycle. 
Invasion relies on an actinomyosin motor within the parasite and is also associated 
with the proteolytic shedding of a number of merozoite surface proteins, including 
the essential proteins AMA1 and MSP1. Both are shed by a merozoite surface 
'sheddase' called MESH. The leading candidate for MESH is PfSUB2, an essential 
membrane-bound subtilisin-like protease (subtilase). In this project I have used 
transfection of the parasite to explore the role of PfSUB2 within the asexual blood 
stage life cycle of P. falciparum. PfSUB2 has been epitope tagged by targeted 
homologous recombination, and shown to initially accumulate in apical organelles 
called micronemes. Following merozoite release PfSUB2 is capped to the rear of the 
parasite in an actin-dependent manner and following invasion is detected distributed 
around the plasma membrane of the intracellular parasite. This pattern of trafficking 
is similar to that predicted for MESH. The tagged PfSUB2 has been purified from 
parasite extracts and the activity assessed. I have also attempted to over-express 
PfSUB2 from an episome within the parasite. As part of this work I have begun to 
characterise the pfsub2 promoter. A region at the 5' region of the gene has been 
shown to display promoter activity.
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1. Introduction
1.1 Malaria
The phylum Apicomplexa comprises a wide array of obligate intracellular 
parasites including Toxoplasma gondii, the causative agent of toxoplasmosis, and 
Plasmodium the causative agent of malaria. P. falciparum is one of four species of 
Plasmodium which infect humans and is the species primarily associated with 
mortality. Malaria is found in tropical and sub-tropical areas of the world and causes 
an estimated 300-500 million cases and 2.3 million deaths per year although recent 
work by Snow et al. suggests that the number of cases is vastly underestimated, 
particularly in areas outside Africa [1, 2]. Unsurprisingly, the burden placed on 
countries with endemic malaria is reflected economically; the increase in gross 
domestic product (GDP) between 1965-1990 for countries with severe malaria was 
0.4% compared with 2.3% average growth in other countries [3],
The disease seen in vertebrates infected with Plasmodium is associated with 
replication of the asexual erythrocytic stage (see below). In infection with P. 
falciparum the clinical outcome varies from an asymptomatic infection to the more 
severe forms of the disease, such as severe anaemia and cerebral malaria, often 
resulting in death. There are drugs, such as the first-line antimalarial chloroquine, 
that can be used to treat malaria infections. However the emergence of drug 
resistant forms of the parasite means that the first-line drugs are no longer very 
effective and alternatives are required. The drugs required to treat chloroquine- 
resistant P. falciparum malaria are over ten times more expensive than chloroquine 
and cannot be afforded by many of the countries most affected [4], There is a 
pressing need for new antimalarials and the identification of novel chemotherapeutic 
targets. Indeed Breman argues that without effective intervention the number of 
cases in children under 5 in endemic areas could double by 2020 [5],
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1.2 Life cycle
The P. falciparum life cycle, illustrated in Figure 1.1, requires two hosts; an 
Anopheles mosquito for the sexual reproductive stages and a human host for the 
asexual reproductive stages. In brief, a mosquito takes up male and female 
gametocytes in a blood meal which undergo fertilization in the insect midgut to form 
ookinetes. These cells penetrate the midgut wall and form oocysts. The parasite 
undergoes replication within the oocyst which then ruptures releasing sporozoites. 
Sporozoites exhibit gliding motility and migrate through tissues to the salivary glands 
from where they enter the vertebrate host at the mosquito’s next blood meal. The 
sporozoites invade hepatocytes, undergo schizogony and differentiate into 
merozoites. The merozoites are released into the blood stream and invade red 
blood cells (RBCs). Within the RBC the parasite progresses through a number of 
morphologically distinct stages called ring, trophozoite and schizont. The RBC then 
ruptures and releases daughter merozoites which initiate another cycle of replication 
by invading new RBCs. The length of time from merozoite invasion to release varies 
amongst Plasmodium species, and in P. falciparum is 48 hours. P. falciparum 
merozoites must attach and invade erythrocytes efficiently as the invasive half-life is 
very short [6 ]. During the erythrocytic replication cycle gametocytes are also formed 
which the mosquito takes up during a blood meal and the cycle continues.
1.3 The merozoite
The merozoite, as seen in Figure 1.2, is an ovoid cell which varies in size 
between Plasmodium sp. and in P. falciparum is approximately 1.6 pm long and 1.0 
pm wide [7]. The surface of the parasite is covered in a coat of bristle-like filaments 
[8], The parasite cell wall consists of a three-layered pellicle with a plasma 
membrane and two inner membranes known as the inner membrane complex 
(IMC). The apical prominence of the cell contains the rhoptries, twin pear shaped 
organelles, and the smaller micronemes, clustered around the rhoptry ducts. The
15
Figure 1.1 The P. falciparum lifecycle
Schematic representation of the P. falciparum lifecycle. In brief, male and female 
gametocytes undergo fertilization in the insect midgut to form ookinetes (1). These 
penetrate the midgut wall and form oocysts. The parasite undergoes replication 
within the oocyst which then ruptures releasing sporozoites (2). These migrate to the 
salivary glands and enter the vertebrate host at the mosquito’s next blood meal. 
Sporozoites invade hepatocytes, undergo schizogony and differentiate into 
merozoites which are released into the blood stream (3). Within the RBC the 
parasites undergo schizogony and form daughter merozoites (4). The RBC ruptures 
and merozoites are released which initiate another cycle of replication. Gametocytes 
are also formed during this cycle which the mosquito takes up in a blood meal.
This figure is taken from ‘Malaria’, Edited by A.J Knell for The Wellcome Trust, 
Oxford University Press (1991).
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Figure 1.2 Anatomy of the P. falciparum merozoite
This figure is taken from Bannister et al, (2000) ‘A Brief Illustrated Guide to the 
Ultrastructure of P. falciparum Asexual Blood Stages’.
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dense granules lie separately within the apical cytoplasm of the merozoite.
1.4 Invasion of the RBC
Merozoite invasion of the erythrocyte is a very rapid process undergoing 
completion within a few seconds [9], Despite this limitation the steps comprising the 
process of invasion have been well defined at the microscopic level and these are 
outlined in Figure 1.3.
Invasion is initiated by the merozoite attaching in any orientation to the 
erythrocyte surface. This initial binding appears to be low affinity and reversible. The 
parasite then re-orientates itself so the apical end of the merozoite is in contact with 
the host cell, and an electron-dense tight junction is formed between the merozoite 
and the host cell surface. The erythrocyte surface then invaginates and the tight 
junction moves along the merozoite surface as the parasite is propelled forward into 
the RBC. As the tight junction moves along the parasite surface the protein coat of 
the parasite is shed [8], Once inside the erythrocyte the membrane fuses at the 
parasite’s posterior end forming the parasitophorous vacuole (PV), which surrounds 
the newly invaded merozoite.
During this invasion process the contents of the secretory organelles are 
released sequentially. Firstly the micronemes secrete their contents as the parasites 
attach to the host cell and this is followed by rhoptry release as the parasite invades 
[10]. The dense granules only appear to release their contents once invasion has 
gone to completion [10 , 11],
1.5 Invasion is driven by a parasite actinomyosin motor
Erythrocyte invasion by Plasmodium merozoites is blocked in the presence 
of cytochalasin, an inhibitor of actin polymerisation and butane-2 ,3-dione monoxime
20
Figure 1.3 The erythrocytic cycle of P. falciparum
The P. falciparum merozoite (a) attaches in any orientation and then (b) re­
orientates so its apical end is in contact with the RBC surface, (c); the tight 
junction is formed and the contents of the secretory organelles released, (d); 
the tight junction sweeps over the parasite surface as it enters the RBC. (e); 
merozoite surface proteins are shed and the parasite enters the cell enclosed 
in the PV.
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(BDM), an inhibitor of the myosin ATPase [12, 13]. These compounds have also 
been shown to inhibit the invasion of host cells by T. gondii tachyzoites and other 
apicomplexa such as Eimeria tenella [14-16], These results implicate an 
actinomyosin motor as being involved in the invasion of host cells by apicomplexa 
[17].
P. falciparum possesses two actin genes coding for P. falciparum actin 1 (Pf- 
ACT1) and PfACT2 [18]. PfACT2 expression appears limited to the sexual stages of 
the P. falciparum lifecycle while PfACTI is expressed throughout indicating that this 
is the actin involved in erythrocyte invasion [19]. Although Plasmodium does contain 
filamentous actin it has proven difficult to visualise [20], This is also true of T. gondii 
where the actin is predominantly in a globular state and filaments are detected only 
upon treatment with jasplakinolide (JAS), a stabiliser of actin polymerisation [21, 22], 
In vitro recombinant PfACTI appears only capable of forming short filaments [23],
There are at least three P. falciparum myosins PfMyo-A, B and C [17]. 
PfMyo-A is expressed during late schizogony, merozoite release and invasion 
implicating a role for the protein during this process [13]. PfMyo-A shows a high 
degree of similarity with TgMyo-A which has shown to be essential for both 
tachyzoite gliding motility and host cell invasion [13, 24], The components of an 
actinomyosin motor have been localised to the IMC in both Plasmodium and T. 
gondii [13, 15,22, 25],
1.6 The actinomyosin motor interacts with parasite proteins
Both T. gondii and Plasmodium express proteins that interact with the 
actinomyosin motor present within the parasite. The Thrombospondin-Related 
Anonymous Protein (TRAP) family are integral membrane proteins containing a 
number of adhesive domains that are found throughout apicomplexa [26], Members 
of this protein family have been shown to be crucial for the invasion process [27-30], 
The first member to be described was TRAP, found on the surface of P. falciparum
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sporozoites, but also detected during the erythrocytic stage indicating a general role 
in invasion [31]. Other examples of this protein family include the paralog PfCTRP, 
expressed in the ookinete stage and MIC2 expressed in T. gondii tachyzoites [30, 
32]. TRAP and MIC2 have been shown to interact with glycosaminoglycans (GAGs) 
present on cell surfaces indicating that their role may be in adhesion to the host cell 
[33, 34],
TRAP and MIC2 initially accumulate in the micronemes of the parasites 
before release onto the cell surface and subsequent capping to the posterior of the 
cell [28, 32 , 34-36]. The cytoplasmic domain of TRAP family members contain a 
number of conserved residues, including a number of acidic residues and a 
tryptophan, and the function of this region appears conserved amongst apicomplexa 
[28, 37], These conserved residues present in the cytoplasmic tail are responsible 
for an interaction with aldolase, an enzyme known to bind F-actin and shown to 
interact with parasite actin [38-40], This interaction means that TRAP and MIC2 are 
bound to the actinomyosin motor via aldolase and it is presumably this interaction 
that is responsible for the capping of the proteins during invasion.
As invasion proceeds MIC2 and TRAP are shed from the parasite surface 
[28, 32, 36]. The shedding of MIC2 constitutes a C-terminal cleavage by the action 
of a serine protease named microneme protein protease 1 (MPP1) and is essential 
for the parasite to detach from the host cell surface and invade [41, 42]. The 
mechanism of shedding of these proteins is likely to be conserved as TRAP 
expressed in T. gondii also undergoes C-terminal cleavage [43],
The capping and interaction with the actinomyosin motor of parasite proteins 
has led to a ‘capping’ model being proposed for cell invasion in T. gondii, and other 
related Apicomplexa [44, 45]. Transmembrane proteins, such as MIC2 and TRAP, 
move from the anterior to the posterior end of the parasite where they are shed. The 
transmembrane proteins adhere to the host cell on their ectoplasmic side, and are 
linked to the sub-membranous actinomyosin complex, so the rearward movement of
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these proteins drives entry into the host cell. Final parasite release from the host cell 
surface and entry into the cell is coupled with eventual proteolytic removal of the 
adhesins. This proteolysis is likely to be essential for invasion to go to completion 
[41].
1.7 Protein shedding from the merozoite surface
The invasion of erythrocytes by the Plasmodium merozoite is also 
associated with surface adhesions that undergo shedding from the parasite 
membrane. Erythrocyte binding protein-175 (EBA-175) is a member of the ebl family 
of proteins that binds to glycophorin A, the dominant glycoprotein on the surface of 
the RBC [46-48], The cytoplasmic tail of EBA-175 is essential for function of the 
protein but can be replaced with the TRAP tail despite no obvious homology 
between the two domains [49]. Parasites without EBA-175 are able to invade 
erythrocytes efficiently, albeit with a different ligand pathway [47],
Apical Membrane Antigen 1 (AMA1) is an integral membrane protein 
expressed late in the erythrocytic cycle of all the species of Plasmodium so far 
studied [19]. The protein is also expressed and shown to have a role during 
sporozoite invasion of hepatocytes [50], The pfamal gene cannot be knocked out in 
the blood stages indicating that AMA1 is essential to the parasite [51]. Erythrocyte 
invasion and hepatocytes invasion can be blocked by anti-AMA1 antibodies and this 
has led to the development of AMA1 vaccines with varying degrees of success [50, 
52-54]. There is a homologue, TgAMAI, present in T. gondii tachyzoites that also 
appears essential to the parasite [55],
In late schizogony PfAMAI initially accumulates as an 83 kDa molecule in 
the micronemes where it undergoes N-terminal processing to form a 66  kDa protein 
[56-59], This form relocates over the surface of the parasite upon merozoite release 
and is then shed [57]. The shedding of AMA1 is caused by a serine protease and 
may be essential for invasion [57, 60],
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The structure of AMA1 is comprised of three domains characterised by the 
disulphide bonding pattern [61]. The recently solved crystal structure revealed that 
domains I and II resemble PAN domains, found in proteins with diverse adhesion 
functions and believed to be involved in binding interactions [62, 63], AMA1 has 
been shown to bind to erythrocytes and may be involved in the re-orientation of the 
parasite on the host cell surface [64-66], A conditional knock out of TgAMAI has 
been achieved and the parasites are able to glide and initially attach to the host cell 
but are inhibited in their ability to intimately attach to host cells, release rhoptry 
contents and invade [67],
Merozoite Surface Protein 1 (MSP1) is another parasite surface protein 
believed to play a role in parasite adhesion to the RBC, in this case via erythrocyte 
proteins such as band 3 erythrocyte protein and spectrin [68, 69], MSP1 is thought 
to be essential as attempts to knock out the pfmspl gene have been unsuccessful 
[70], The ability to block Plasmodium infection with anti-MSP1 antibodies has led to 
interest in the protein as a vaccine candidate [71].
MSP1 is attached to the parasite membrane by its C-terminus via a glycosyl- 
phosphatidylinositol (GPI) anchor [72]. The protein is synthesised as a 200 kDa 
precursor protein that undergoes extensive processing to give fragments called 
MSP183, M SPI30, MSPI38 and M SPI42 which form a non-covalent complex on the 
merozoite surface [73], During invasion the MSPI42 fragment undergoes secondary 
processing, by the action of a serine protease, which releases the bulk of the protein 
but leaves a 19 kDa fragment (MSPI19) bound to the parasite surface which is then 
carried into the RBC [74, 75], If the secondary processing of MSP1 is blocked the 
parasites are unable to invade indicating that this cleavage is essential for invasion 
[6 , 75],
The sites at which AMA1 and MSP1 shedding occur have no sequence 
similarity and the MSP1 site lies many residues further away from the membrane 
than the AMA1 site [60, 76], However the two epidermal growth factor (EGF) domain
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structure of MSP1i9) conserved amongst Plasmodium, means that the cleavage site 
probably lies in close proximity to the GPI anchor and at a similar distance to the 
membrane from the AMA1 cleavage site [6, 70, 77, 78], Intriguingly Howell et al. 
demonstrated that the shedding of AMA1 was sensitive to the exact set of inhibitors, 
including specific compounds discovered from library screens, as MSP1 secondary 
processing [60], It is highly unlikely that the parasite possesses two enzymes with 
identical inhibition profiles but rather that MSP1 and AMA1 are shed from the 
merozoite surface by the action of a single serine protease [60].
1.8 Sheddases
Sheddases are a group of enzymes that cleave integral membrane proteins 
or GPI anchored proteins releasing the protein from the membrane [79], Proteins 
cleaved in this way include |3-Amyloid precursor (APP), the protein involved in 
Alzheimer’s disease, and transforming growth factor-a (TGF-a) [80], The 
conformation and steric availability of a sheddase cleavage site is thought to be 
more important than the specific sequence [80-83], A stalk of minimum length is also 
required [80], Although sheddases are often metalloproteases there is growing 
evidence for alternative classes of enzymes, such as serine proteases, cleaving in 
this way [79, 84],
Because of its apparent sequence independent substrate recognition, the 
enzyme responsible for the shedding of both AMA1 and MSP1 from the parasite 
surface is considered to be a sheddase and has been named MErozoite surface 
SHeddase (MESH). Since, as described above, AMA1 and MSP1 shedding may be 
essential for the parasite to invade [6, 57, 60, 75], MESH therefore represents an 
attractive drug target candidate. However, at present the identity of MESH is 
unknown.
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1.9 Serine proteases
Serine proteases are a large and diverse class of proteases that can be 
grouped into 6 clans [85], The two largest of these are the chymotrypsin-like and 
subtilisin-like clans. Wu et al. identified members of both chymotrypsin-like and 
subtilisin-like clans within the P. falciparum genome alongside a number of more 
unusual serine proteases [86], There appear to be only two chymotrypsin-like serine 
proteases both of which are homologues of DegP [86]. DegP protease (also known 
as HtrA) is a member of a family of serine proteases involved in cell fate and it is 
likely that the P. falciparum chymotrypsin-like proteases play a similar role within the 
parasite [87],
Plasmodium has eight putative rhomboids, a novel group of serine 
proteases, that cleave substrates at an intramembrane site [88-90], These enzymes 
require a glycine/alanine motif, believed to destabilise the helix arrangement, in the 
transmembrane domain of substrates to allow cleavage [91]. These enzymes have 
been more extensively studied in T. gondii which has 6 rhomboids (TgROM1-6), four 
of which are expressed in the tachyzoite stage [92, 93], MMP1, the enzyme 
responsible for the cleavage of MIC2, has recently been shown to be a rhomboid 
and this enzyme is likely to cleave other microneme proteins such as TgMIC6 and 
TgMIC12 [43, 91, 94]. Although TgROM2 has been shown to cleave the 
transmembrane domains of TgMIC2 and TgMIC12 in vitro, TgROM5 is considered 
to be MMP1 and has been localised to the posterior end of the cell [92, 93].
A number of transmembrane domains of Plasmodium proteins contain a 
rhomboid cleavage motif including members of the ebl family such as EBA-175 [95]. 
The rhomboid cleavage of MIC2 suggests that other members of this protein family, 
such as TRAP, may also undergo intramembrane cleavage from the parasite 
surface. A small proportion of PfAMAI undergoes inefficient rhomboid cleavage and 
in the presence of compounds that inhibit the action of MESH this proportion is 
increased [60, 96], This indicates that while AMA1 is not the physiological substrate
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the parasite expresses active rhomboids. However, TgAMAI is shed exclusively by 
the action of a rhomboid indicating differences in the shedding of membrane 
proteins between P. falciparum and T. gondii [96]. Rhomboids are not capable of 
cleaving GPI-anchored proteins, such as MSP1, indicating the need for proteases 
other than rhomboids to cleave Plasmodium surface proteins. As yet there is no 
evidence for a sheddase, such as MESH, in T. gondii and it may be that surface 
proteins in this parasite are removed solely by the action of intramembrane 
cleavage.
Subtilisins are characterised by an Asp/His/Ser catalytic triad surrounded by 
characteristic sequence motifs [97, 98]. The proteins are produced as inactive 
zymogens before autocatalytic cleavage to remove a propeptide and reveal an 
active protease [98-101], Subtilisin propeptides are involved in the folding of the 
protein, which is critical for the formation of an active protease, and can also act as 
specific potent inhibitors of their respective enzyme [102-108], There are 3 subtilisin- 
like serine protease genes found within the P. falciparum genome, called subtilisin- 
like serine protease 1 (PfSUBI), PfSUB2 and PfSUB3. The function of none of 
these proteases is known.
PfSUBI is expressed during the erythrocytic cycle with maximum expression 
at the schizont stage and is located in the dense granules of the parasite [19, 109], 
Attempts to knock out the sub1 gene in both P. berghei and P. falciparum have been 
unsuccessful suggesting an essential role for the protein within the parasite [110,
111]. PfSUBI can be expressed in a recombinant active form allowing study of the 
enzyme’s substrate specificity [112]. The site of MSP1 cleavage is a leucine- 
asparagine bond and it has been shown that PfSUBI cannot cleave this motif [76,
112]. PfSUBI therefore cannot be responsible for the secondary cleavage of MSP1 
and therefore cannot be MESH.
PfSUB3 is transcribed in gametocytes and sporozoites as well as during the 
erythrocytic cycle indicating a role throughout the lifecycle [19]. The pfsub3 gene
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has recently been knocked out in blood stage parasites and, while there was a slight 
growth defect in blood stage parasites, the shedding of MSP1 and AMA1 appeared 
normal indicating that PfSUB3 is not MESH [113].
1.10 PfSUB2
PfSUB2 is a large putative type I integral membrane protein expressed 
during the erythrocytic stage of the P. falciparum life cycle, specifically 40-48 hours 
post merozoite invasion and represented schematically in Figure 1.4 [19, 114]. 
Orthologues of PfSUB2 are found in all the species of Plasmodium so far studied 
and an alignment is shown in Figure 1.5 [115]. PfSUB2 is found as a very small 
proportion of the total protein content of the merozoite and is thought to be located 
in the dense granules at the apical end of the merozoite [114, 116].
The PfSUB2 primary sequence comprises a putative N-terminal secretory 
signal peptide, followed by a hydrophilic domain, a subtilase catalytic domain, 
transmembrane domain and finally a cytoplasmic domain [114]. The protein 
undergoes extensive post-translational processing. It is first expressed as a 160 kDa 
form which is rapidly converted to a 74 kDa intermediate form, before further 
processing to a 72 kDa form [114]. The localisation of PfSUB2 and time of 
expression suggest a role for the protein in erythrocyte invasion. The presence of a 
putative transmembrane domain may mean that the mature form(s) of PfSUB2 exist 
as a membrane-bound protease.
The protein appears to be essential as attempts to disrupt the sub2 gene in 
both P. falciparum and P. berghei have been unsuccessful [115, 117], PfSUB2 has 
also been detected in gametocytes and the orthologue PbSUB2 has been detected 
in the mosquito stages of the lifecycle, during ookinete invasion of the mosquito mid­
gut cell, further suggesting a general role in invasion [118, 119].
For a number of reasons, PfSUB2 is the best candidate for MESH, the 
sheddase responsible for the cleavage of MSP1 and AMA1 from the merozoite
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Figure 1.4 PfSUB2
Schematic representation of the putative domain structure of PfSUB2. The 
protein has a signal peptide, relatively large propeptide, catalytic domain, 
transmembrane domain and cytoplasmic domain. The predicted processing sites 
are indicated.
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Figure 1.5 Multiple alignment of predicted SUB2 sequences from P. 
falciparum, P. knowlesi, P. vivax, P. chabaudi, P. berghei and P. yoelii
The predicted catalytic triad residues are indicated in red (aspartate), blue (histidine) 
and pink (serine). The putative signal peptide and transmembrane domain are 
shaded. The region between the putative catalytic domain and transmembrane 
domain is well conserved and is indicated in yellow. : and . denote conserved or 
similar residues, * denotes identical residues. This alignment was produced by S. 
Yeoh using the ClustalX program.
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Signal peptide
Falciparum MLNIIYWSLILIKFIFyKECNNNNNYYLSNIELYNYKLRKR-NRILNNNINDRKSFLSDLEQNYKPLFDiyELSANFEKRRKELEKKTKGEENEIEKKKENDLEEKKENEIEKKKENDL 119
Knowlesi MLSLLYVLWLMLMNIFFQYDWHR--KKILSELGNYNVKLVKRKSRILSDSKTGRINFLDEIKESYRPLFDVYELSAKFEKLRNTKEKEEEKRGRQKQKQKKKKKKKKKNDHIEEEEQ  115
Vivax MLSSLYVLPLILVNILFQNDWHR--KKILSELGNYNVKLVKR-SRVLSNRTTGRINFLDEIKESYKPLFDVYELSAEFEKLRNAKGKGEEKRGRKK KKKKKKKKNDHIGGGD  109
Chabaudi MLRTFYVLSLILIEFILHKGQYN--KHILSTN-LKNYNFVDKDHRILVSDIEDSEKHIEDIKDAYKPIFNIYEISAEFHKKKYIANKKKKQKDGSE-----QSIEKKINSEGDERSQ  109
Berghei MLRTFYVLSLMLIEFILHNGQYN--KHICSKN-SKKYNFVGKKHRILVSDIEDRENHIEGIADIYKPIFNIYEISAEFHKKKNIADKKKKRKYGIN-----QSIEKRRIAEENERRQ 109
Yoelii MLRTFYVLSLMLIEFILHKGQYN--KHICSKN-LKKYNFVGKKHRILASIIEDREKQVEDITDGYKPIFNIYEISAAFHKKKDIADKKKRRRYGNQ-----QSIENRRIAEENERRL  109**   . * . . .  . *.* . * . ...
Falciparum EKEYNDVINLLELSLSSEYKELN--------ADVS------NNDNSGHEENNKHKLNKKNSSNYKNDK-------------------------- SLDELIKG--------------------- 181
Knowlesi -DKKTPSLNLIQLSSTQSDETEHIKKRISKPFPIALAHRRKPISIKKHAADSIHMLNDGKSDKEGDARMNVNNDADVFTKLVNEGNIEDFGKLGEDEQGETKERNLKSQSFQGDDTEEVN 234
Vivax -DKETPRLNLIKLSATQPDGGEHTQKGKSTEAPIREAHSGKSTGINKRAANFIQMLNDGNSNGRGDAEMGVENEPDTFSKLINEGNIEDFDHLEKDEP-EGEEEKKQEEAGEAEAGAAEG 227
Chabaudi -LNQNEGITSLELSDRHP--------------------------------------------------------------------------------------------------------------  126
Berghei - LNKTEGTQFLELSNRYPN------------------------ IGKQNSQQNKVNEINNQNAASNSNDNI------------------------- GNDNI------------------------- 159
Yoelii -SNQLDDIQFIELSNKYPN------------------------ 1GKQNSQQNK VNKINNQNG ASNSNDNI------------------------- RNDE------------------------- 158
Falciparum ---------- AILKLKQNPNIKNKNMLDYDKIFK11KEKLINKNLASNKIK------------------------- GGDNEKLKEEKKQSDISTN------ VEVKKDIIN-------------250
Knowlesi SWKEGRHSNERKREDKNDDEDDQDVEGKADQETIQKTDQRAEQEANQR------- AVQETNQREEQEANQREEQEANQREEQEADEESNQRAEQEANQREEQEADEES-------------336
Vivax KEKGEEAERKEEQEEAKQPQEQEQRDHKSMREEESQSASREEERQSNMRESPPGGESPQEGGDNIEGGTEVAARKGGDKSKGQEREGEKNLMASKKEGVKAEKPSEEGSPSGHSLQGEGA 347
Chabaudi  DAENDDHDDLIEERDDTLEQEDSAENNDGILP--------------------------- RGKIYEQDEENKNIY------------ TIPSDENS------------ 181
Berghei --------GNDNIGNDEDDDEDDDEDLIEGRKDNLEEDDLIEKNDSNLP--------------------------- RGKMHEKEEKNKNIN------------ TTPGNESS------------ 223
Yoelii ------------- DEDEGEDEDEDDDLIEGRKDNLEEDDLVEKNGANLK--------------------------- RGNMHGQEEKNKNIN------------ TTPGNENN------------ 217
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Falciparum  DQLNKGIPTKIENKDDMINKESNKEDITNEGKSNSLNNLNTLNNDGNIITKVYDHYTIVTNSNDILNDISIDASDISKNSIGGINIPFNENDNSSFTHQRYIVLSNNGEKKYKIV 3 65
Knowlesi ---------NQRAEQEADEESNQRAEQEADE-EADQEAEYELKEGENV-AQQDIIVQEFDHYKIVTNSHDILNDIYVDASDISKLSIGSINIAYSEQNKTSFTHQRHIVLNNRGNKKYRW 446
Vivax EEAPAASPAEDSDEKKEEEEEEEEEEEEED-SNDQGREYQLNDGNSV-AQEDIITQEFDHYTIVTNSNDVLNDIRVDASDISKLSIESINIPYSEANKTSFTHQRHIVLTNKGNKKYRW 465
chabaudi  NEKVYDKKSD-ISLKDKIDYKE-RGYGN FKSKEKN-LDENIKTYTFDHYKIITNSENILNDIKVDASDISKLSINSLNIEYNEKNKAEYTHQRHIILSNEGNRRYKIF 286
Berghei --------NKNVNDKKKNGISLKDKIDNKQ--NNGG LKEKGNN-LDDNIKTYTFDHYKIITNSDNILNDIKVDASDISKLSINSINIEYNEKNKAEYTHQRHIVLSNNGNRRYKIF 328
Yoelii -------- SKNVNDNKKSGISLKDKIDNNE-QHNSG LKGTTKY-LDDNIKTYTFDHYKLITNSDNILNDIKVDASDISKLSINSLSIEYNEVNKTEYTHQRHIVLTNKGNRRYKIF 323
Falciparum LMTKNPKFMDMEX3IYDEEEKKESLIELNQKVNKEENTN--LYDGTGTLYYGKKSKKEKENTQQKGGNNPNVDINILNNNNNNNNNNNNNSNNNSNSMNDEEINYNNNNNKESPSMFRRFI 483
Knowlesi----- LMTKNPKFTELEDEESENAATNTFIEKEKVERKKTSDGHGEEDNDRTNLYGGKGTLDFSKAYRSNRK-------------- GSGRQVGNPNVEMYSAGDT----SGGGIRGTINRLFSFL 548
Vivax-------- LMTKNPKFIELEDEPDEKAENNTFIERESMEQKRTPNGRGEHTSDRTNLYGGKGTLDFSKVYSGNGR-------------- GSGREVENPHVETHTGGGT----GEGGIRATINRLFSFL 567
chabaudi LMTKNPKFTKTDDIPQP---EMNFIQTKAVQNEGATEE--EDKYYNENLYSGFGTLDFEKGYSKTKKK------ IDNGHASGVNDQNSNHQNIEKNDSHE NEKHNHGFIGKVRSFF 391
Berghei LMTKNPKFTKTEDIEEP-- GMSFIQTETGENEDEKED--EENYLNENLYSGFGTIDYENDYSKKKKK------ IESEHASGLNDKISNSQNIEKSGSHE NEKYNHGYIEKIRSFF 433
Yoelii LMTKNPKFTKTEDIEEP---EMSFIQTETGENTNEKED--EENYLNENLYSGFGTIDYENGYSKKKKK------ INSEHASELNDKISNSQNIEKSDSHE NEKYNHGFIGKIQSFF 428
Falciparum NFLSFSGNENETEDTLIYHNKN DNSYKNKKEGTGKNNDNNDPNNNNNKKILLNVDKLVDQYLLNLKNNHTSKQELILVLKGELDLHSKNMKNVINNAKKNLEKYFKEHFKE 594
Knowlesi SFKGNPDESASGTDPSKDSGGR----- SGDNEDQKGNANEGGNRHGSIPQDDRTHDLNEILSVDKLVDQYLLNLKNNTPDKQELILVLRGDLDLHSPYMKLVIKRSNAKFEQHIKRNFEQ 663
Vivax TFGGNPGESARGAGESKDGGGKKESANGGGDRHHHHYRHDLQSRDNRRSRHDRTKDLNEILSADKLVDQYLLNLKNNTPERQELIFVLRGDLDLHSTYMRRVIKRSNAKFEEHIKKNFQQ 687
Chabaudi SFLSVS----NSQKDDNIESGKK--------- NEESNNADSKTRLNEKTDDTTRKDSLNEFLSVDKLTDQYLLNLKNKNVKEQELILIFQGDLDLHSKEMRKVIDEANAKLTNYLNMHFKD 499
Berghei SFLSMP----SSKKDDSIGSEKK--------- TEERSNTDSKAKLNKKTNDMAKKNNSNAFLSVDKIIDQYLLNLKNKNMKEQELIFIFHGNLDLHSKEMKTVINEANAKFTKYINMHFKD 541
Yoelii SFLSIP----SSKKDDSIGSEKK--------- SEERNNVDSKPKLNKKPNDTAKKNNSNKILTVDKVTDQYLLNLKNKNMKEQELIFIFHGDLDLHSKKMKTIINEANVKFTKYINMHFKD 536
Falciparum FDKISYDISTPINFLCIFIPTLFDMNNMDLLKQALLILHNDLHEYVENWSFSSTYHTYEADYIKE---------- Q-DS--------- VYDRSPK   KKY 672
Knowlesi IDKIVYDISSPINFLCFFVPTIFDMNNFHLLKEALMVLHKELERYMENWSFSNTYVTLDAPQIQGDGSGASADWRNDSQKKDAPIEGGAGSQADHHG------- KDHAEG-SQYRKGRKF 775
Vivax VDSIVYDVSSPINFLCFFVPTVFDMSNFHMLKEALLVLQKELERYMENWSFSNTYVTLDAPHVGGEG-GASAGAGHDG-RKDAHMGSRAGDQADGHADDRETGHTDHREGGAPHGKPRKF 805
chabaudi IKNMNYDISSPINFVCFFIPTVFDISNLNILKEALIMSHNELKDYIDNWNFSNTYIAFDRNYEDEDI-----KKEDIDN--------- VMNKLNEHG----------------------EKY 585
Berghei VKNIRYDISSPINFVCFFIPIIFDMSNLKILKEALIILNNELKDYIDNWNFSNTYVAFDNNYENE--......--DIDN...... ...VMNKLNENM--------------------- EKY 622
Yoelii VKNIRYDISSPINFVCFFIPIIFDMSNLKILKEALIILHNELKNYIDNWNFSNTYIAFDTDYENE---------- DIDN--------- AMNKLNENM----------------------KKY 617
★ ★ ★ ★ ★ *
Cat. Domain->
Falciparum IKASKKLYNNKYSFLNKFLNIEPLILFAKKLNSKRSNIEKEILNFLPKELRDYSTWNLSIIRVFNAWFLAGYGNKNVKVCWDSGADIKHVDLNGNLYIPEYNEKYEMTQDFYNFMVKNP 792
Knowlesi IKKKKKLYNGKYSFLRKIWSFDTISAFAAKMKKKNTDIENEILNFLPKELREYSTWNLSVIRVFNAWFLAGYGNKNVKVCIIDSGIDKNHVDLMKNVYIPEYSEQYEMTEDFYDFMVKNP 895
Vivax VKKKKNLYNVKYSFLRKFWSFDSIIAFARKMNKKNMDIEKEILNFLPKELREYSTWNLSVIRVFNAWFLAGYGNKNVKVCIIDSGVDKNHIDLMKNVYIPEYSEQYEMTQDFYDFMVKNP 925
Chabaudi IKKPKKLYNIKYSFLRKIWGLESIISLYKGKNKKEADIEERILNALPKELKEYSTWNLSFIRVFNAWLLSGYGNKNVKICVIDSGIDKNHIDLASNVYIPKYSDKYEMTDEFFDFMVQNP 705
Berghei IKKPKKLYNIKYSFLRKIWGLKSIISLSKNQDKKDAEIEEKILSALPKELKEYSTWNLSFIRVFNAWLLSGYGNKNVKICVIDSGIDKNHIDLANNIYTPKYSDRYEMTDELFDFMVKNP 742
Yoelii IKKPKKLYNIKYSFLRKMWGLESIFSLSKNRNQKNAGIEEKILNALPKELKEYSTWNLSFIRVFNAWLLSGYGNKNVKICVIDSGVDKNHIDLAKNIYTPKYSDRYEMTDDFFDFMVKNP 737
. *  ★ . ★ *  ★ ★ ★ * *  ★ * .  . *  * * . *  *  ★ . * . *  ★ * . *  . . * * * *  * * * . ★ ★
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TDASGHGTHVTGIIGGVANDLGWGVAPNITLISLRFIDGKKYGGSFHAIKALNVCILNKAPIINASWGSSHFDVNLHLAVERLKYTLNGKGSVLIAASGNKSNDNDISPLYPATFTFPH 912 
TDSSGHGTHVTGIVGGVANGLGMVGVAPDVTLISLRFIDGVKYGGSFHAIKAINVCILNKTPIINASWGSNKYDANIYLAVQRLKYTFNGKGTVLVTAAGNENKNNDEHPLYPSNFKLPH 1015
TDSSGHGTHVTGIVGGLANDLGMVGVAPNVTLISLRFIDGVKYGGSFHAIKAINVCILNKAPIINASWGSSKYDANIYLAVQRLKYTFNGKGTVLVTAAGNENKNNDEHP--------L- 1036
SDTSGHGTHVSGIAGASANSLGMVGVAPNIKLISLRFIDGDNYGGSFHVIKAINVCILNKSPIINASWGSRNYDTNMYLAIQRLKYTFKGKGTVWAAAGNENKNNDLYPIYPASYKLQN 825 
IDTSGHGTHVSGIAAASANSLGMVGVAPNINLISLRFIDGDNYGGSFHVIKAINICILNKSPIINASWGSRNYDTNMFLAIERLKYTFKGKGTVFIAAAGNENKNNDLYPIYPASYKLQN 862 
IDTSGHGTHVSGIAAASANSLGMVGVAPDVNLISLRFIDGDSYGGSFHVIKAINVCILNKSPIINASWGSRNYDTNMFLAIERLKYTFKGKGTVFIAAAGNENKNNDLYPIYPASYKLPN 857 
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CYMKSRKHSDKKCSKNLMKSNYIPEMDDGMEETQQLQQERRQYFRELFGENLEKNYDQHFVQDFGQDFRQDFKLGSTPDLKQYSDIDLQNKIQQPERKTVKIIINNFEDRKKETK 1272
[IFIKRKRHSKYCDDEDHYHNILRSSVLEQHHILGNTTNQQLEVAKRN--HAEKMRHSVRFSLLMGKQNACLFKERASQRLNF-----------------------------------1341
[VFIKRKRHSKYCDDEDHDHNMMRNSVFEHHHILSGNTNHALKMAKRSHVEKIRNSVRFSWMGTQNNCVFKERAPKKLDFENYGDLIKKPLLKSPPKKFVNHRAEQNWGHEAEK 1393
IVIVSIVFFFKHHQNKHRDYEQYMNQKMADRAYDIKYNFNDVGPGGIKKSCSLDGNINNHRDTQRFTIVQNEDNMYVLKKKSSIKSKYE--- ARNELTKR-PLIKRPIVKHKDTNVNFNN 1181
IVLASIVFFLKHHQSKQRDGEKYMHQKMVDRTYNVKYNFKDSGTDGIKRINTLDDNINNHRNTQRFTIVQNEDNMYVLKKKSSIQAKYE--- PRNELVKR-SLVKRPIVKHADINVNFSN 1217
IALASIVFFLKHHQSKQRDAEKYMHQKMVDRAHGIKYNFKDAGADGIKRINTMDDNINNHRNTQRFTIVQNEDNMYVLKKKSSIQAKYE--- PRNELVKR-PLVKRPIVKHADINVNFKN 1212
Falciparum RRLLKGLNYDGENAKKHDFTNESISNSRKNFKFSNNTEMKKNTIKSEDVKIASDDNVNKAMNQLDDMFMK 1342
Knowlesi --------------------------------------------------------------------------- 1341
Vivax KDPRD---------------------------------------------------------------------  1398
Chabaudi MEALYESHGNLSE------------------------------------------------------------  1194
Berghei VDVLYEPKNNSSE------------------------------------------------------------  1230
Yoelii IDELYEPQNNSPE------------------------------------------------   1225
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surface. The protein is predicted to be a membrane-bound, calcium dependent 
serine protease, like MESH. PfSUB2 is expressed at the correct point in the 
erythrocytic cycle and may be located on the parasite surface during invasion which 
is the location of MSP1 and AMA1 shedding. Most convincingly the PfSUB2 pro­
domain can be used to specifically inhibit both AMA1 and MSP1 shedding from the 
parasite during merozoite shedding assays [120], If PfSUB2 is MESH it represents a 
good candidate for drug design and development. However, to date studies on 
PfSUB2 have been hampered by the inability to express the protein in an 
enzymatically active recombinant form. Also the low levels of the protein present 
within the parasite make detection of the protein difficult.
1.11 Transfection technology
The genetic manipulation of organisms has long enabled scientists to gain 
important knowledge of the expression of genes and the function of the proteins 
they encode. Transfection of P. falciparum has only been possible relatively recently 
[121]. The parasites are electroporated with a circular bacterial derived plasmid that 
then replicates episomally within the parasite. Transfection efficiency remains low; 
recent calculations by O’Donnell et al. put the Figure for transfection efficiency at 
0.8x1 O'6 [122]. Selectable markers such as the T. gondii and human dihydrofolate 
reductase thymidylate synthase (dhfr-ts) genes confer resistance to pyrimethamine 
and WR99210 respectively and allow for the selection of parasites stably harbouring 
the plasmid [123-125]. Replication of episomally carried plasmids within the parasite 
appears to be relatively efficient but there is inefficient segregation of the plasmids 
between daughter merozoites, and in the absence of drug pressure these plasmids 
are rapidly lost [122, 126]. Where plasmids carry suitable targeting sequences, 
homologous recombination into the genome can take place by both single and 
double crossover events [123, 124, 127]. Targeted gene disruption, expression of 
transgenes, allelic exchange and promoter studies have all been described [123,
37
124, 127-131], Attempts to use similar technology to over-express P. falciparum 
proteins within the parasite have been less successful. Healer et al. [132], for 
example, attempted to over-express AMA1 using the amal gene encoded on an 
episomal plasmid. The total levels of AMA1 in transfected parasites were found to 
be equivalent to the levels found in untransfected parasites. Inducible control of 
individual gene expression is available in T. gondii and the system has recently 
been adapted for use in P. falciparum however, it has yet to used to conditionally 
knock out an endogenous P. falciparum gene [133, 134],
As recombinant, enzymatically active PfSUB2 has yet to be obtained, studies 
within the parasite using some of the techniques mentioned above will help to 
understand the role of PfSUB2 within the erythrocytic cycle.
1.12 Project Aims
The objective of this project was to elucidate the function of PfSUB2 in the 
asexual blood-stage life cycle of the parasite. Two related strategies were used, 
both involving genetic manipulation of the parasite. In the first of these the aim was 
to study the enzymatic activity of purified PfSUB2 obtained from the parasite. 
Purification was to be facilitated by the over-expression of modified PfSUB2 in the 
parasite. In the second approach the aim was to define the sub-cellular location and 
fate of the protease by ‘tagging’ the endogenous gene product with suitable epitope 
or fluorescent tags.
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2. Materials and Methods
2.1 Molecular Biology: DNA preparation and manipulation
2.1.1 E. coli strains used
Plasmodium falciparum DNA is often unstable in E. coli, due in part to the 
high A+T content of coding sequences and intergenic regions. The E  coli PMC103 
(Genotype: mcrA A (mcrBC-hsdRMS-mrr) 102 recD sbcC) and XL-10 Gold® 
Ultracompetent cells (Stratagene) are recommended for cloning Plasmodium DNA 
[135]. Vectors 2.2.1 to 2.2.4 were cloned initially into PMC103 cells; however the 
transformation efficiency and DNA yields from these cells were unsatisfactory, and 
further plasmids were cloned using XL-10 Gold® cells. As the stability problems 
found with Plasmodium DNA seem only to manifest themselves in cloning steps, 
vectors 2.2.1 to 2.2.4 were subsequently transformed into E. coli DH5a™ cells 
(Invitrogen) to increase DNA yields [135],
All pMOSBlue constructs were maintained in the MOSblue E. coli strain 
(Amersham Biosciences). Plasmids requiring digestion with Cia I, a restriction 
endonuclease unable to digest methylated DNA, were transformed into SCS110 E. 
coli cells (Stratagene) which are deficient in dam and dcm methylases. For protein 
expression E. coli strain BL21(DE3) (Stratagene) was used.
2.1.2 Preparation of PMC103 competent cells
A glycerol stock of PMC103 cells was streaked onto a Luria-agar (L-agar) 
plate and left to grow overnight at 37°C. A colony from this plate was picked and 
placed in a 5 mL Luria-broth (L-broth) culture and left to grow shaking overnight at 
37°C. 40 mL SOB medium (with 10 mM MgCI2 added just before use) was 
inoculated with 400 pL of the overnight culture and left shaking overnight at 18°C. 
The culture was then chilled on ice for 10 minutes before being transferred to a 
polypropylene centrifuge tube (Corning) and centrifuged at 3,000 g for 10 minutes at 
4°C. The supernatant was discarded and the pellet re-suspended in 12.8 mL of ice-
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cold TB buffer (10 mM PIPES, 15 mM CaCI2, 250 mM KCI, pH 6.7, 55 mM MnCI2). 
This suspension was held on ice for 10 minutes and then pelleted as before. The 
supernatant was discarded and the pellet re-suspended in 3.2 mL of ice-cold TB 
buffer. 240 pL of dimethyl sulphoxide (DMSO) was then added drop wise. The 
suspension was then held on ice for 10 minutes before dispensing into 100 pL 
aliquots and freezing in an ethanol bath. Aliquots were stored at -70°C.
2.1.3 Transformation of E. coli
Transformation of DH5a™, XL-10 Gold®, MOSblue, SCS110 and 
BL21(DE3) cells was according to manufacturers’ instructions. PMC103 cells were 
transformed according to the following method. DNA was added to 100 pL of 
competent cells. The cells were then held on ice for 1 hour and then heat shocked in 
a water bath at 42°C for 45 seconds. The cells were then held on ice for 2 minutes 
before placing in an Eppendorf tube containing 50 pL L-broth and left shaking at 
37°C for one hour. The cells were then plated on a selective LB agar plate.
2.1.4 DNA production
DNA for cloning steps and sequencing was prepared using the S.N.A.P kit 
(invitrogen) according to manufacturers’ instructions. DNA for transfections was 
prepared using the Qiagen® Plasmid Maxi kit according to manufacturers’ 
instructions. E. coli were grown in Terrific broth to obtain maximal yields of bacteria. 
Plasmids pHHT-sub2, pHHT-sub2HA, pHHT-sub2w and pHHT-sub2wHA (see 
2.2.1-2.2.4) were expressed poorly and were difficult to produce in the amounts 
needed for transfection. For these plasmids the Very Low-Copy Plasmid protocol 
was used, as described in the manufacturers’ guide. DNA yields and purity were 
assessed by absorbance using a spectrophotometer (Unicam UV1). Samples were 
finally ethanol precipitated and re-dissolved in water to a final concentration of 3.3 
MQ/ML-
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2.1.5 Genomic DNA preparation and plasmid recovery from P. falciparum
Plasmodium falciparum genomic DNA was extracted using the DNeasy® 
Tissue Kit (Qiagen). This kit was also used for the recovery of plasmid DNA from 
transfected parasite lines.
2.1.6 Polymerase Chain Reaction (PCR)
PCR for amplification of sequences used in the construction of plasmids was 
performed using Pfu Turbo® DNA polymerase (Stratagene) or Platinum® Taq High 
fidelity DNA polymerase (Invitrogen). Both enzymes were used according to the 
respective manufacturers’ instructions. AmpliTaq® DNA polymerase (Roche) was 
used for PCR reactions where proofreading action was not required. The PCR 
reaction was performed according to the manufacturers’ instructions. 
Oligonucleotide primers for use in PCR and sequencing were purchased from 
Oswel. PCR purification was performed using the QIAquick® PCR Purification Kit 
(Qiagen).
2.1.7 Site directed mutagenesis (SDM)
Site directed mutagenesis was performed using the QuikChange® XL Site- 
Directed Mutagenesis Kit (Stratagene) according to manufacturers instructions.
2.1.8 Automated sequencing
BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) was 
used with reaction mix set up according to instructions. The reactions were placed in 
a PCR machine (ThermoHybaid Omn-E) and the following program applied: 96°C 
for 45 s, 50°C for 30 s and 60°C for 2 min, for a total of 25 cycles. Samples were 
then ethanol precipitated in 0.5 mL Eppendorf tubes by the addition of 50 pL 95% 
ethanol and 2 pL 3 M sodium acetate (pH 3.0) followed by incubation at room 
temperature for an hour before centrifugation at 13,200 rpm for 20 min. The ethanol
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was then aspirated and the DNA pellet washed once in 0.5 mL 70% ethanol. The 
ethanol was removed and the pellet dried for 1 min in a heating block set at 95°C. 
The pellet was then re-suspended in 10 pL MegaBACE™ Loading Solution 
(Amersham Biosciences) and loaded on a MegaBACE™ sequencing machine 
(Amersham Biosciences).
2.1.9 DNA-Modifying Enzymes
Restriction endonucleases were purchased from Roche with the exception of 
Bgl II which was purchased from NEB. All restriction digests were carried out 
according to manufacturers’ instructions. Clean up after restriction digests was 
performed using the QIAquick® PCR Purification Kit (Qiagen). Alkaline phosphatase 
and T4 polynucleotide kinase were purchased from Roche and used according to 
manufacturers’ instructions.
2.1.10 DNA Ligation
Ligations were performed using the Rapid DNA Ligation Kit (Roche).
2.1.11 Gel extraction
Gel extractions were carried out using the QIAquick® Gel Extraction Kit 
(Qiagen) according to manufacturers’ instructions.
2.2 Vector construction
2.2.1 Construction of pHHT-sub2
A 3.5 kb fragment encoding the predicted ectodomain of a synthetic pfsub2 
(pfsub2synth) gene was constructed using the method of Withers-Martinez et a/., with 
codon usage optimised for Trichoplusia ni [136]. The synthetic gene was designed 
to facilitate cloning and expression of the pfsub2 gene as the A+T content is lower 
than the authentic gene. Note that the parasite is known to be capable of
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transcribing such genes as all reporter genes used in P. falciparum transfections 
derived from organisms with a lower A+T content. The pfsub2synth fragment was 
cloned into pMOSBlue, forming the plasmid FIM which was then linearised with 
EcoR I. A 20 bp linker, designed to contain terminal overhangs complimentary to 
those left following digestion by EcoR I, as well as an internal BstE II site (in bold), 
was produced by annealing together oligonucleotides sb2LNK1 (5'- 
AATTGGTTACCCGGGATCCG-31) and sb2LNK2 (5'-AATTCGGATCCCGGGTAACC-3'). 
The linker was ligated into the EcoR I site of FIM forming FIM-LNK. The PfSUB2 
ectodomain coding sequence was then excised using Pst I and BstE II and gel 
purified. Plasmid pHHT was constructed by excision of the tk gene from pHHT-TK 
using Xho I [127], Oligonucleotides pH-LNK1 (5'-TCGACTGCAGACCCGGGTTACCA- 
3') and pH-LNK2 (5'-TCGATGGTAACCCGGGTcrGC/AG-3') were annealed together to 
form a linker containing terminal overhangs complimentary to those left following 
digestion with Xho I, as well as an internal Pst I site (in italics) and an internal BstE II 
site (in bold). The linker was ligated into pHHT, forming plasmid pHHT-LNK. pHHT- 
LNK was digested with Pst I and BstE II and gel purified. The gel purified pfsub2 
ectodomain was ligated into pHHT-LNK forming pHHT-sub2. This entire procedure 
is shown schematically in Figure. 2.1
2.2.2 Construction of pHHT-sub2HA
To insert sequence encoding a single haemagglutinin (HA) epitope tag 
(YPYDVPDYA) within the coding sequence of the pfsub2synth  gene, overlap 
extension PCR was performed using FIM-LNK as template and using primers C (5- 
TACCCCTACGACGTACCCGACTACGCCCATCATCATCACC-3) and B (5'- 
GGCGTAGTCGGGTACGTCGTAGGGGTAGCTGTCGTATTCG -3) [137, 138], 
Sequence encoding the HA tag is marked in bold. Primers A (5'-
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Figure 2.1 Construction of pHHT-sub2
Schematic representation of the construction of pHHT-sub2. The construct places 
the region of the pfsub2synth gene encoding the putative PfSUB2 ectodomain under 
the control of the hsp86 promoter.
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AAAGGTT GAAAT ACACCTT GAACGGAAAAGGCT CAGT GTT -3') and D (5’- 
GGGCGATCGGTGCGGGCCTCTTCGCTATTACGC-3') were then used to amplify 
the region flanking the tag. The amplified fragment was digested with Xho I and 
BstE II, gel purified, and ligated into Xho I/BstE ll-digested FIM-LNK to create 
plasmid FIM-LNKHA. This plasmid was then digested with Xho I and BstE II and the 
fragment containing the HA tag ligated into Xho I/BstE II digested pHHT-sub2 to 
create the plasmid pHHT-sub2HA. This procedure is shown schematically in Figure. 
2 .2 .
2.2.3 Construction of pHHT-sub2W
To construct a full-length pfsub2synth gene encoding a C-terminal hexa- 
histidine (Hise) tag, a 850 bp gene fragment was synthesised comprising sequence 
encoding the last 200 bp of the ectodomain, the transmembrane domain and the 
cytoplasmic domain of PfSUB2. This was done using the method of Withers- 
Martinez et al. with codon usage optimised for Trichoplusia ni [136]. The fragment 
was cloned into pMOSB/ue, excised using BstE II and Sac II and gel purified. This 
fragment was then ligated into BstE II/Sac I digested FIM-LNK to create plasmid 
FIM-LNKfi. FIM-LNKfi was then digested with Xho I and BstE II and the pfsub2synth 
fragment gel purified. pHHT-sub2 was digested with BstE II and Xho II and gel 
purified. The gel purified pfsub2 fragment was ligated into the BstE II /Sac II 
digested pHHT-sub2 forming pHHT-sub2w. This procedure is shown schematically 
in Figure. 2.3.
2.2.4 Construction of pHHT-sub2wHA
To construct a full length pfsub2synth gene encoding a single HA epitope tag 
(YPYDVPDYA), followed by a C-terminal hexa-histidine (His6) tag, a 900 bp gene 
fragment was synthesised comprising sequence encoding the last 200 bp of the 
ectodomain, the transmembrane domain and the cytoplasmic domain of PfSUB2
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Figure 2.2 Construction of pHHT-sub2HA
Schematic representation of the construction of pHHT-sub2HA. The construct 
places the region of the pfsub2synth gene encoding the putative PfSUB2 ectodomain 
with a C-terminal HA tag under the control of the hsp86 promoter.
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Figure 2.3 Construction of pHHT-sub2w
Schematic representation of the construction of pHHT-sub2w, designed for episomal 
expression in P. falciparum of the full-length pfsub2synih gene. The construct places 
the full-length pfsub2synth gene encoding PfSUB2 under the control of the hsp86 
promoter.
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with a HA and His6 tag. This was also done using the method of Withers-Martinez et 
al., with codon usage optimised for Trichoplusia ni [136]. The fragment was cloned 
into pMOSB/ue then excised using BstE II and Sac II and gel purified. FIM-LNK was 
digested with BstE II and Sac II and the 900 bp fragment ligated in to create the 
plasmid FIM-LNKaha pHHT-sub2 was digested with BstE II and Xho I and gel 
purified. FIM-LNKaha was then digested with Xho I and BstE II and the synthetic 
pfsub-2 N-terminal fragment gel purified. The gel purified fragment was ligated into 
the BstE II /Sac II digested pHHT-sub2 forming pHHT-sub2wHA.
2.2.5 Construction of pHH1-T996HA3
The HA3 sequence, encoding three consecutive HA tags, was 
amplified from pREP(HA3)42 (a kind gift of Dr Jonathan Millar, Division of 
Yeast Genetics, NIMR) using the primers HA-1 (5 -  
AG ACACT GCT CG AGT ACCCTT ACGAT GTT -3') and HA-2 (5'-
GGACACTGGTCGACTCAAGCGTAATCTGG -3') [139]. These primers 
placed Xho I and Sal I sites at the 5' and 3' ends of the HA3 sequence and 
introduced a stop codon (shown in bold) at the end of the HA3 sequence. 
The product was cloned into pMOSBlue, excised using Xho I and Sal I and 
ligated into the unique Xho I site in pHH1-ASERA4 [140], This creates the 
plasmid pHH1-HA3. The 3’ end of the pfsub2 gene was amplified from T9/96 
Plasmodium falciparum genomic DNA [114]. The primers used (T996-1; 5'- 
g c c c c a g g t c a t c a c a t a t a t t c t a c t a t t c c -3', and T996-2; 5'-
GGACACTGCTCGAGTTTCATAAACATATCATC -3') remove the stop codon 
from the end of the pfsub2 coding sequence and form a continuous reading 
frame into the HA3 region at the end of which a new stop codon has been 
created. The amplified fragment includes a Bgl II site and the reverse primer
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places a Xho I site (in bold) at the 3' end. The fragment was cloned into 
pMOSBlue and then excised using Bgl II and Xho I. The sera4 gene fragment 
was excised from pHH1-HA3 using Xho I and Bgl II. The T9/96 DNA 
fragment was ligated into this position. This procedure is shown 
schematically in Figure. 2.4.
2.2.6 Construction of pHH1-T996w
Primers T9961 (5'-GCCCCAGGT CAT CACAT AT ATT CT ACT ATT C-30 and 
T996w (5'- CTCGAGTCATTTCATAAACATATCATCAAGTTGATTCATTGC-3') were 
used to amplify a 1.2 kb fragment of the 3' end of the pfsub2 gene, including the 
stop codon, from T9/96 Plasmodium falciparum genomic DNA [114]. Primer T996w 
places an Xho I site (in bold) after the stop codon. There is an internal Bgl II site 
within the fragment. The fragment was cloned into pMOS Blue and excised using 
Bgl II and Xho I. The sera4 gene fragment was excised from pHH1-ASERA4 [140] 
using Bgl II and Xho I and the pfsub-2 fragment ligated in. This creates the plasmid 
pHH1-T996w.
2.2.7 Construction of pHC1-CATprom plasmids
To characterise the pfsub2 promoter a series of fragments of the region 
immediately 5’ to the pfsub2 gene were amplified from T9/96 Plasmodium 
falciparum genomic DNA. The reverse primer R1 (5’- 
CTCGAGTATACGGAAAGAGAAAAAAAAAATAAC-3’) inserts an Xho I site (in bold) 
at a position which lies directly before the start of the pfsub2 coding sequence. The 
forward primers used were F1 (5-
GCTCAGCCTACAATTTTAAATATATTCATATTATGG-S'), F2 (5-
GCT CAGCG G ACCAT AT AT AAT GTTTT AT GG-3'), F3 (5-
G CT C AG CAT AT AT ATGT AT ATAT ATAT ATATG G G- 3’), F4 (5*- GCTCAGCATAATA
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Figure 2.4 Construction of pHH1-T996HA3
Schematic representation of the construction of pHH1-T996HA3, designed to insert 
an HA3 epitope tag at the 3' end of the endogenous pfsub2 gene by single­
crossover, targeted homologous recombination.
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CACAACAAAGAAAACATT CC-3'), F5 (5'-
GCTCAGCGGTTTTTTTTAATATATATAGATAAATGG-3,) and F6 (5'- 
GCT CAGCTT CCT CTTT CAT CAT ACACAT G AGG-3').
A Cel II site is marked in bold in each forward primer. Amplification with the 
primer pairs produced products of 1.459 kb with primer pairs F1/R1, 1.267 kb with 
F2/R1, 1.054 kb with F3/R1, 824 bp with F4/R1, 624 bp with F5/R1 and 286 bp with 
F6/R1. The amplified fragments were cloned into pMOS Blue, excised using Cel II 
and Xho I and gel purified. pHC1-CAT was digested with Cel II and Xho I and the 
pHC1 backbone and cat gene fragments gel purified [130], The promoter fragments 
were cloned into the Cel II/ Xho I digested pHC1. The pHC1-promoter plasmids 
were then digested with Xho I and the cat gene inserted. This resulted in the 
plasmids pHC1-CATF1, pHC1-CATF2, pHC1-CATF3, pHC1-CATF4, pHC1-CATF5 
and pHC1-CATF6. This entire procedure is shown schematically in Figure. 2.5.
2.2.8 Construction of pHHT-sub2i, pHHT-sub2HAj, pHHT-subWj and pHHT- 
sub2wHAj
Plasmid Pfs2S-ApPIC3.5k (S. Yeoh, unpublished data) contains part of the 
pfsub2synth gene encoding the PfSUB2 ectodomain with the active site serine codon 
(Ser961) substituted with an alanine codon, within the Pichia pastohs expression 
vector pPIC3.5k (Invitrogen). The plasmid was digested with Ksp I and Sac I to 
excise a 2 kb fragment containing a section of the synthetic gene surrounding the 
Ser961Ala mutation. This fragment was gel purified. FIM-LNK (see 2.2.1) was 
digested using Ksp I and Sac I and the backbone gel purified and treated with 
alkaline phosphatase. The Ser961Ala fragment was then ligated into FIM-LNK 
forming FIM-LNKS961A. This method was repeated for FIM-LNKHA, FIM-LNKfl and 
FIM-LNKfiHA, forming the vectors FIM-LNKHAS961A, FIM-LNKf,S961 A and FIM- 
LNKahaS961 A respectively. pHHT-sub2 was digested with Ava I and BstE II and the
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Figure 2.5 Construction of pHC1-CATprom plasmids
Schematic representation of the construction of pHC1-CATprom plasmids. The 
constructs place the cat gene under the control of fragments of the region 5' to the 
pfsub2 gene.
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backbone gel purified and phosphatased. FIM-LNKS961A was digested with Ava I 
and BstE II and the 300 bp fragment gel purified. This fragment was then ligated into 
the pHHT-sub2 backbone forming pHHT-sub2j. This modification was also 
performed on FIM-LNKHAS961A, FIM-LNKf,S961A and FIM-LNKf,HAS961A to form 
the vectors pHHT-sub2HAj, pHHT-sub2Wj and pHHT-sub2wHAj
2.2.9 Construction of pAMA15'-sub2wHA
Plasmid pAMA15'-ACPGFP (a kind gift of Dr J. Healer, Division of Infection 
and Immunity, WEHI) contains sequence encoding the plastid targeting sequence of 
acyl carrier protein (ACP), fused to the gene encoding Green Fluorescent Protein 
(GFP), under the control of the amal promoter. The plasmid was digested with Xho 
I to excise the acp-gfp gene and the backbone gel purified. A 20 bp linker 
comprised of the annealed oligonucleotides pHLNK 1 and pHLNK 2 (see 2.2.1) was 
ligated into the Xho I site in pAMA15' to create pAMA15'-LNK. The linker region 
contains both a Pst I and BstE II site. A 4 kb fragment comprising the pfsub2synth 
gene coding for the full length PfSUB2 with a single HA tag was excised from pHHT- 
sub2wHA (see 2.2.4) using Pst I and BstE II. This was ligated into Pst I/BstE II 
digested pAMA15'-LNK to create the plasmid pAMA15'-sub2wHA.
2.2.10 Construction of pAMA15'-sub2wHA3Rep20
Construct pAMA15'-sub2wHA3Rep20 was designed to express a triple HA 
tagged PfSUB2 under the control of the amal promoter. The Rep20 sequence was 
included to improve plasmid segregation [122], The vector pAMA15'-sub2wHA was 
linearised with Not I. Plasmid pHHC*/DR1.4 was digested with Not I to release a 1.4 
kb fragment, comprised entirely of the 21 bp Rep20 repeat 
(TAAGACCTA(T/A)(G/A)TTAGT(G/T)A(A/T)(A/C/G)(G/T)), which was gel purified 
[122]. The Rep20 sequence was ligated into the linearised pAMA15'-sub2wHA to 
create the vector pAMA15'-sub2wHARep20. The triple HA tag sequence, encoding
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three consecutive HA tags, was amplified from pREP(HA3)42 using the primers 
HA3F (5'-AT CGATT ACCCTT ACG AT GTT CCTG ACT AT GC-3') and HA3R3 (5- 
GGTAACCTCAAGCGTAATCTGGAACGTCGTAAGGG-3') [139], This inserts a C/a I 
(shown underlined) site at the 5' end and a stop codon (shown in bold) directly 
followed by a BstE II (shown in italics) site at the 3' end of the triple HA tag 
sequence. The product was cloned into pMOS8/ue and excised using C/a I and 
BstE II. A 850 bp gene fragment comprising sequence encoding the last 850 bp of 
the pfsub2synth cloned into pMOS Blue (see 2.2.3) was used as a template for site- 
directed mutagenesis (SDM). Primers SDMF (5-
CT GGACGACAT GTT CAT GAAGATCGAT CACCACCAT CACC-3') and SDMR (5'- 
GGTGATGGTGGTGATCGATCTTCATGAACATGTCGTCCAG-3') were used to 
insert a unique C/a I site (in bold) at the end of the synthetic gene directly before the 
stop codon. The modified end of the pfsub2 synthetic gene was then excised from 
the pMOSB/tve backbone using BstE II and Sac II. This fragment was gel purified 
and ligated into pAMA15’-sub2wHARep20 that had been digested with BstE II and 
Sac II. This construct was then digested with C/a I and BstE II and the triple HA tag 
sequence ligated into it to create pAMA15'-sub2wHA3Rep20. This procedure is 
shown schematically in Figure. 2.6.
2.2.11 Construction of pGEXHA3
Plasmid pGEXHA3 was designed to fuse three copies of the HA tag onto the 
3' end of glutathione S transferase (GST). The commercially available plasmid 
pGEX-6P.1 (Amersham Biosciences) was linearised with Xho I. The triple HA tag in 
pMOS Blue (see 2.2.5) was excised using Sal I and Xho I and ligated into the 
pGEX6P.1 backbone to form the vector pGEXHA3.
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Figure 2.6 Construction of pAMA15'-sub2wHA3Rep20
Schematic representation of the construction of pAMA15'-sub2wHA3Rep20. The 
construct places the full-length pfsub2synth gene encoding PfSUB2 with a C-terminal 
HA3 tag, under the control of the amal promoter, and was designed for episomal 
expression of the tagged gene. The construct also contains a Rep20 sequence to 
improve plasmid segregation.
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Name Sequence Vector
sb2LNK1 5'-AATTGGTTACCCGGGATCCG-3' 2.2.1
sb2LNK2 5'-AATT CGGAT C CCGGGT AACC-3' 2.2.1
pH-LNK1 5’-T CGACT GC AGACCCGGGTT ACCA-3' 2.2.1
pH-LNK2 5'-T CGAT GGT AACCCGGGT CT GC AG-3' 2.2.1
A 5-AAAGGTT GAAATAC ACCTT G AACGG AAAAGGCT CAGT GTT-3' 2.2.2
B S'-GGCGTAGTCGGGTACGTCGTAGGGGTAGCTGTCGTATTCG-S' 2.2.2
C 5'-TACCCCTACGACGTACCCGACTACGCCCATCATCATCACC-3' 2.2.2
D 5'-GGGCGATCGGTGCGGGCCTCTTCGCTATTACGC-3' 2.2.2
HA-1 5-AG AC ACTGCTC G AGT ACCCTT AC GAT GTT-3' 2.2.5
| HA-2 5-GGACACTGGTCGACTCAAGCGTAATCTGG -3' 2.2.5
T996-1 5-GCCCCAGGTCATCACATATATTCTACTATTCC-3' 2.2.5
T996-2 5-GGACACTGCTCGAGTTTCATAAACATATCATC -3' 2.2.5
T996w 5'- CT CGAGT CATTT CAT AAAC AT AT CAT C AAGTT GATT C ATT GC-3’ 2.2.6
R1 5’-CTCGAGTATACGGAAAGAGAAAAAAAAAATAAC-3' 2.2.7
F1 5-GCT C AGCCT AC AATTTT AAATATATT CAT ATT ATGG-3' 2.2.7
;F 2
|
5 - GCT C AGCGGACC AT AT AT AAT GTTTT AT GG-3' 2.2.7
; F3 5 - GCTCAGCATATATATGTATATATATATATATGGG-3' 2.2.7
F4 5'- GCTCAGCATAATACACAACAAAGAAAACATTCC-3' 2.2.7
F5 5 - GCTCAGCGGTTTTTTTTAATATATATAGATAAATGG-3' 2.2.7
F6 5'- GCTCAGCTTCCTCTTTCATCATACACATGAGG-3’ 2.2.7
HA3F 5'-AT C GATT ACCCTT AC GAT GTT CCT G ACT AT GC-3' 2.2.10
HA3R3 5-GGTAACCTCAAGCGTAATCTGGAACGTCGTAAGGG-3' 2.2.10
SDMF 5-CT GG ACGAC AT GTT CAT GAAGAT CGAT CACCACC ATC ACC-3’ 2.2.10
SDMR 5-GG T GATGGT GGT GATCGAT CTT CAT GAACAT GT CGTCCAG-3' 2.2.10
Table 2.1 Oligonucleotides used in vector construction.
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2.3 Parasite culture and analysis
2.3.1 Drug stocks
Pyrimethamine (Sigma) was first made up at 10 mM concentration in 1% glacial 
acetic acid before dilution in PBS to a concentration of 200 pM. This was then filter 
sterilised and stored at 4°C before addition to culture medium. A 20 mM solution of 
WR99210 (Jacobus Pharmaceuticals) was made up in DMSO. This was then diluted 
to 20 pM in RPMI-1640 (GIBCO), filter sterilised, and stored at 4°C before addition 
to culture medium.
2.3.2 P. falciparum culture and transfection
Plasmodium falciparum line D10 (a laboratory clone of FC27 from Papua 
New Guinea, supplied by M. Grainger, NIMR) was cultivated and synchronised 
using standard procedures [141, 142]. Ring stage parasites were transfected with 
100 pg of purified plasmid DNA for stable transfection as described previously [125], 
In brief, a culture at approximately 5% parasitemia was pelleted by centrifugation 
and washed in incomplete cytomix (120 mM KCI, 0.15 mM CaCI2, 2 mM EDTA, 5 
mM MgCI2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES, pH 7.6). The culture was then 
pelleted again and the cytomix removed. 200 pL of the pelleted cells were added to 
200 pL incomplete cytomix containing 100 pg plasmid DNA and placed in a 0.2 cm 
cuvette (Bio-Rad). The sample was then electroporated using a Gene PulserXcell™ 
electroporator (Bio-Rad) with settings of 0.31 kV and 960 pF. The sample was then 
removed from the cuvette and placed in a flask containing 25 ml_ medium (RPMI- 
1640 supplemented with 25 mM HEPES, 200 pL hypoxanthine, 20 pg/mL 
gentamicin, 0.25% (w/v) Albumax II, 0.2% NaHCC>3, pH 6.72, 2 mM L-glutamine, 5% 
human serum) pre-warmed to 37°C. The flask was then supplemented with a further 
200 pL fresh RBCs. Parasites were cultured for 48 hours post-transfection prior to 
addition of drug. Parasite cultures transfected with plasmids containing the human
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dhfr gene were supplemented with 10 nM WR99120, and this concentration of drug 
was maintained until parasite establishment. Parasites transfected with plasmids 
containing the pyrimethamine-resistant Toxoplasma gondii dhfr gene were treated 
for 48 hours with 0.2 nM pyrimethamine before this was reduced to 0.1 nM. Medium 
was replaced every 4 days until parasite establishment. At day 14 half of each 
culture was added to 12.5 ml_ medium plus 200 pL fresh RBCs. Parasites were 
generally detectable in blood smears after approximately 3 weeks. Parasites 
containing integrated forms of plasmids were selected by drug cycling as follows. 
The parasites were cultured without drug selection for 3 weeks before re-addition of 
drug. Once parasites were again detectable the process was repeated until an 
integration line had been established as determined by Southern blot analysis (see 
2.3.6).
2.3.3 Plasmid recovery
Once parasites could be seen in blood smears, and had reached a 
parasitemia of approximately 5%, plasmid DNA was recovered (see Materials and 
Methods 2.1.5). DNA was subjected to Dpn I digestion to remove any residual input 
DNA, then cleaned using a PCR purification kit (Section 2.1.8). Transformation of 
competent E. coli (strain DH5a) were then transformed with the recovered DNA. 
Colonies were picked and plasmid DNA recovered. These clones were then 
analysed by restriction digest and compared on agarose gel electrophoresis to 
similar digests of the original plasmid used for transfection to confirm the absence of 
rearrangements.
2.3.4 Five-day growth rate assay
Transfected parasites were cultured in the absence of drug for a week prior 
to start of the growth assay. Schizont stage parasites of both transfected and 
parental untransfected lines were purified from culture using 70% (v/v) Percoll
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(Amersham Pharmacia) [143], The schizonts were then added to fresh media 
containing RBCs and allowed to invade for 2 hours before sorbitol treatment [142]. 
The parasitemia of all the cultures was adjusted to 0.5% parasitemia at a 4% 
haematocrit. Every 48 hours the cultures were diluted 1:5 with fresh medium 
containing fresh red blood cells at a 4% haematocrit. Thin films were made every 24 
hours, stained with Giemsa and the parasitemia assessed by microscopic 
examination.
2.3.5 Time course
Schizont stage parasites were purified from parasite culture using 70% 
Percoll. The parasites were cultured in fresh medium containing no added RBCs for 
a further 3 hours to ensure the schizonts were fully mature. Fresh blood was then 
added and the parasites allowed to invade for 2 hours. Parasites were then treated 
with sorbitol leaving a culture of 2 hour old ring stage parasites. Thin films were 
taken immediately and then at 6-7 hour intervals for 48 hours. Samples were stained 
with Giemsa for microscopic analysis as well as being processed for indirect 
immunofluorescence assays (IFA) (see 2.4.5).
2.3.6 Southern blot
DNA recovered from transgenic lines was digested with various restriction 
enzymes to provide fragment sizes suitable for Southern blotting. Digested samples 
were electrophoresed on a 0.7% agarose (Bio-Rad Laboratories) gel overnight at 40 
V. Following staining with ethidium bromide the gel was visualised on a UV 
transilluminater next to a ruler and left for 5 minutes for the UV light to nick the DNA. 
The gel was then incubated for 1 hour in denaturing solution (0.5 M NaOH, 0.75 M 
NaCI). The gel was rinsed in double-distilled water (ddH20) and incubated for a 
further 1 hour in neutralising solution (0.5 M Tris-HCI, pH 7.4, 0.75 M NaCI). The 
DNA was transferred to a Hybond N+ membrane by capillary transfer overnight. A
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DNA probe was radiolabelled with a-32P adenine triphosphate (dATP) (Amersham 
Biosciences) using the Prime-lt® II Random Primer Labelling kit (Stratagene) 
according to the manufacturers’ instructions. The probe was hybridised overnight 
with the membrane in hybridisation buffer (6 x SSC, 5 x Denhardts, 0.5% SDS, 0.01 
mg/mL salmon sperm DNA) at 62°C. The next day the probe was removed and the 
membrane washed for 20 minutes at 62°C in 2 x SSC. This wash step was repeated 
a further 2 times. The membrane was then wrapped in Saran wrap and exposed to 
X-ray film at -70°C to visualise bound probe.
2.3.7 Chloramphenicol Acetyl Transferase (CAT) Assay
A parasite culture containing approximately 200 pL 5% parasitised blood 
was centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and the 
pellet re-suspended in 1.5 volumes of 0.15% (w/v) saponin and left on ice for 10 
minutes. The sample was then centrifuged for 10 minutes at 2800 rpm. The 
supernatant was discarded and the pellet re-suspended in 500 pL TEN buffer (40 
mM Tris-HCI pH 7.6, 1 mM EDTA pH 8.0, 150 mM NaCI). The sample was then 
centrifuged at 14000 rpm for 1-2 minutes and the supernatant removed. This step 
was repeated once. The pellet was then re-suspended in 220 pL 0.25 M Tris-HCI 
(pH 7.6) and freeze/thawed 3 times in a dry ice/ ethanol bath to lyse the parasites. 
The sample was then heated for 65°C and then centrifuged for 1 minute at 14000 
rpm. 200 pL of the resulting supernatant was transferred to a fresh tube. To 100 pL 
of each sample a substrate mix of 20 pL acetyl CoA (40 mM) and 1 pL 14C- 
chloramphenicol was added. A negative control of substrate mix added to 100 pL 
0.25 M Tris-HCI (pH 7.6) was prepared. The positive control was as for the negative 
control but with the addition of 0.5 pL (5 units) bacterial CAT enzyme (Promega) 
pre-diluted 1/500 in 0.25 M Tris-HCI (pH 7.6). The reactions were incubated 
overnight at 37°C. Each tube was then supplemented with 500 pL ethyl acetate and 
vortexed for 1 minute. The sample was then centrifuged at 14000 rpm for 2 minutes
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and the top phase collected into a fresh tube. The sample was then evaporated 
overnight in a fume hood. 10 pL of ethyl acetate was added to each tube and the 
samples spotted onto a thin layer chromatography (TLC) plate (Silica gel, 250 pM 
layer, 20 x 20 cm, Whatman®). Ascending chromatography was performed in a TLC 
chamber equilibrated with 97% (v/v) chloroform 3% (v/v) methanol. Once the 
samples had resolved the plate was removed from the chamber and allowed to dry 
in the fume food. The TLC plate was then exposed to X-ray film to detect positions 
of migration of radiolabelled species.
2.3.8 Inhibitor studies
PfSUB2HA parasites were synchronised using standard procedures [142], 
Approximately 46 hr later, mature schizont stage parasites were isolated using 70% 
Percoll [143], The purified schizonts were divided equally between Eppendorfs each 
containing 0.5 mL media and an appropriate concentration of drug added (see table 
2.2) or 0.5% DMSO as a control. The tubes were then incubated at 37°C for 4 hours 
to allow schizont rupture and release of merozoites into the medium. After 4 hrs thin 
blood films smears were made and stored with desiccant at -70°C. The effect of the 
various inhibitors on the trafficking of PfSUB2 on the free merozoite surface was 
then analysed by IFA.
Alternatively, to assess the affect of the drugs on RBC invasion by the 
parasite, RBCs were added to the Eppendorf alongside the mature schizonts (to 
create a haematocrit of 2%) and the tube then incubated for 4 hours at 37°C. After 
this time smears were made and Giemsa stained to assess invasion.
2.4 Immunochemical methods
2.4.1 Antibodies and associated reagents.
A number of antibodies and associated reagents were used in this work (see 
Table 2.3). For detection of proteins on Western blots either a horseradish
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Chemical Mode of action Cone. Supplier Reference
BAPTA-AM
Inhibition of
microneme
secretion
25 pM Molecular
Probes
[34]
BDM Inhibitor of myosin 
ATPase
5mM Sigma [15]
Colchicine
Inhibition of
microtubule
polymerisation
1 mM
Sigma
[144]
Cytochalasin
B
Inhibition of actin 
polymerisation
4 pM Sigma [12]
Cytochalasin
D
Inhibition of actin 
polymerisation
4 pM Sigma [60]
EGTA Calcium chelator 10 mM Sigma [145]
JAS
Stabilisation of 
actin
polymerisation
5 pM Molecular
Probes
[21]
Latrunculin A Inhibition of actin 
polymerisation
5 pM Sigma [146]
Staurosporine
Inhibition of
microneme
secretion
5 pM Sigma [15]
Table 2.2 Drugs used to study PfSUB2 movement
68
Antibody
name
Type Target Cone
(IFA)
Cone.
(Western
blot)
Reference/
Supplier
3F10 mAb HA epitope 1/500 1/1000 [147], Roche
12CA51
mAb HA epitope 1/200 Culture
supernatant
[148], in house
H5 mAb RAP2 N/A Culture
supernatant
[149], in house
58F8 mAb AMA1 N-terminus 1/100 N/A [56], in house
HIS-1 mAb Polyhistidine tag N/A 1/1000 Sigma
X509 mAb MSP1 1/1,6
00
N/A [150], in house
Alexa Fluor® 
594 4G2
mAb AMA1 1/50 N/A [151], in house
Alexa Fluor® 
594 61.3
mAb RhopH2 1/50 N/A [152], in house
Alexa Fluor® 
594 H5
mAb RAP2 1/50 N/A [149], in house
Alexa Fluor® 
594 anti­
human
Polyc
lonal
Human IgG 1/500 N/A Molecular probes
Anti-rat 
biotinylated
Polyc
lonal
Rat IgG 1/500 1/8000 Chemicon
Anti- mouse 
biotinylated
Polyc
lonal
Mouse IgG N/A 1/1000 Jackson
Immunological
Research
Fluorescein
streptavidin
N/A Biotin 1/500 N/A Vector
Laboratories
HRP-
streptavidin
N/A Biotin N/A 1/8000 Bio-Rad
Table 2.3 Antibodies and associated reagents used in this work.
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peroxidase (HRP)-conjugated secondary antibody or a combination of biotin-labelled 
secondary and HRP-labelled streptavidin was used. For IFA a biotin-labelled 
secondary antibody followed by fluorescein (FITC)-labelled streptavidin was used to 
label target proteins with fluorescein. All other antibodies used in IFA were either 
directly labelled with Alexa Fluor® 594 or were used in combination with an Alexa 
Fluor® 594-labelled secondary antibody.
2.4.2 Purification of monoclonal antibodies (mAbs) 12CA5, H5 and 58F8
Hybridoma supernatant was passed over a Protein G Sepharose column 
(Amersham Pharmacia) overnight and the column washed in PBS. Bound antibody 
was eluted with 0.2 M glycine-HCI, 0.15 M NaCI, pH 2.7 containing 0.02% NaN3. 
Eluted protein was collected into 1 M Tris-HCI (pH 8.2) to neutralise it. The collected 
antibody was then concentrated by ultrafiltration using an XM50 membrane 
(Amicon) and then run on a PD-10 desalting column according to the manufacturers’ 
instructions (Amersham Pharmacia). 12CA5 was eluted in PBS before addition of 
0.02% sodium azide and storage at 4°C. H5 and 58F8 were eluted in 0.1 M sodium 
bicarbonate buffer (pH 9.0) before conjugation to a fluorophore (see 2.4.3).
2.4.3 Alexa Fluor® 594 labelling of antibodies
Monoclonal antibodies 4G2 (anti-AMA1, [151]), 61.3 (anti-RhopH2, [152]), 
X509 (anti-MSP1, [150]) and H5 (anti-Rap2, [149]) were labelled with Alexa Fluor® 
594 carboxylic acid, succinimidyl ester (Molecular Probes) according to the 
manufacturers instructions. The labelled mAb was separated from unreacted 
labelling reagent by the use of PD-10 desalting columns (Amersham Pharmacia) 
according to the manufacturers’ instructions. The labelled mAb was eluted from the 
column using 300 pL fractions of PBS with 1% BSA. For all the directly labelled 
antibodies fraction 8 was used in IFAs at a dilution of 1/50.
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2.4.4 Western blots
Parasite cultures were centrifuged (3 minutes at 2000 rpm) and the 
supernatant removed. The RBCs were saponin-lysed and the culture centrifuged as 
before to pellet the parasites. The sample was then re-suspended in an equal 
volume of 2 x sodium dodecyl sulphate (SDS) sample buffer (95 mM Tris-HCI, 20% 
glycerol, 4.6% (w/v) SDS and 0.01% Bromophenol blue) and boiled for 5 min. 
Alternatively parasitised RBCs were re-suspended in 4 volumes of Triton X-100 (TX- 
100) buffer (1% TX-100, 50 mM Tris HCI pH 8.0, 2 mM EDTA, 2 mM EGTA) and 
incubated on ice for 30 min. These samples were then centrifuged for 20 min at 
13,000 rpm at 4°C and the TX-100 soluble supernatant re-suspended in an equal 
volume of 2 x SDS sample buffer and boiled. For samples that needed reducing 100 
mM DTT was added to the SDS sample buffer before addition to the sample. 
Samples were electrophoresed on a 10% SDS polyacrylamide gel (SDS-PAGE) and 
transferred onto nitrocellulose membrane (Hybond-C extra, Amersham Life Science) 
electrophoretically overnight. The membranes were then blocked for one hour in 5% 
(w/v) milk powder in PBS with 0.05% Tween 20 (PBST) containing 0.1% sodium 
azide. The membrane was then washed once for 5 minutes in PBST before being 
incubated with the primary antibody for 1 hour. The membrane was then washed 3 
times for 5 minutes each in PBST. The secondary antibody was added and 
incubated with the membrane for 1 hour. For HRP-conjugated antibodies the 
membrane was then washed 3 times (twice for 5 minutes and once for 30 minutes) 
in PBST. 2 mL of Enhanced Chemiluminescent solution (ECL, Pierce) was added 
per membrane and incubated for 5 minutes. The ECL solution was removed and the 
membrane exposed to X-ray film (Biomax MR film, Kodak®) to visualise bound 
antibody. For biotin-conjugated secondary antibodies the membrane was washed 3 
times for 5 minutes in PBST and then incubated for an hour with the HRP- 
conjugated streptavidin. The membrane was then washed 3 times (twice for 5 
minutes and once for 30 minutes) before ECL addition and visualisation as before.
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2.4.5 Immunofluorescence assay (IFA)
Air-dried thin blood films from parasite cultures were fixed by plunging into 
ice-cold acetone for about 30 seconds, dried again, and circles drawn on the sample 
using an Immunopen™ (Calbiochem®). 50 pL of primary antibody (diluted in 1% 
BSA in PBST) was added to each circle with the exception of a negative control 
which comprised 50 pL of 1% BSA in PBST. The slide was incubated in the dark at 
room temperature for 30 minutes before being washed in PBS. If required 50 pL of 
secondary antibody (diluted as before) was added to each circle and the slide 
incubated in the dark at room temperature for 30 min before washing in PBS. For 
IFAs using the biotin-streptavidin system the tertiary FITC-labelled streptavidin 
antibody (diluted in PBST with 1% BSA) was added to each circle and the slide 
incubated in the dark at room temperature for 30 minutes. The slide was washed in 
PBS and dipped in a solution (1 pg ml_'1) of 4,6-diamidino-2-phenylindole (DAPI) in 
PBS to visualise parasite nuclei. The slide was re-washed in PBS and a drop of 
Citifluor (Citifluor Ltd) added to each circle. A coverslip was then placed over the 
slide and the sample viewed using a Zeiss Axioplan 2 imaging system. For dual 
labelling the method used was as above but with the addition of extra antibody steps 
and washes before the DAPI staining.
2.4.6 Affinity purification of parasite-derived PfSUB2HA
Schizonts of the PfSUB2HA line or clones thereof were purified by density 
centrifugation with 70% Percoll as described above [143]. 5 x volume of TX-100 
buffer supplemented with protease inhibitors (1% TX-100 in 50 mM Tris-HCI pH 8.2 
containing 10 pM E-64 and 1 pM pepstatin) was added to the schizont pellet and the 
solution incubated on ice with occasional vortexing for 30 minutes. The solution was 
then centrifuged for 20 min at 13,000 rpm at 4°C. The supernatant was removed 
precleared by being added to 1/10th volume of ‘dry’ Protein G Sepharose™ 4 Fast
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Flow (Amersham Biosciences) and left shaking at 4°C for 30 min. The sample was 
centrifuged through a Spin-X® column (Costar) to remove the Protein G 
Sepharose™ beads. A 1 /50th volume of purified mAb 12CA5 (7.8 mg mL-1) was 
then added to the sample which was then incubated overnight at 4°C. The sample 
was then added to 1/10th volume of ‘dry’ Protein G Sepharose beads and left 
shaking for 30 min at 4°C. The beads were then washed 2 x 1  mL with wash buffer 
1 (50 mM Tris HCI pH 8.2, 0.5% TX-100, 1 mg/mL BSA, 0.5 M NaCI), followed by 4 
x 1 mL washes with wash buffer 2 (50 mM Tris HCI pH 8.2, 0.5% TX-100). Once the 
washes were complete the beads were re-suspended in 2.5 bead volume of 
digestion buffer (0.05% TX-100, 50 mM Tris-HCI pH 8.2, 5 mM CaCI2), divided into 
50 pL aliquots, snap frozen and stored at -70°C. These are referred to as 
PfSUB2HA beads. The process was repeated with extracts of PfSUB2w parasites 
and the beads (referred to as PfSUB2w beads) used as a negative control in 
subsequent manipulations.
As an alternative to working with protein immobilised on beads, attempts 
were made to elute bound protein eluted from the beads by addition of a synthetic 
HA peptide corresponding to the HA3 sequence
(YPYDVPDYAGGGYPYDVPDYAGGGYPYDVPDYA; made in house by P. 
Fletcher). Prior to the wash steps described above, 200 pL of TX-100 buffer, 
containing a final concentration of 1 mg mL'1 HA peptide, was incubated with the 
beads at 4°C with shaking for 30 minutes. The solution was then centrifuged and the 
supernatants removed and analysed for the presence of eluted PfSUB2. The beads 
were then washed as before and analysed.
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2.5 Protein expression and purification methods
2.5.1 Expression of GST-HA3
A starter culture of E. coli cells BL21(DE3) cells transformed with pGEXHA3 
was grown overnight in Terrific broth containing 50 pg mL'1 ampicillin (Amp). The 
following day this culture was diluted 1/50 into fresh Terrific broth with Amp. The 
culture was grown for approximately 2 hrs at 37°C until an optical density (OD) at 
600 nm of 0.6-1.0 had been reached. 1mM isopropyl beta D thiogalactopyranoside 
(IPTG) was then added to the culture and the cells grown for a further 4 hours. Cells 
were then pelleted and stored at -70°C.
2.5.2 Purification of GST-HA3
The bacterial pellet (see 2.5.1) was re-suspended in PBS containing 10 mM 
EDTA, 1 mM PMSF and 10 pM E-64 and run twice through a Cell Disrupter 
(Constant Systems). The lysate was then centrifuged at 18,000 rpm for 20 min at 
4°C and the supernatant removed and clarified by filtration. The filtered supernatant 
was then chromatographed on a Glutathione Sepharose 4B (Amersham Pharmacia) 
column, which was then washed with PBS and eluted with 4 mL fractions of 10 mM 
reduced glutathione in 50 mM Tris-HCI pH 8.2. Eluate fractions were analysed by 
SDS-PAGE and Coomassie staining. Fraction 2 was shown to contain the most 
protein. This fraction was concentrated down to a volume of 1 mL using a Vivaspin 
500 tube (Vivascience) and loaded onto a HiLoad™ 26/60 Superdex™ 200 prep 
grade column (Amersham Pharmacia) equilibrated in PBS, and 5 mL samples 
taken. Fractions 40-54 were analysed and fraction 47 shown to contain GST-HA3 
and what are presumably two breakdown products (as all reacted with 3F10 on 
Western blot). Attempts to further purify the individual species by HPLC failed and 
were abandoned.
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2.5.3 Estimation of the amount of purified PfSUB2
Various dilutions of the purified GST-HA3 (the full-length intact protein 
presumed to be the slowest migrating band of the three seen on SDS PAGE of 
purified samples; see 2.5.2) were electrophoresed under reducing conditions 
alongside known amounts of bovine serum albumin (BSA) (Sigma). Following 
Coomassie staining the intensity of the bands used to estimate the amount of GST- 
HA3 present. Further gels were then run of varying amounts of GST-HA3 alongside 
PfSUB2HA and the intensity of the bands seen by Western blot used to estimate the 
amount of PfSUB2HA present in affinity-purified samples.
2.5.4 Construction of a fluorogenic peptide
The N-acetylated synthetic peptide Ac-CQDMLNISQHQC, designed to mimic 
the MSP1 secondary cleavage site was synthesised by P. Fletcher (NIMR) [76]. 
The peptide was then coupled to tetramethylrhodamine to produce a fluorogenic 
peptide substrate, essentially using the approach described by Blackman et al. 
[153], A 10 mM solution of Ac-CQDMLNISQHQC in dimethylformamide (DMF) was 
added to 50 mM Tris-HCI, pH 8.0 to a final concentration of 1.0 mM. 
Tris(carboxyethyl)phosphine (TCEP), from a freshly prepared 40 mM aqueous 
solution, was added to the peptide solution to a final concentration of 2.0 mM. The 
mixture was incubated at room temperature overnight. The reduced peptide was 
then purified by reversed-phase high-performance liquid chromatography (RP- 
HPLC) on a Vydac 10 mm x 25 cm semipreparative C18 column that was eluted at 1 
mL min'1 with a 10-65% (v/v) gradient of acetonitrile in 0.1% TFA over 60 min. The 
purified reduced peptide was freeze-dried overnight and then taken up in 410 pL 
DMF and added to an equal volume of 6-iodoacetamidotetramethylrhodamine (6- 
IATR) in DMF (21.3 mM). This was added to 3.28 mL degassed 50 mM Tris-HCI pH
7.6 containing 0.2 mM EDTA with continuous stirring. This was left incubating 
overnight in the dark at room temperature. The reaction was then quenched by
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addition of sodium 2-mercaptoethanesulphonate (MESNA) to a final concentration of 
64 mM. After a further 2 hour incubation at room temperature the crude reaction 
mixture was applied to a 1.6 x 65 cm G10 Sephadex column (Amersham 
Pharmacia) equilibrated in 30% (v/v) aqueous acetic acid and eluted at 4 mL h'1 with 
the same solvent. 2 mL fractions were collected and 20 pL aliquots of these were 
analysed on a Vydac 4.6 mm x 25 cm C18 reversed phase column and eluted at 1 
mL min-1 with a 25-35% (v/v) gradient of acetonitrile in 0.1% TFA over 30 min. 
HPLC analysis detected two peaks which were collected manually (in 33 % (v/v) 
acetonitrile plus 0.1% TFA) and analysed by mass spectrometry (performed by P. 
Fletcher). The mass spectrometry showed the two peaks to posses the same mass, 
and to correspond to the peptide labelled with a tetramethylrhodamine group at each 
cysteine side-chain. The peptide peaks were dried and re-suspended in 20 pL 
DMSO, then stored at -20°C. To measure the concentration of the peaks a 1/400 
solution of the peptide in 0.05% NP-40 was made and the absorbance measured 
using an Unicam UV1 spectrophotometer from 300-650 nm. To confirm the labelled 
peptide could be cleaved 1 mg mL'1 Pronase (Roche) was added to the cuvette and 
the absorbance re-measured. The labelled peptide was named MSP1rh0-
2.5. 5 Detection of PfSUB2 activity using a fluorogenic substrate
The fluorogenic substrate described above (MSP1rh0) was diluted to 0.2 pM 
in digestion buffer (50 mM Tris HCI pH 8.2, 12 mM CaCI2, 0.05% NP-40). 100 pL of 
this was added to wells of a white microtitre plate (Scientific Lab Supplies). Wells 
contained either 50 pL of PfSUB2w beads, 50 pL of PfSUB2HA beads (see 2.4.6), 
50 pi of chymotrypsin (Sigma, at a final concentration of 1 pM) or 50 pL of buffer 
(0.05% TX-100, 50 mM Tris-HCI pH 8.2, 5 mM CaCI2) added. The level of 
fluorescence of each well was measured using a fluorescence spectrophotometer 
(Varian) with measurements taken every 5 min over 400 min.
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2.5.6 Detection of PfSUB2 activity -  recombinant PfSUB2 ectodomain
The pfsub2synth gene encoding the putative PfSUB2 ectodomain was 
expressed in Pichia pastoris where it was found to be unfolded and inactive (M. 
Blackman and S. Yeoh, unpublished). 4 pL of the unfolded PfSUB2 ectodomain was 
added to 100 pL of PfSUB2HA or PfSUB2w beads (see 2.4.6) in an Eppendorf. The 
beads were then immediately pelleted and 5 pL of the supernatant removed, added 
to SDS sample buffer and boiled for 5 min. The beads were then re-suspended and 
incubated at 37°C. Further samples of the supernatant were taken after 30, 90, 150, 
210, 270, 310 and 340 min. Western blots were then performed on the samples (see 
2.4.4) to detect cleavage of the PfSUB2 ectodomain into smaller fragments.
2.5.7 Detection of PfSUB2 activity -  MSP1CiiP peptide
Synthetic peptide MSP1CiiP (LQGMLNISQH) was designed to mimic the 
MSP1 secondary cleavage site and was synthesised by P. Fletcher (NIMR). The 
peptide was suspended in DMSO at 40 mg mL'1. 5 pL of the stock peptide was 
added to 100 pL of PfSUB2HA or PfSUB2w beads (see 2.4.6) and the mixture 
immediately spun down and a 20 pL sample of the supernatant taken. The mixture 
was then re-suspended and incubated at 37°C for 2.5 hr. After this time a 20 pL 
sample of the supernatant was taken as before. The samples were analysed for 
cleavage of the peptide on a Vydac 4.6 mm x 25 cm C18 reversed phase column, 
eluted at 1 mL min'1 with a 10-40% (v/v) gradient of acetonitrile in 0.1% TFA over 15 
min.
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Chapter 3: Epitope tagging and localisation of PfSUB2 within the 
parasite
Introduction
PfSUB2 is found as a very small proportion of the total protein content of the 
merozoite and as a result has proved difficult to detect using standard 
immunochemical approaches such as IFA [114]. This means there are still many 
unanswered questions concerning the trafficking and sub-cellular location of the 
protease. PfSUB2 has previously been localised to the dense granules of the 
schizont which, alongside the micronemes and rhoptries, are one of three sets of 
secretory organelles found within the apical domain of the merozoite [116]. 
However, this location is inconsistent with the belief that PfSUB2 is responsible for 
shedding of AMA1 and MSP1 as the contents of apicomplexan dense granules are 
thought to be secreted predominantly after the parasite has invaded the RBC [10, 
11]. The cleavage of both AMA1 and MSP1 from the parasite surface occurs prior to 
or during parasite entry into the RBC and, as described in the Introduction, may be 
essential for invasion to proceed [74, 154].
Advances in the transfection technology of P. falciparum have allowed the 
integration of sequences into the parasite genome [123, 124]. This has enabled the 
fusion of the reporter protein GFP to parasite proteins to allow detailed study of 
trafficking [155]. In T. gondii, sequence encoding short peptide epitope tags such as 
c-myc and triple haemagglutinin tags (HA3) are commonly integrated onto proteins 
to aid detection by immunochemical methods [156-159], The P. berghei SUB2 
(PbSUB2) has previously been successfully tagged at the C-terminus with an 
TrimycDuoXpress (TmDX) epitope tag [115]. In anticipation that an epitope tagged 
form of PfSUB2 might prove easier to detect within the parasite and allow detailed
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investigation of the sub-cellular location of the protein, attempts were made to 
modify the C-terminus of the protein by the addition of an epitope tag.
3.1 Modification of PfSUB2 to integrate 3 copies of the HA tag
There are a number of anti-HA mAbs available for sensitive detection of 
proteins modified with this tag [157-159]. The HA3 tag therefore appeared suitable 
for the epitope tagging of PfSUB2. However, it was considered important to ensure 
that the tag was placed within PfSUB2 such that it did not interfere with the function 
of the protein and have detrimental effects on the parasite. The C-terminus of SUB2 
is not highly conserved amongst Plasmodium species suggesting that the precise 
sequence of this region of the protease is not functionally critical (Figure 3.1). The 
successful C-terminus tagging of PbSUB2 referred to above also suggested that this 
region could be modified without detrimental effects [115]. It was therefore decided 
to attempt to incorporate an HA3 tag within the C-terminus of the protein.
Two plasmids were designed for this work; pHH1-T996HA3 and pHH1- 
T996w. pHH1-T996HA3 was designed to modify the pfsub2 gene by the integration 
of sequence coding for a HA3 tag onto the 3' end of pfsub2 gene [160]. The 
construct contains approximately 1 kb of targeting sequence derived from the 3' end 
of the pfsub2 gene fused in frame with sequence encoding the HA3 tags and 
followed by a stop codon. This was placed upstream of the P. berghei hsp86 3' UTR 
sequence to ensure correct transcription termination and polyadenylation of the 
targeted gene. pHH1-T996w was designed as a control vector to simply ensure that 
integration could be achieved at the pfsub2 locus. The construct contained the same 
pfsub2 targeting sequence and stop codon but lacked the sequence encoding the 
HA3 tag. Integration of pHH1-T996w was therefore predicted to resurrect the wild- 
type pfsub2 coding sequence but result in the replacement of the pfsub2 3’UTR (see 
Figure 3.2).
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Figure 3.1 Multiple alignment of predicted 3' end of SUB2 sequences from P. 
falciparum, P. knowlesi, P. vivax, P. chabaudi, P. berghei and P. yoelii
The predicted cytoplasmic domain, which exhibits low conservation across SUB2 
orthologues, is highlighted in yellow. : and . denote conserved or similar residues, * 
denotes identical residues. This alignment was produced by S. Yeoh using the 
ClustalX program.
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Falciparum DCYFVKFNLEKGKKKHIPWFSAYKKGVYETDIVIAIIPIDGKSKIYGEIHIPIKIVTDVNIPNFQESPRRGKNYTIDSNEAQHDEVLSYICENALYNLYEYDSHYLLASVILFFLALLS 1152
Knowles i DCHFVKFNLESGKKKHIPWFSAYKKGIYETDIVIAVISTEENSNVYGEILIPIRIVTDPKVDNFKESPRTGKKMIIDENEASHDEVLSYICENALYNLYEMDSNFLVTSLVLFFVAFIL 1255
Vivax DCHFVKFNLEGGKEKHIPWFSAYKKGIYETDIVIAVIPTEENSKVYGEILIPIRIVTDPKAENFKESPRNGKKMIIDENEASHDEVLSYICENALYNLYEMDSNFLVMSLVLFFVAFIL 1273
Chabaudi DCHFAKFYLNKDKQKSIPWFSAYKDGMYETDIIIGIKPVDTNSKEYGEIVIPIKILTNPNLKDFSASPRIGKKIHIDANESIDDDILSYICENALYNLYEHDNTFLISSLILFFLGIIL 1065
Berghei DCHFAKFYLNENKQKSVPIVFSAYKDGVYESDIIIGIQPEDANSKEYGEIVIPIKILTNPKLKDFSLSPRVGKKIRIDENES-NDDILSYICENALYNLYEHDNSFLISSLILFFIGIIL 1101
Yoelii DCHFAKFYLNKDQQKNIPWFSAYKDGMYESDIIIGIQPEDSNSKEYGEIVIPIKILTNPKLKNFNLSPRVGKKIHIDANES-NDDILSYICENALYNLYEHDNSFLISSLILFFIGIIL 1096
* * * it .
Falciparum IFVGMIYMKSRKHSDKKCSKNLMKSNYIPEMDDGMEETQQLQQERRQYFRELFGENLEKNYDQHFVQDFGQDFRQDFKLGSTPDLKQYSDIDLQNKIQQPERKTVKIIINNFEDRKKETK 1272
Knowlesi MWGTI1FIKRKRHSKYCDDEDHYHNILRSSVLEQHHILGNTTNQQLEVAKRN--HAEKMRHSVRFSLLMGKQNACLFKERASQRLNF---------------------------------  1341
Vivax IWGTIVFIKRKRHSKYCDDEDHDHNMMRNSVFEHHHILSGNTNHALKMAKRSHVEKIRNSVRFSWMGTQNNCVFKERAPKKLDFENYGDLIKKPLLKSPPKKFVNHRAEQNWGHEAEK 1393
Chabaudi IVIVSIVFFFKHHQNKHRDYEQYMNQKMADRAYD1KYNFNDVGPGGIKKSCSLDGNINNHRDTQRFTIVQNEDNMYVLKKKSSIKSKYE ARNELTKR-PLIKRPIVKHKDTNVNFNN 1181
Berghei IVLASIVFFLKHHQSKQRDGEKYMHQKMVDRTYNVKYNFKDSGTDGIKRINTLDDNINNHRNTQRFTIVQNEDNMYVLKKKSSIQAKYE PRNELVKR-SLVKRPIVKHADINVNFSN 1217
Yoelii IALASIVFFLKHHQSKQRDAEKYMHQKMVDRAHGIKYNFKDAGADGIKRINTMDDNINNHRNTQRFTIVQNEDNMYVLKKKSSIQAKYE PRNELVKR-PLVKRPIVKHADINVNFKN 1212
Falciparum RRLLKGLNYDGENAKKHDFTNESISNSRKNFKFSNNTEMKKNTIKSEDVKIASDDNVNKAMNQLDDMFMK 1342
Knowlesi  1341
Vivax KDPRD-----------------------------------------------------------   1398
chabaudi MEALYESHGNLSE------------------------------------------------------------  1194
Berghei   1230
Yoelii IDELYEPQNNSPE--------------------------------------------------------------1225
Figure 3.2: Constructs designed for modification of the pfsub2 locus and 
schematic representation of single crossover integration of pHH1-T996HA3.
Integration reconstitutes a full-length pfsub2 gene with a triple HA tag at the 3' end. 
Correct transcription termination and polyadenylation of this gene is regulated by the 
presence of the P. berghei dihydrofolate reductase 3' UTR (Pb DT 3' UTR). hdhfr, 
human dihydrofolate reductase, conferring resistance to the antifolate WR99210. 
The Sea I sites (S) and sequence used for a probe (P) in Southern blot analysis are 
indicated.
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PHH1-T996HA3
T
hdhfr cassette S
pfsub2 3' 3 X HA Pb DT 3' UTR
pHH1-T996w
hdhfr cassette s
pfsub2 3' Pb DT 3'UTR
if
4.4 kb
D10 parasites were transfected with both pHH1-T996HA3 and pHH1-T996w 
and parasites detected in thin films after 24 days of selection with the antifolate 
WR99210. Plasmid was rescued from both lines by transformation into E. coli and 
three clones of each selected for restriction digest analysis alongside the ‘original’ 
plasmids used in the initial transfections. No rearrangements of the plasmids were 
detected in any of the clones selected (data not shown). The parasites were then 
subjected to two rounds of drug cycling before analysis by Southern blot.
Southern blots were performed, using 500 bp of the 3' end of the pfsub2 
gene as a probe, on transfected parasite DNA alongside DNAfrom the parental D10 
line and the plasmid used in the initial transfection (see Figure 3.2 and Figure 3.3). 
The probe was selected to hybridise to the endogenous pfsub2 as well as the 
pfsub2 sequence contained in the transfection plasmids. The presence of bands of
5.8 kb and 4.4 kb in the transfected parasite lanes confirmed integration had 
occurred. The parasite line containing the tagged PfSUB2 was named PfSUB2HA 
and the control parasite line with the 3' replacement but no tag was named 
PfSUB2w. The 3.4 kb band seen in the D10 lane, derived from the endogenous 
pfsub2 locus, was absent in both the PfSUB2HA and PfSUB2w lines. This 
suggested that parasites still carrying the plasmid as an episome were absent from 
these lines and that in all cases the plasmid had integrated into the pfsub2 locus. P. 
falciparum carries bacterial plasmids as trimeric concatamers with multiple 
concatamers per parasite [126]. This often leads to the integration of multiple copies 
of the plasmid in single cross-over events. The presence of a 7 kb band, migrating 
at the same size as the linearised ‘input’ plasmid, in Southern blot analyses of both 
the PfSUB2HA and PfSUB2w lines showed that multiple integration events had 
occurred. However as neither plasmid contains a functional pfsub2 cassette the 
integration of multiple copies of the plasmid should not result in additional copies of 
the complete gene and is therefore considered unlikely to result in increased 
PfSUB2 levels. Importantly, no additional DNA species were detected in the
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Figure 3.3: Southern blot analysis of PfSUB2HA and PfSUB2w genomic DNA 
shows targeted integration.
Genomic DNA was prepared from parasite lines PfSUB2HA, PfSUB2w and 
untransfected (wild type) D10 parasites. DNA was digested with Sea I, alongside the 
input plasmid pHH1-T996HA3, and transferred to nylon membranes. Blots were 
probed with a 500 bp fragment (see Fig. 3.2) corresponding to a region within the 3' 
end of the pfsub2 gene. The 4.4 kb and 5.8 kb bands correspond to the fragments 
produced upon Sea I digestion of genomic DNA if pHH1-T996HA3 or pHH1-T996w 
have integrated (see Figure 3.2).
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Southern blots, indicating that the plasmids did not integrate at any other 
sites within the parasite genome.
The PfSUB2HA and PfSUB2w lines were then cloned by limiting dilution. 
This produced PfSUB2HA clones 2D and 10E and PfSUB2w clones D8 and F7. 
Southern blots, using the same probe as before, were performed to confirm that 
integration had occurred in the clones selected (see Figure 3.4).
3.2 Detection of the tagged PfSUB2
The previous work had shown that sequence encoding a HA3 tag had 
integrated at the pfsub2 locus in the PfSUB2HA line. The next step was to 
determine whether the tagged protein could be detected by standard 
immunochemical methods such as Western blot and IFA. Previous pulse chase data 
has shown that PfSUB2 is expressed as a full length protein of 160 kDa which is 
converted to a 74 kDa and finally a 72 kDa form [114]. This processing is typical of 
subtilisin-like serine proteases where the inactive full-length protein (the zymogen) is 
activated by the autocatalytic removal of the propeptide [99, 100, 161].
Western blots were performed using mAbs 3F10 and H5, a rhoptry protein, 
(anti-Rap2) to probe TX-100 lysates of the PfSUB2HA clones in parallel with those 
of PfSUB2w clones (Figure. 3.5). The blot probed with the anti-Rap2 antibody was 
used to assess the loading of the gels and showed an equivalent amount of sample 
loaded in each lane. The 3F10 probed blot revealed a number of bands in the 
PfSUB2HA lanes, migrating with apparent masses of 150 kDa, 72 kDa, 55 kDa, and 
36 kDa. There were no bands present in the PfSUB2w lanes, indicating that the 
bands detected in the PfSUB2HA lanes possess the HA3 tag and were not artefacts 
resulting from non-specific binding of 3F10. The 150 kDa and 72 kDa species seen 
in the PfSUB2HA lane are likely to correspond to the full length PfSUB2 and 
processed ‘active’ PfSUB2 respectively as the sizes are the same as the species 
seen in previous work [114]. The detection of a processed form of PfSUB2
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Figure 3.4: Southern blot analysis of PfSUB2HA and PfSUB2w transgenic 
clones shows targeted integration at the pfsub2 locus.
Genomic DNA was prepared from PfSUB2HA clones 2D, 10E and PfSUB2w clones 
D8 and F7 and untransfected (wild type) D10 parasites. The DNA was digested with 
Sea I. was and electrophoresed alongside Sea I digested input plasmid pHH1- 
T996HA3. All samples were then transferred to nylon membranes. Blots were 
probed with a 500 bp fragment (see Figure 3.2) corresponding to a region within the 
3' end of the pfsub2 gene. The 4.4 kb and 5.8 kb bands correspond to the fragments 
produced upon Sea I digestion of genomic DNA if pHH1-T996HA3 or pHH1-T996w 
have integrated (see Figure 3.2).
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Figure 3.5 PfSUB2 can be detected by Western blot
Western blot of schizont lysates from parasite clones PfSUB2HA, clones 2D and 
10E, and PfSUB2w, clones D8 and F7. The blots were probed with the anti-HA mAb 
3F10 or the anti-Rap2 mAb H5, used as a loading control. The identities of the 
authentic PfSUB2 species are indicated. The presumed PfSUB2 breakdown 
products are marked by the *.
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suggested that the modified protease retained autocatalytic processing activity. In 
order for a PfSUB2 fragment to contain the catalytic triad, necessary for protease 
activity, as well as the transmembrane domain and C-terminal HA3 tag necessary 
for detection with 3F10, it would be predicted to have a mass of at least 67 kDa. 
This means that all fragments detected with a molecular mass below 67 kDa and 
detected by 3F10 are unlikely to contain a functional catalytic domain. As the two 
further species detected in the PfSUB2HA lanes of the 3F10 blot migrate with 
apparent masses of 55 kDa and 36 kDa they are unlikely to correspond to active 
protease and were therefore presumed to be breakdown products.
IFAs were then performed, using both 3F10 and a second anti-HA mAb 
called 12CA5, on the PfSUB2HA and PfSUB2w parasite lines as well as the 
parental D10 line to confirm that the tag could be detected by IFA (Figure 3.6). No 
fluorescence signal was detected with the PfSUB2w or parental D10 line. In 
contrast, the PfSUB2HA IFAs showed a punctate pattern in schizonts, distant from 
the nucleus, with what appeared to be a predominantly apical location seen in 
individual merozoites. A signal could also be detected in free merozoites of the 
PfSUB2HA line with what appeared to be accumulation of the protein at the apical 
end of the parasite. The IFAs were repeated with the PfSUB2HA and PfSUB2w 
clones and the results from the un-cloned lines confirmed (data not shown).
Theses results indicated that the HA3 tag allows specific detection of 
PfSUB2 within the PfSUB2HA line by both Western blot and IFA. This means that 
studies into the sub-cellular location of PfSUB2 could now be undertaken as well as 
investigation of the time of expression of the protein.
3.3 Tagging PfSUB2 does not affect parasite growth
Previous attempts to knock-out SUB2 within both P. falciparum and P. 
berghei have been unsuccessful suggesting an essential role for the protein in the 
RBC cycle [115, 117]. This important role for PfSUB2 means that any alterations to
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Figure 3.6 Detection of epitope-tagged PfSUB2 by IFA using anti-HA 
monoclonal antibodies
IFA images of schizonts and free merozoites from uncloned parasite lines 
PfSUB2HA and PfSUB2w. Samples were probed with either mAb 3F10 or 12CA5 
(both of which are specific for HA). Parasite nuclei are stained throughout with DAPI 
(blue). The anti-HA mAb reacts with the PfSUB2HA parasite line but not the 
PfSUB2w parasite line. Magnification 100x.
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the function of the protein may prove detrimental to the growth of the parasite. The 
HA3 tag was placed at the C-terminus of PfSUB2 in a bid to prevent the tag 
affecting the activity of the protease and affecting the growth of the parasite. Certain 
Plasmodium 3' UTR elements have been shown to enhance expression of parasite 
proteins, and it was therefore considered a possibility that the replacement of the 
endogenous pfsub2 3'UTR with the P. berghei hsp86 3' UTR might affect expression 
of PfSUB2 and as a result affect parasite growth [162]. The next set of experiments 
were therefore designed to explore this possibility.
Multiple growth assays were performed on the PfSUB2HA and PfSUB2w 
clones alongside the parental D10 line in an attempt to detect any growth defect or 
enhancement caused by either the addition of a HA3 tag or replacement of the 
pfsub2 3' UTR. Tightly synchronised cultures with identical parasitemias were 
cultured over five days and every 24 hours thin films were made, stained with 
Giemsa and the parasitemia assessed by microscopic examination.
The PfSUB2HA and PfSUB2w clones grew at the same rate as the parental 
D10 line in all the assays (data not shown). It was concluded that neither the 
addition of a HA3 tag at the C-terminal of PfSUB2 nor the replacement of the 3' UTR 
affected growth of the parasite. This implied that the modified PfSUB2 was 
functioning as in wild type parasites as inhibition of its activity is likely to be 
deleterious to growth of the parasite.
3.4 PfSUB2 is expressed during schizogony
The previous work had shown that the addition of a HA3 tag to the C- 
terminus of PfSUB2 greatly facilitated detection of the protein by IFA. Previous work 
has shown that PfSUB2 is maximally expressed 40-48 hour post invasion, 
corresponding to the latter stages of schizogony and merozoite release from the 
RBC [19, 114, 116]. The microarray data of Le Roch et al. places PfSUB2 in a 
cluster of genes that are all highly transcribed at the schizont stage and many of
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which code for proteins thought to have a role in cell invasion [19]. In order to 
confirm these results by IFA a time course was performed to pinpoint the time of 
F>fSUB2 expression.
Thin films of a culture tightly synchronised parasites were made every 6-8 
hours over the period of an entire blood-stage cycle, and then analysed by IFA using 
the anti-HA mAb 3F10 (see Figure 3.7). A signal could first be detected in early ring 
stage parasites (2 hours post invasion) and appeared ‘ring’ shaped which may 
indicate a parasite plasma membrane location for the protein. The signal had 
disappeared by the next slide taken at 8 hours post invasion and was not detected 
in the trophozoite stage slides. PfSUB2 was next detected at 37 hours post invasion 
at the early schizont stage where the 3F10 signal appeared diffuse. In the next slide, 
at 44 hours post invasion, the signal was apical and typical of that seen with 
previous late schizont smears.
These experiments indicate that F>fSUB2 appears in the schizont stage and 
is present throughout invasion as well as during the early ring stage. This is 
consistent with the previous microarray data, and the timing of expression of 
PfSUB2 is consistent with it playing a role in invasion [19]. The results also imply 
that neither the addition of a HA3 tag to the C-terminus nor the replacement of the 
pfsub2 3'UTR altered the time of expression of PfSUB2.
3.5 Localisation of PfSUB2 within the blood-stage parasite
PfSUB2 had previously been detected by IFA in the schizont, free merozoite 
and early ring stages of the P. falciparum RBC cycle (see 3.6 and 3.7). The protein 
appeared to concentrate at the apical end of the merozoite, both in the segmented 
schizont and free merozoite, before re-localisation across the entire surface of the 
parasite in the ring stage parasites. Further work focused on the use of mAbs 
against other parasite proteins to perform a more detailed study of the location of 
the protease within the parasite.
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Figure 3.7 Time course experiment showing that PfSUB2 is expressed during 
schizogony and detectable immediately following erythrocyte invasion
Giemsa stained or IFA images of intraerythrocytic stages of the transgenic 
PfSUB2HA parasite line at various points during the asexual blood-stage cycle. For 
IFA, samples were probed with the anti-HA mAb 3F10 and parasite nuclei are 
stained with DAPI. Time (in hours) since invasion is indicated below each pair of 
images. Magnification 100x.
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Micronemes and rhoptries are both found at the apical prominence of the 
merozoite while dense granules are found within the apical cytoplasm [7], A number 
of proteins have been localised to the Plasmodium micronemes or the rhoptries, 
including RhopH2, a rhoptry protein, and AMA1, a microneme component [58, 59, 
152]. MSP1 is found on the merozoite surface [68]. Antibodies against RhopH2, 
AMA1 and MSP1 were used in dual labelling of PfSUB2HA clone 2D schizonts with 
3F10 (anti-HA), and the results of these analyses are shown in Figure 3.8. The anti- 
MSP1 signal did not overlap with the 3F10 signal indicating that there was no 
PfSUB2 present on the parasite surface. The anti-RhopH2 (61.3) signal was 
adjacent to the 3F10 signal at the apical end of the merozoites but again merging 
the signals demonstrated no co-localisation, indicating that PfSUB2 was not present 
in the rhoptries. However the anti-HA and anti-AMA1 (4G2) signals completely 
overlapped suggesting that in mature schizonts PfSUB2 accumulates in the 
micronemes of the parasite. This differs from the dense granule location previously 
described but is consistent with the hypothesis that PfSUB2 cleaves MSP1 and 
AMA1 from the merozoite surface prior to parasite entry into the RBC [116], since 
micronemes, unlike dense granules, release their contents at or during invasion and 
the cleavage of MSP1 and AMA1 occurs prior to RBC entry [10, 11].
The location of PfSUB2 in early ring stage parasites was then studied. 
MSP119 is the membrane bound MSP1 fragment that remains on the parasite 
surface after the rest of the protein is cleaved from the surface and is carried into the 
RBC on the parasite surface [74], IFAs were performed on ring stage parasites with 
1E1, an anti- MSP1i9 mAb, and 3F10 (Figure 3.9). The signal from the two mAbs 
completely co-localised, confirming a surface location for PfSUB2 in the ring stage 
parasites. AMA1 and MSP1 are both cleaved from the parasite surface and 
therefore the protease responsible is expected to be located here. The surface 
location of PfSUB2 in ring stage parasites indicates that during invasion PfSUB2
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Figure 3.8 PfSUB2 localises to the micronemes of the schizont
IFA images of schizonts of PfSUB2HA clone 2D dual-labelled with mAb 3F10 (anti- 
HA) and either mAb X509 (anti-MSP1), mAb 61.3 (anti-RhopH2), or mAb 4G2 (anti- 
AMA1). Parasite nuclei are stained throughout with DAPI (blue). Magnification 100x.
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Figure 3.9 PfSUB2 remains at the plasma membrane of the newly invaded 
parasite
Ring stages of PfSUB2HA clone 2D (<2 h post-invasion) probed with anti-MSP1i9 
mAb 1E1 and anti-HA mAb 3F10. Parasite nuclei are stained throughout with DAPI 
(blue). Magnification 100x.
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moves onto the parasite surface and is therefore in a position to cleave AMA1 and 
MSP1.
The location of PfSUB2 on free merozoites was then analysed (Figure 3.10). 
Previous IFAs of free merozoites had shown the 3F10 signal as a tight dot at the 
end of the parasite with a faint signal detected around the merozoite surface and it 
had been presumed that this corresponded to protease still resident in the 
micronemes (Figure 3.6). However on closer inspection some intriguing results were 
obtained. IFAs were performed on the free merozoites with both 3F10 and 61.3 
(anti-RhopH2) (Figure 3.10). Remarkably, the 3F10 signal was found to localise at 
the opposite end of the parasite to the RhopH2 signal indicating that one of the 
proteins had translocated over the parasite surface to the posterior end of the 
parasite. A mAb against a second rhoptry protein Rap2 was then used alongside 
3F10 to confirm this unexpected result and once again the rhoptry protein was at the 
opposite end of the parasite to the PfSUB2. However it remained to be determined 
whether it was PfSUB2 or the rhoptry proteins that were translocated to the posterior 
of the cell. The mAb 58F8 recognises the N-terminal of AMA1 which is cleaved from 
the rest of the protein within the micronemes of the parasite [56]. The mAb therefore 
only reacts with the intact protein found in the micronemes and can be used to 
determine the apical end of the parasite. IFAs of PfSUB2HA free merozoites with 
both 58F8 and 61.3 showed the two signals adjacent to each other. This implies that 
the RhopH2 was still located in the rhoptries at the apical end of the free merozoites, 
in turn indicating that it was the PfSUB2 that had re-localised to the posterior of the 
parasite. Further study of the PfSUB2HA merozoites on these slides revealed that in 
a very small proportion of cases (< 5%) the PfSUB2 signal appeared as twin foci on 
either side of the merozoite implying the PfSUB2 was circling the parasite on its way 
to the posterior.
These experiments used an HA3 tag to enable study of the location of 
PfSUB2 within the parasite. PfSUB2 was shown to accumulate in the micronemes of
104
Figure 3.10 PfSUB2 translocates to the posterior of the merozoite upon 
release from the schizont
IFA images of free merozoites of the PfSUB2HA clone labelled with mAb 3F10 (anti- 
HA) and either mAb 4G2 (anti-AMA1), mAb X509 (anti-MSP1) or mAb 61.3 (anti- 
RhopH2). Nuclei are stained throughout with DAPI (blue). The PfSUB2 signal in (A) 
is located at the posterior of the cell. The PfSUB2 signal in (B) appears to form twin 
foci on either side of the merozoite, consistent with it representing PfSUB2 
‘captured’ en route to the merozoite posterior. Magnification 100x.
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the schizont until merozoite release upon which the protein was observed to 
translocate over the parasite surface to the posterior of the parasite. During or after 
invasion the protein then re-localises over the membrane of ring stage parasite 
surface.
3.6 Translocation of PfSUB2 is dependent on the actinomyosin motor
Work in the previous section had shown that PfSUB2 moves onto the 
merozoite surface upon schizont rupture and is subsequently capped to the 
posterior end of the parasite. The T. gondii rhomboid protease TgROM5 localises to 
the posterior of the tachyzoite and is believed to be involved in cleaving MIC2 from 
the parasite surface [92]. MIC2, expressed in T. gondii tachyzoites, and TRAP, 
expressed in Plasmodium sporozoites are both members of the TRAP family of 
proteins and also exhibit a similar pattern of movement to PfSUB2. These proteins 
are both released from micronemes and capped to the posterior of the parasite and 
both have been shown to be involved in host cell invasion [10, 27-29, 34, 35], The 
TRAP and MIC2 C-termini bind to aldolase and this in turn mediates an interaction 
with actin [28, 39, 40], The movement of MIC2 has been also shown to be 
dependent on myosin through the use of inhibitors of this protein [15]. The similarity 
of the capping on the parasite surface of TRAP and MIC2 with PfSUB2 suggested a 
role for an actin-myosin motor in the movement of this protein. The next set of 
experiments attempted to explore this possibility.
PfSUB2HA schizonts were cultured and allowed to release merozoites in 
the presence of various compounds known to inhibit actin polymerisation or myosin- 
based processes, and the PfSUB2 location on the free merozoites analysed by IFA 
(see Figure 3.11). The results were also summarised in Table 3.1.
The first compound tested was colchicine which destabilises microtubules 
and has been shown to inhibit merozoite invasion of RBC [144]. The P. falciparum 
merozoite has several microtubules which are responsible for the translocation of
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Figure 3.11 PfSUB2 translocation to the posterior of the cell is dependent on 
actin polymerisation
IFA images of free PfSUB2HA merozoites stained with mAb 3F10 (anti-HA) and 
mAb 61.3 (anti-RhopH2). Parasite nuclei are stained throughout with DAPI (blue). 
Merozoites were released from schizonts in the presence of 1% (v/v) DMSO only, 5 
pM latrunculin A (Latrunc) or 4 pM cytochalasin D (CytD). Latrunculin but not 
cytochalasin D appeared to interfere with posterior accumulation of PfSUB2. 
Magnification 100x.
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Chemical Mode of action Inhibition of PfSUB2 
movement (%)
BAPTA-AM 
(25 pM)
Inhibition 
of microneme 
secretion
40
BDM 
(5 mM)
Inhibitor of myosin 
ATPase
50
Colchicine 
(1 mM)
Inhibition of 
microtubule 
polymerisation
0
Cytochalasin B 
(4 pM)
Inhibition of actin 
polymerisation
0
Cytochalasin D 
(4 pM)
Inhibition of actin 
polymerisation
0
EGTA 
(10 mM)
Calcium chelator 0
JAS 
(5 pM)
Stabilisation of actin 
polymerisation
0
Latrunculin A 
(5 pM)
Inhibition of actin 
polymerisation
70-90
Staurosporine 
(5 pM)
Inhibition of 
microneme 
secretion
N/A
Table 3.1 Effect of various chemicals on the translocation of PfSUB2 to the 
posterior of the merozoite
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micronemes to the apical end of the parasite [58], Merozoites released in the 
presence of colchicine displayed no inhibition of PfSUB2 movement when compared 
to the DMSO control (data not shown). It was concluded that microtubules do not 
play a role in the capping of merozoite surface PfSUB2. Since PfSUB2 is a 
microneme protein, compounds that inhibit the release of the contents of these 
organelles, such as staurosporine and BAPTA-AM, would be expected to restrict the 
movement of PfSUB2 on the merozoite surface by preventing secretion of the 
protein [15, 34], Unfortunately schizonts cultured in the presence of staurosporine 
were unable to rupture and appeared phenotypically abnormal (data not shown). 
This was unexpected as a previous report with P. knowlesi merozoites reported no 
toxicity at concentrations of staurosporine higher than those used in these 
experiments [163], However BAPTA-AM did not inhibit the rupture of schizonts and 
release of merozoites and therefore the effects of this compound could be studied. 
In free merozoites released in the presence of BAPTA-AM only 60% of merozoites 
showed PfSUB2 at the posterior of the cell in comparison with the DMSO control. 
The PfSUB2, instead of appearing as a tight signal at the posterior of the parasite, 
was detected in many of the parasites as a diffuse signal spread over the parasite 
surface or else still adjacent to the rhoptries. The BAPTA-AM did not effect AMA1 
localisation over the parasite surface, as determined by IFAs with the anti-AMA1 
mAb 4G2. This suggests that the BAPTA-AM may be inhibiting PfSUB2 capping by 
a mechanism other than inhibition of microneme release as this would also be 
expected to prevent relocalisation of AMA1 over the parasite surface.
EGTA is a calcium chelator that inhibits merozoite invasion of RBC and the 
release of AMA1 and MSP1 from the surface of the RBC [60, 75, 145], Subtilisin-like 
serine proteases often require calcium for stability, e.g. PfSUBI has been shown to 
require calcium to cleave its substrates [112, 164], PfSUB2 may also be a calcium 
dependent protease. IFA analysis of merozoites released into EGTA indicated that 
this compound had no effect on PfSUB2 movement (data not shown). If PfSUB2 is a
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calcium dependent serine protease, as the inhibition of MSP1 and AMA1 processing 
by EGTA would imply, then it is possible that the protease does not need to be 
active to be trafficked to the posterior of the cell [60].
The next compounds tested were cytochalasin B and D and latrunculin A, 
both of which inhibit actin polymerisation although through different mechanisms. 
Cytochalasins bind to the barbed end of F-actin filaments and block all association 
and dissociation reactions at the end while latrunculins bind G- actin noncovalently 
and prevent actin assembly [165, 166]. Interestingly, merozoites released in the 
presence of latrunculin A showed clear inhibition of PfSUB2 capping. In these 
parasites the PfSUB2 had moved to the posterior of the parasite in only 10-30% of 
parasites as compared to the DMSO control parasites. The PfSUB2 pattern on the 
majority of the free merozoites appeared as a diffuse signal over the parasite 
surface or adjacent to the RhopH2 signal in the rhoptries. This suggested that the 
capping of PfSUB2 is actin dependent. IFA analysis of these merozoites using the 
anti-AMA1 mAb 4G2 showed the AMA1 in a circumferential pattern over the parasite 
surface as with the control merozoites, suggesting latrunculin does not inhibit 
microneme release per se. Cytochalasin B and D both inhibit merozoite invasion of 
RBCs, an observation long known to indicate that Plasmodium actin is susceptible 
to these compounds [12, 60]. However, neither of these drugs had any affect on the 
capping of PfSUB2. The protein was detected as a tight dot at the posterior of the 
parasite, not discernibly different from control parasites released in the presence of 
DMSO solvent only. Although this result was unexpected there are numerous 
accounts of differences in the effects of latrunculin and cytochalasin, presumably 
due to their differing modes of action on actin polymerisation [167-169]. P. 
falciparum has unusually short actin filaments [23], Latrunculin which prevents the 
assembly of actin filaments rather than the cytochalasin which binds to the filaments 
and prevents lengthening may therefore have a greater effect. Cytochalasins can
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inhibit invasion of the cell and this may reflect a need for longer filaments for 
invasion as opposed to shorter filaments capable of capping PfSUB2.
Jasplakinolide is a compound which stabilises actin filaments and in T. gondii 
increases the rate of gliding motility while decreasing the rate of invasion [21]. This 
compound was found to have no effect on the movement of PfSUB2 when 
merozoites were released in its presence. As actin polymerisation appears 
necessary for capping of PfSUB2 it is not surprising that compounds which stabilise 
actin in this state do not inhibit the movement. It is possible that jasplakinolide might 
increase the rate of PfSUB2 capping though at present it would be technically very 
difficult to study this.
BDM inhibits the ATPase activity of myosin and has previously been shown 
to inhibit invasion in many Apicomplexa [13, 15, 16, 170]. The affect of this 
compound on capping of PfSUB2 was therefore tested. In initial experiments 
PfSUB2HA merozoites were released in the presence of 50 mM BDM, but this 
proved to be toxic to the parasite. IFAs showed ‘shrivelled’ schizonts with no 
merozoite release (data not shown). A lower concentration of 5 mM BDM was then 
used, and this did not appear toxic to the parasites. In the merozoites released 
under these conditions there was a marked inhibition of PfSUB2 movement to the 
posterior of the parasite. Compared to the control parasites released in DMSO, 
PfSUB2 was capped in only 50% of BDM-treated parasites. The pattern of PfSUB2 
expression in parasites where the capping was inhibited was the same as previously 
seen, with either a diffuse pattern over the parasite surface or the protein still 
adjacent to the rhoptries. The inhibition of PfSUB2 movement on the merozoite 
surface by both myosin inhibitors as well as inhibitors of actin polymerisation 
suggests that the action of both these proteins is necessary for the capping of the 
protein.
The ability of P. falciparum to invade RBC in the presence of a number of 
these compounds was then tested. EGTA has previously been shown to inhibit RBC
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invasion and was used as a positive control [145]. The presence of EGTA inhibited 
invasion by 90% in comparison with the DMSO control. Cytochalasin D has 
previously been shown to block RBC invasion but to confirm the active state of the 
drug used in these experiments the stocks were tested to confirm that lack of 
inhibition of PfSUB2 capping was not due to the use of inactive cytochalasin D [60], 
At the concentrations used, cytochalasin D blocked 100% of parasite invasion. It 
was concluded that the compound was active. Latrunculin A was tested and shown 
to inhibit invasion by 90%, as compared to the DMSO control. At a concentration of 
5 mM, BDM reduced parasite invasion by 75%, approximately consistent with 
previous studies of others that noted a 50% invasion at this concentration [13).
Translocation of AMA1 and TRAP on the sporozoite surface is not affected 
by cytochalasin D despite this compound inducing total blockage of invasion [50],
Although the compounds that were found to inhibit capping of PfSUB2 also 
inhibited erythrocyte invasion by the parasite it is unlikely that the lack of PfSUB2 
capping is the sole reason for the reduced ability to invade. Cytochalasin D blocks 
P. falciparum RBC invasion but appeared to have no affect on the capping of 
PfSUB2. This indicates that the actin cytoskeleton plays a further role in invasion 
than capping PfSUB2 to the posterior of the parasite.
The region of PfSUB2 that may be interacting with the actinomyosin complex 
is unknown. The C-termini of both TRAP and MIC2 have been shown to be 
necessary for this interaction [28], However this region of PfSUB2 is not highly 
conserved and this study shows that it can clearly be modified without phenotypic 
affect by the addition of an HA3 tag. This suggests that another region of the 
molecule is responsible for interaction with the actin-myosin motor, either directly or 
via another protein.
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Discussion
PfSUB2 is a minor parasite component and as a result had proved difficult to 
localise accurately within the parasite. In this study, the successful tagging of 
PfSUB2 with a HA3 tag has enabled a detailed study of the localisation of the 
protein within various stages of the RBC cycle. The presence of the HA3 tag at the 
PfSUB2 C-terminus does not appear to affect either the processing of the protein or 
the growth of the parasite. PfSUB2 has been localised to the micronemes of the 
schizont and upon merozoite release re-localises over the parasite surface where it 
is capped to the posterior of the merozoite. The capping of PfSUB2, like that of 
MIC2 on the surface of T. gondii tachyzoites, appears to be linked to both the actin 
cytoskeleton and the myosin motor [15, 40], Both MIC2 and TRAP, expressed in 
Plasmodium sporozoites, have both been shown to interact via their C-terminus to 
aldolase and in turn to the actin cytoskeleton [39, 40], The residues necessary for 
this interaction are conserved within the TRAP family C-terminus and include a 
tryptophan residue and a number of acidic residues [28]. These features are absent 
in the PfSUB2 cytoplasmic tail and as this region is unconserved amongst 
Plasmodium species and can be modified by the addition of a tag it seems unlikely 
that it is this region of the protein that is responsible for interactions with the actin 
cytoskeleton.
Unlike MIC2 capping, which takes place explosively at the point of interaction 
with a host cell, the movement of PfSUB2 to the posterior of the parasite can clearly 
occur efficiently in the absence of attachment to erythrocytes [10]. This fact could 
explain the limited shedding of MSP1 and AMA1 from the surface of free merozoites 
[60, 75].
The invasive half-life of P. falciparum merozoites is extremely short and 
shedding of MSP1 is known to go to completion during the brief (~30 seconds) time 
course of erythrocyte invasion [6 ], The free merozoites studied by IFA in this work 
are therefore unlikely to still be invasive and the observed capping of PfSUB2 may
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not reflect what occurs during invasion. As invading P. falciparum merozoites are so 
difficult to visualise, due in part to both the speed of invasion and the small size of 
the cell, studies of this stage were not undertaken [7, 9]. On the invading parasite, 
PfSUB2 capping may occur simultaneously with entry into the parasitophorous 
vacuole with the protease concentrating at the moving junction and sweeping back 
around the parasite cleaving the AMA1 and MSP1 as it moves.
In the absence of invasion both AMA1 and MSP1 are shed inefficiently from 
the parasite surface [60], However PfSUB2 is considered to be present on the 
parasite surface and in a position to cleave both proteins. AMA1 and MSP1 are both 
thought to bind to the RBC and in this way mediate attachment of the merozoite to 
the RBC surface [64, 65, 6 8 , 69], It is possible that binding to the host cell surface 
causes a conformational change in the proteins leading to the cleavage sites 
becoming sterically available and allowing more efficient cleavage of the proteins 
from the surface by PfSUB2.
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Chapter 4: Purification of PfSUB2 and activity studies 
Introduction
AMA1 and MSP1 are both shed from the parasite surface by the action of a 
serine protease prior to or during P. falciparum merozoite entry into the RBC [60, 74, 
154], AMA1 is cleaved 29 residues upstream of the start of the predicted 
transmembrane sequence at a threonine residue (Thr517) within the sequence 
RAEVN'SNNEV [60]. MSP1 is cleaved 96 residues upstream of the GPI anchoring 
sequence between a leucine (Leu1606) and an asparagine (Asn1607) residue within 
the sequence QDMLlNISQHQ [76], Despite the difference in the number of 
residues above the membrane at which these cleavage sites occur, the structure of 
the MSPI19 fragment means that the cleavage site probably lies in close proximity to 
the GPI anchor and at a similar distance from the membrane as does the AMA1 
cleavage site [6 , 77]. Also, despite the lack of sequence similarity flanking the sites 
of AMA1 and MSP1 cleavage earlier evidence has indicated that the enzyme 
responsible is the same [60]. As explained in the Introduction sheddases are a 
group of enzymes that cleave ectodomains of integral membrane proteins and, 
rather than recognising a particular amino acid sequence, appear only to require an 
exposed or unhindered sequence of minimum length between the transmembrane 
domain and cleavage site [79-82], The enzyme responsible for the shedding of 
AMA1 and MSP1 is therefore considered to be a sheddase and has been named 
MESH (merozoite surface sheddase) [60, 95]. The best candidate for MESH, as 
discussed in the Introduction, is PfSUB2 [95],
The sequence of PfSUB2 indicates that it is a secreted subtilisin-like type I 
integral membrane protein possessing all the primary structural requirements for 
protease activity [114, 116]. PfSUB2 is first synthesised as a 160 kDa protein which 
undergoes processing to form a 74 kDa and finally a 72 kDa protein, presumed to 
be the active form of the enzyme [114]. This processing is reminiscent of that of 
PfSUBI and is typical of subtilisins which are synthesised as inactive zymogens
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before autocatalytic cleavage to remove the propeptide and reveal an active 
protease [99-101], Subtilisin propeptides are involved in the folding of the protein, 
which is critical for the formation of an active protease, and can also act as specific 
potent inhibitors of their respective enzyme [102-108], As an example of this, the 
PfSUBI propeptide has been used as a specific inhibitor of the enzyme [171]. The 
PfSUB2 propeptide can also be used in vitro to specifically inhibit both AMA1 and 
MSP1 shedding from the parasite surface, further supporting the hypothesis that 
PfSUB2 is MESH [120],
Attempts at expressing correctly folded and active PfSUB2 in heterologous 
expression systems have proved unsuccessful [172], As PfSUB2 is present as a 
relatively small proportion of the total protein content of the parasite there have been 
no previous attempts to purify the protein directly from the parasite [114]. However it 
was considered that the successful HA3 tagging of PfSUB2 in Chapter 3 might 
enable purification of active PfSUB2 from the parasite, allowing studies of the 
function of the protein. The aim of the work described in this chapter was to purify 
active PfSUB2 from the PfSUB2HA line.
4.1 Affinity purification of HA-tagged PfSUB2 from the parasite
The work in this chapter focused on purifying active PfSUB2 from the 
parasite and these attempts utilised the HA3 tag present at the C-terminus of 
PfSUB2 in the P. falciparum line PfSUB2HA (see Chapter 3). The work in Chapter 3 
had also created the control line PfSUB2w in which the PfSUB2 had no tag present 
and so this line was used as a control in purification experiments.
PfSUB2 had previously been shown to be maximally expressed in the 
erythrocytic cycle during late schizogony and merozoite release and these results 
were confirmed with the PfSUB2HA line [19, 114, 116] (Chapter 3). Schizont stage 
parasites can be purified from culture and this enabled the purification to be carried 
out only on parasites that would be expressing PfSUB2 [143],
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In order to purify PfSUB2 from the parasite a protocol that comprised a 
number of steps was developed. Firstly a TX-100 lysate of PfSUB2HA or PfSUB2w 
schizonts was incubated with Protein G Sepharose beads. This was designed as a 
preclearing step to remove any proteins that bound non-specifically to the beads. 
The beads were then removed and the anti-HA mAb 12CA5 added. The 12CA5 was 
expected to bind to the HA3 tag present at the C-terminus of the tagged PfSUB2 in 
the PfSUB2HA line. The lack of a HA3 tag in the PfSUB2w line meant that the 
12CA5 was not expected to bind to any proteins in this lysate. After incubation 
overnight to ensure antibody binding had gone to completion the lysates were 
incubated with a second batch of Protein G Sepharose beads to bind the antibody- 
antigen complex. The beads were then pelleted by centrifugation, the supernatant 
removed and discarded, and the beads washed several times to remove any 
unbound proteins. The 12CA5 bound to the PfSUB2 in the PfSUB2HA line was 
expected to bind to the Protein G Sepharose beads and this would result in PfSUB2 
bound to the beads via the antibody. As the PfSUB2w lysate was not predicted to 
contain any proteins that would bind to the 12ACA5 it was expected that the Protein 
G Sepharose beads would have only the antibody bound to them. The Protein G 
Sepharose beads from the PfSUB2HA line purification were named PfSUB2HA 
beads and those from the purification involving the PfSUB2w line were named 
PfSUB2w beads.
Western blots were then performed using the anti-HA mAb 3F10 to probe the 
samples taken during the PfSUB2HA purification in parallel with samples from the 
control PfSUB2w purification. These are shown in Figure. 4.1. Lanes 1 and 2 
contain samples of the initial PfSUB2HA TX-100 lysate. Four bands were detected 
in these lanes, migrating with apparent masses of 150 kDa, 72 kDa, 55 kDa, and 36 
kDa. These bands were identical to those previously detected with the PfSUB2HA 
line (Chapter 3) and were presumed to correspond to the full-length protein (150 
kDa), processed active forms of PfSUB2 (72 kDa) and two breakdown products (55
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Figure 4.1 PfSUB2 can be affinity-purified purified from parasites expressing 
epitope-tagged protease
Western blot of samples taken from various steps in the affinity-purification of HA- 
tagged PfSUB2, probed with the anti-HA mAb 3F10.
Lanes 1 and 2, TX-100 lysates of PfSUB2HA schizonts;
Lane 3, TX-100 lysate of PfSUB2w schizonts;
Lanes 4 and 5, PfSUB2HA lysates after preclearing;
Lane 6 , PfSUB2w lysate after preclearing;
Lanes 7 and 8 , PfSUB2HA lysates after addition of the anti-HA mAb 12CA5;
Lane 9, PfSUB2w lysate after the addition of 12CA5;
Lanes 10 and 11, PfSUB2HA lysates after depletion of the mAb 12CA5/PfSUB2HA 
complexes by incubation with Protein G Sepharose beads;
Lane 12, PfSUB2w lysate after depletion of mAb 12CA5 by incubation with Protein 
G Sepharose beads;
Lanes 13 and 14, PfSUB2HA beads;
Lane 15 PfSUB2w beads.
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kDa and 36 kDa). Lane 3 contained the PfSUB2w TX-100 lysate and here there was 
a slight smear detected around 150 kDa to 70 kDa. This is likely to be due to 
unspecific binding of the antibody or an error made during production of the Western 
blot. Previous Western blots performed on the PfSUB2w line (Chapter 3) with 3F10 
detected no species indicating that there were no proteins within TX-100 soluble 
fraction of the parasite that reacted with the 3F10.
Lanes 4 and 5 contained samples of the PfSUB2HA purification taken after 
the preclearing step. The four PfSUB2 species as seen in the previous PfSUB2HA 
lanes were detected and the intensity of these bands remained the same. This 
indicated that the amount of PfSUB2 had not decreased after the preclearing step 
and therefore that the tagged PfSUB2 did not bind non-specifically to the Protein G 
Sepharose beads. Lane 6 contained a sample of the PfSUB2w purification after the 
preclearing the step. The smear seen previously was not detected in this lane. This 
indicated that either the proteins had bound non-specifically to the Protein G 
Sepharose beads and been removed or that the previous result had been an 
artefact.
Lanes 7,8 and 9 contained samples of the lysates taken after the addition of 
the anti-HA mAb 12CA5. The PfSUB2HA lanes (7 and 8 ) contained the four PfSUB2 
bands previously detected and an additional doublet migrating with an apparent 
mass of 25 kDa. The 25 kDa doublet was also detected in the PfSUB2w lane (9) as 
the only bands detected. The samples are likely to contain 12CA5, which is a mouse 
mAb, and as the primary antibody used to probe the Western blot is a rat mAb the 
anti-rat secondary antibody was likely to cross react with any 12CA5 present. IgG 
light chains have a mass of ~25 kDa and therefore the doublet was presumed to 
correspond to 12CA5 light chain.
Lanes 10 and 11 contain samples of the supernatant after incubation with 
the Protein G Sepharose beads of the PfSUB2HA purification. The intensity of the 
74 kDa, 55 kDa and 36 kDa bands previously detected had decreased and the 150
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kDa species, presumed to be the full length PfSUB2, and the 25 kDa doublet, 
presumed to be the 12CA5 light chains, were no longer detected. This indicated that 
the 12CA5 and a proportion of the PfSUB2 had been removed from the supernatant 
and was presumably bound to the Protein G Sepharose beads. Lane 12 contained a 
sample of the supernatant after incubation with the Protein G Sepharose beads of 
the PfSUB2w purification. There were no bands detected in this lane. The 
disappearance of the 25 kDa doublet previously detected indicated that the 12CA5 
had been bound to the Protein G Sepharose beads.
The final three lanes 13,14 and 15 contained samples of the Protein G 
Sepharose beads after the wash steps. Lanes 13 and 14 contained samples from 
the PfSUB2HA purification. These lanes contained the four PfSUB2 species, the 25 
kDa doublet and an additional doublet migrating with an apparent mass of 58 kDa. 
The heavy chains of IgG have a mass of around 50 kDa and it was therefore likely 
that the 58 kDa doublet represented the heavy chains of the 12CA5. The presence 
of the 12CA5 bands indicated that the antibody had bound to the Protein G 
Sepharose and the presence of the PfSUB2 bands indicated that the protein had 
bound to the Protein G Sepharose via the 12CA5. Taken together, these results 
indicated that the purification of PfSUB2 from the PfSUB2HA parasite had been 
successful. The presence of a HA3 tag on the four species of PfSUB2 meant that all 
had been purified. Unfortunately the 150 kDa protein, presumed to be the full length 
PfSUB2, is unlikely to be active as it contains the propeptide which is likely to be an 
inhibitor of the enzyme. Similarly, the 55 kDa and 36 kDa species are also unlikely 
to be active they are likely too small to contain the catalytic triad needed for 
protease activity as well as the C-terminal HA3 tag, and are therefore presumed to 
be breakdown products. The 72 kDa species is presumed to represent the active 
terminal processing product and is probably the only active form of the enzyme that 
had been purified. This means that only a proportion of the purified PfSUB2 bound
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to PfSUB2HA beads is likely to exhibit activity and that detecting this activity may be 
challenging.
Lane 15 contained a sample of the PfSUB2w beads from the PfSUB2w 
purification. The only bands detected in this lane were the 25 kDa doublet. This 
indicated that the 12CA5 had bound to the beads but that there were no other 
proteins present. These beads could then be used as a negative control to ensure 
any activity detected with the PfSUB2HA was specifically due to the PfSUB2 
present.
The previous work had resulted in the purification of PfSUB2 onto Protein G 
Sepharose beads. The next step was to attempt to remove the PfSUB2 from the 
PfSUB2HA beads. Protein can be removed from the Protein G Sepharose beads by 
lowering the pH to 3.0-2.5; however, this pH was considered likely to inactivate the 
protease. Attempts were therefore made to remove the purified PfSUB2 from the 
Protein G Sepharose beads by competitive elution using a peptide based on the 
HA3 tag sequence (YPYDVPDYAGGGYPYDVPDYAGGGYPYDVPDYA; 
synthesised in house by P. Fletcher). It was hoped that this peptide would compete 
with the PfSUB2 for binding to the 12CA5 and in turn release the protein into the 
supernatant.
A 1 mg mL'1 solution of the peptide was incubated with the PfSUB2HA beads 
and resulting supernatants analysed by western blots, probing with the anti-HA mAb 
3F10 (data not shown). Unfortunately it was impossible to detect whether the 
PfSUB2 had been released or not as the lanes containing the peptide produced a 
strong signal consisting of a smear down the length of the blot. This was likely to be 
due to the 3F10 reacting with the high concentration of the HA3 peptide present in 
these samples. This made detection of any other bands in this lane impossible and 
it could not be determined if the PfSUB2 had been released from the beads or not. 
As a result further attempts to remove the PfSUB2 from the beads using this 
approach were abandoned.
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PfSUB2 is predicted to be a type I integral membrane protein, anchored to 
the parasite membrane by its C-terminal transmembrane domain. It was therefore 
considered that the purified protein may remain active attached to the Protein G 
Sepharose beads via the 12CA5. It was decided that further attempts to detect 
protease activity mediated by the purified PfSUB2 would be carried out without 
removal of the protein from the beads. The PfSUB2HA and PfSUB2w beads were 
aliquoted and stored at -70°C in peptide digestion buffer (50 mM Tris-HCI pH 8.2, 12 
mM CaCI2). These were the same storage conditions as used previously for purified 
recombinant PfSUBI [112]. PfSUB2 shows the closest homology to the prokaryotic 
subtilases which are almost all predicted to contain calcium binding sites and 
therefore PfSUB2 may require calcium to exhibit enzyme activity [98, 114, 116]. This 
is further indicated by the buffer conditions used for MSP1 shedding assays where 
supplementation with calcium is required for the enzyme to cleave the protein [75]. 
PfSUB2 appeared to have been purified from the parasite and appropriate 
conditions for activity chosen. It could now be determined if the purified PfSUB2 
exhibited activity.
4.2 Construction of a fluorogenic peptide
Peptides labelled with a rhodamine group at each end are commonly used 
as substrates in studies of enzymatic function [153, 173, 174]. The high local 
concentration of rhodamine on the peptide causes intramolecular dimerisation of the 
dye and this results in the fluorescence of the rhodamine being quenched [173, 
174], Incubation of the peptide with an appropriate enzyme results in its cleavage 
and the local high concentration of rhodamine is lost. The dye molecules dissociate 
and this results in a corresponding rise in fluorescence that can be detected and 
measured. As an example of the use of such a substrate, the pH and cation 
dependence, inhibitor profile, and affect of the propeptide on PfSUBI have all been 
studied through the use of a rhodamine labelled peptide [112, 153, 171].
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As previously mentioned, cleavage of MSP1 occurs between the leucine and 
asparagine residues within the sequence QDML'l'NISQHQ [76], It was therefore 
hypothesised that a rhodamine labelled peptide based on the MSP1 secondary 
cleavage site might therefore be used as a potential substrate for detecting purified 
PfSUB2 activity.
To prepare this substrate the peptide Ac-CQDMLNISQHQC, based on the 
MSP1 secondary cleavage site, was first synthesised in house by P. Fletcher. The 
method of Blackman et al. was used to attach rhodamine groups to the two cysteine 
residues on the peptide forming the peptide MSP1rh0 [153]. The final product was 
analysed by RP-HPLC and resolved under the conditions used into two separate 
peaks indicating the presence of two separate species (Figure 4.2). However when 
these peaks were collected and analysed by mass spectroscopy (performed by P. 
Fletcher) they exhibited identical m/z values, suggesting that they were chemically 
identical and both corresponded to the same product, namely the peptide labelled 
with a tetramethylrhodamine group at each cysteine side-chain (Figure 4.3). In the 
following work both species were used to assess the activity of PfSUB2.
4.3 Evaluation of the experimental PfSUB2 fluorogenic substrate
The fluorogenic peptide MSP1rh0 had been constructed but it remained to be 
seen if it could be cleaved and a rise in fluorescence detected. The absorption 
spectrum of dimeric tetramethylrhodamine has its peak at 520 nm with a shoulder at 
554 nm. When the dye dissociates to form monomers there is a shift in the 
absorption profile with the peak now at 554 nm with the shoulder at 520 nm [153, 
173, 174], When overlaid the two spectra cross at the isosbestic point, 528 nm 
[175]. This phenomenon can be exploited to determine whether cleavage of the 
modified peptide results in monomerisation of the dye.
Pronase, a non-specific protease, was first used to determine the effects of 
cleavage of MSP1rh0. The visible absorption spectrum of MSP1rh0 was measured
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Figure 4.2 RP-HPLC analysis of MSP1rho produces two peaks
Reversed phase HPLC fractionation of crude MSP1rho preparations. The two peaks 
corresponding to the tetramethylrhodamine-labelled peptide are indicated with 
asterisks (*).
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Figure 4.3 Peaks 1 and 2 of MSP1rho are indistinguishable by mass 
spectrometry
The masses of the two MSP1rho peaks collected following RP-HPLC, were 
determined by electrospray mass spectrometry (performed by P. Fletcher). As can 
be seen by the spectra the products exhibited identical m/z values indicating that the 
two products are identical.
129
130
Relative intensity (%)
I
Relative intensity (%)
using a spectrophotometer before and after the addition of Pronase (Figure 4.4). 
There was a clearly visible shift in the spectrum, with the peak moving from 520 nm 
to 554 nm, after the Pronase addition indicating that the peptide had been cleaved.
The next step was to determine if cleavage of the peptide resulted in a 
detectable rise in fluorescence. Chymotrypsin is a serine protease that cleaves 
substrates on the C-terminal side of aromatic and leucine residues and was 
therefore predicted to cleave MSP1rho at the same site as PfSUB2 (i.e. at the Leu- 
Asn bond). MSP1rh0and chymotrypsin were added to two wells of a microtitre plate 
and a series of measurements taken over time with a fluorescence 
spectrophotometer (Figure. 4.5). There was a large, time-dependent increase in 
fluorescence indicating that the peptide was cleaved by the chymotrypsin.
These results confirmed that MSP1rho could be cleaved and a rise in 
fluorescence detected. The next step was to determine if the purified PfSUB2 was 
capable of cleaving the peptide.
4.4 Attempts to detect PfSUB2 activity using a fluorescent peptide
To explore whether the preparations of affinity-purified PfSUB2 possessed 
protease activity, MSP1rh0 was added to seven wells of a microtitre plate, 
PfSUB2HA beads were then added to two of these wells and PfSUB2w beads, 
acting as a negative control, added to a further two. The remaining three wells had 
no further additions and contained only the MSP1rh0 to act as further negative 
controls. The plate was incubated at room temperature and fluorescence of each 
well measured every 5 minutes over 400 minutes using a fluorescence 
spectrophotometer.
The results of this experiment are shown in Figure 4.6. Wells that contained 
MSP1 rho alone showed no rise in fluorescence indicating that the peptide was stable 
during this period of time at room temperature. In contrast, the wells that additionally
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Figure 4.4 Cleavage of MSP1rho causes a shift in absorption spectrum
Absorption spectra of MSP1rho (A) before and (B) after addition of Pronase. The 
absorption spectrum peak of MSP1rh0 before addition of 1 mg ml_'1 Pronase is 520 
nm indicating that the rhodamine has formed dimers. Upon addition of Pronase the 
peak shifts to 554 nm indicating that the peptide has been cleaved and that the dye 
has formed monomers.
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Figure 4.5 MSPI^o is cleaved by chymotrypsin
Progress curve showing the increase in fluorescence upon cleavage of MSP1rho by 
chymotrypsin. The red curve (1) corresponds to 0.2 pM MSP1rho incubated without 
any addition of protease. The blue and black curves (2 and 3) correspond to 
duplicate wells containing 0.2 pM MSP1rho incubated with 1 pM chymotrypsin. The 
slight difference in the curves is presumed to be due to experimental error.
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Figure 4.6 Analysis of affinity-purified PfSUB2 preparations for the presence 
of protease activity that cleaves MSP1rho
The graph depicts progress curves of fluorescence increases associated with 
cleavage of 0.2 pM MSPIrho when incubated with 50 pL PfSUB2w beads (curves 1 
and 4), 50 pL PfSUB2HA beads (curves 2 and 3), or without any additions (curves 
5-7). The activity associated with the PfSUB2HA beads was not significantly 
different from that associated with the control PfSUB2w beads.
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contained PfSUB2HA beads showed a small increase in fluorescence. This 
indicated that the peptide was being cleaved and that there was an active protease 
present. Unfortunately the wells that contained the PfSUB2w beads alongside 
MSP1 rho displayed a similar rise in fluorescence.
These results suggested that the cleavage of the peptide detected in the 
wells containing the PfSUB2HA beads was not due to active PfSUB2. Instead it 
appeared that the purification procedure had resulted in the presence of a 
contaminating protease bound to both the PfSUB2HA and PfSUB2w beads. The rise 
in fluorescence was small and this suggests that the contaminating protease was 
either present at a low concentration or unable to cleave MSP1rh0 efficiently.
The results also suggest that the purified PfSUB2 did not substantially cleave 
MSPIrho. There are a number of potential reasons for this including the following 
(1) the purified enzyme was inactive, (2) MSP1m0 is not a suitable substrate and 
cannot be cleaved by PfSUB2, or (3) the concentration of purified PfSUB2 on the 
beads was too low to detect activity. As explained above, the majority of PfSUB2 
purified onto the PfSUB2HA beads was considered likely to be inactive due to the 
presence of the propeptide or the lack of the catalytic domain. This means it may be 
difficult to detect activity and several potential substrates may have to be tested 
before a suitable one is found.
4.5 Use of an unlabelled peptide substrate to detect PfSUB2 activity
The work in the previous section had shown that cleavage of the rhodamine 
labelled peptide MSP1rho by purified PfSUB2 could not be detected. PfSUB2 is 
considered to be a sheddase and these enzymes require an accessible, disordered 
sequence in order to cleave their substrates [81, 82]. It is conceivable that the 
presence of the rhodamine groups on the peptide may reduce the steric availability 
of the cleavage site and prevent cleavage by PfSUB2. In order to test this possibility 
a second peptide based on the MSP1 secondary cleavage site with the sequence
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LQGMLNISQH (MSP1 cmp), was synthesised by P. Fletcher. This time the peptide 
was not labelled with dye groups. It was hypothesised that if MSP1CiiP was cleaved 
by the purified PfSUB2 it would indicate that the failure to cleave MSP1rho was due 
to steric hindrance from the rhodamine groups present.
In order to determine if the purified PfSUB2 was capable of cleaving 
MSPIciip the PfSUB2HA or PfSUB2w beads were incubated with the peptide at 
37°C. Samples of the peptide were taken immediately and after a further 2.5 hours 
of incubation then subjected to RP-HPLC analysis (Figure 4.7). The MSP1Cnp 
samples taken immediately and incubated with either the PfSUB2HA or PfSUB2w 
beads were identical and contained predominantly the intact peptide. The RP-HPLC 
elution profile of samples taken after 2.5 hours incubation with PfSUB2w beads 
appeared very similar indicating that there had been no significant cleavage of the 
peptide. Similar results were obtained with samples that had been incubated with 
the PfSUB2HA beads, indicating that the peptide had not been cleaved by the 
purified PfSUB2.
In conclusion there was no detection of cleavage of MSP1 Cmp by the purified 
PfSUB2. However it could not be determined if the purified PfSUB2 was inactive or if 
the MSP1CiiP was an unsuitable substrate.
4.6 Use of the recombinant PfSUB2 ectodomain to detect PfSUB2 activity
In previous work performed by others, the PfSUB2 ectodomain had been 
expressed in Pichia pastoris, a yeast expression system, where it was shown to be 
unfolded and inactive [172], Subtilisins undergo autocatalytic cleavage to remove 
the propeptide and reveal an active protease [98-101], PfSUBI can be expressed in 
a recombinant active form and this is capable of cleaving inactive PfSUBI produced 
by in vitro translation [101]. This suggests that if the purified PfSUB2 was active it 
would be capable of cleaving the inactive recombinant PfSUB2. The recombinant 
ectodomain was incubated at 37°C with PfSUB2HA or PfSUB2w beads and
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Figure 4.7 MSP1CiiP is not cleaved by affinity-purified PfSUB2
RP-HPLC analysis of ~ 0.4 mg mL~1 MSP1CiiP before (A) and after (C) incubation 
with PfSUB2w beads, and before (B) and after (D) incubation with PfSUB2HA 
beads. The peak representing intact MSP1Cnp is indicated by an asterisk. The slight 
movement in the position of the MSP1CiiP peak is considered due to slight between- 
run variations in the elution conditions.
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samples taken immediately and after 30, 90, and finally 310 minutes incubation. The 
samples were run on a gel alongside a sample of the ectodomain alone and a 
Western blot performed using an anti- His6mAb to probe the blot (Figure. 4.8). Lane 
3 contained the P. pastoris derived ectodomain alone and a single species migrating 
with an apparent mass of 130 kDa was detected corresponding to the predicted size 
of the full-length intact ectodomain. Lanes 1, 4, 6 and 8 contained the recombinant 
ectodomain incubated with the PfSUB2HA beads for 0, 30, 90 and 310 minutes 
respectively. These lanes contained a number of bands migrating with apparent 
masses of 130 kDa, 65 kDa, a doublet of 56 kDa and a doublet of 25 kDa. The 130 
kDa species was presumed to correspond to the intact full-length ectodomain. The 
samples taken and run on the gel contain some of the PfSUB2HA beads as well as 
the ectodomain and the beads have the anti-HA mAb 12CA5 bound to them and as 
the anti-His and 12CA5 are both mouse mAbs the secondary antibody used in the 
Western blot was likely to cross react with any 12CA5 present. The 56 kDa and 25 
kDa doublets were therefore considered to correspond to the heavy and light chains 
respectively of the 12CA5 mAb. The 65 kDa species was detected in all the lanes 
and the intensity of this band increased as the length of the incubation increased. 
The cleavage of the 130 kDa PfSUB2 ectodomain to release the propeptide was 
predicted to result in the formation of a protein with an approximate mass of 65 kDa. 
The presence of a 65 kDa band in these lanes indicated that the PfSUB2 
ectodomain was being cleaved.
Lanes 2, 5, 7 and 9 contained the ectodomain incubated with the PfSUB2w 
beads for 0, 30, 90 and 310 minutes respectively. These lanes contained the 130 
kDa species, corresponding to the full length ectodomain, alongside the 56 kDa and 
25 kDa doublets presumed to correspond to the heavy and light chains of the 
12CA5. Unfortunately these lanes also contained the 65 kDa species presumed to 
correspond to the cleaved ectodomain with the intensity of the band increasing as 
the length of incubation increased.
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Figure 4.8 PfSUB2HA beads do not specifically cleave P. pastor is derived 
PfSUB2 ectodomain
Western blot analysis of P. pasforis-derived recombinant PfSUB2 ectodomain with a 
C-terminus His6 tag following incubation with either PfSUB2HA or PfSUB2w beads. 
The blot was and probed with an anti-His6 mAb.
Lanes 2, 5, 7, and 9: recombinant ectodomain incubated at 37°C with PfSUB2w
beads forO, 30, 90 and 310 minutes respectively.
Lanes 1, 4, 6, and 8: recombinant ectodomain incubated at 37°C with PfSUB2HA
beads for 0, 30, 90 and 310 minutes respectively.
Lane 3 contains recombinant ectodomain alone.
143
kDa
130-
I
65-
56-
2 3
anti-His
25- wft
kDa
130-
65-
56-
25-
The conclusion drawn from this was that no specific PfSUB2 activity could be 
detected using the recombinant PfSUB2 ectodomain as a substrate. The low-level 
cleavage that was detected of the recombinant PfSUB2 ectodomain was clearly the 
result of a contaminating protease or that the ectodomain was degrading during the 
incubation. It was not known whether the purified PfSUB2 was inactive or if the 
ectodomain was not a suitable substrate. Another possibility is that the 
concentration of PfSUB2 purified onto the Protein G Sepharose beads was too low 
to enable detection of any PfSUB2 protease activity.
4.7 Estimation of the amount of PfSUB2 purified onto the beads.
Previous work in this chapter had focused on the purification of PfSUB2 from 
the parasite and attempts to detect activity with the purified protein. Despite a 
number of potential substrates being tested no specific cleavage by the purified 
PfSUB2 was detected. PfSUB2 is present as a very small proportion of the total 
protein content of the P. falciparum cell and as a result there was unlikely to be a 
high concentration of protein bound to the beads [114]. Analysis of the purified 
protein had revealed that four PfSUB2 species had bound to the Protein G 
Sepharose beads and only the 72 kDa species, presumed to be the terminal 
PfSUB2 processing product, was considered likely to represent an active form of the 
enzyme. This meant that the majority of PfSUB2 bound to the beads was likely to be 
inactive, further reducing the potential concentration of active protein. The 
substrates used to detect purified PfSUB2 activity may not have been sensitive 
enough to detect these low levels of active enzyme. It was therefore decided that 
before further attempts were made to detect activity with the purified PfSUB2 an 
estimate of the amount of protein present on the beads should be attempted.
A HA3 tagged glutathione S transferase (GST-HA3) was expressed in E. 
coli, purified, and lysates analysed by Western blot with the anti-HA mAb 3F10 (data 
not shown). In partially purified extracts three species were detected, migrating with
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apparent masses of 36 kDa, 33 kDa, and 25 kDa. GST-HA3 is predicted to have a 
mass of approximately 36 kDa and therefore the largest fragment was presumed to 
correspond to the full-length protein. The 33 kDa and 25 kDa bands were presumed 
to correspond to breakdown products.
The next step was to purify the full length GST-HA3 away from the 
breakdown products. However purification attempts by both gel filtration and HPLC 
were unsuccessful and were abandoned (data not shown).
The concentration of the purified GST-HA3 was then estimated. A gel was 
loaded with lanes containing known concentrations of BSA alongside dilutions of the 
partially purified GST-HA3. The gel was then run and stained with Coomassie blue 
(Figure 4.9). The intensity of the various BSA bands was used to estimate the 
concentration of the full length GST-HA3 in the preparation. The 36 kDa band in 
lane 1 and the band in lane 7 were stained by Coomassie with an equal intensity 
indicating that these lanes contained the same amount of protein. The 36 kDa band 
in lane 1 corresponds to the full-length GST-HA3 and lane 7 contains 0.16 mg mL1 
BSA. On this basis it was therefore estimated that the GST-HA3 lane contained 0.16 
mg mL'1 of protein and as 5 pL of GST-HA3 had been loaded the total amount of 
protein present was calculated as 0.8 pg.
A Western blot was then performed on dilutions of the same GST-HA3 
preparation, alongside dilutions of the PfSUB2HA beads and probed with the anti- 
HA mAb 3F10 (Figure 4.10). The 72 kDa band, presumed to correspond to the 
active form of PfSUB2, in the initial lane (lane 1) produced a signal with an 
approximately similar intensity to the lane containing 128 pg of GST-HA3. The 
amount of ‘active’ PfSUB2 present in lane 1 was therefore estimated as 128 pg. 10 
pL of PfSUB2HA beads had been loaded into this lane and therefore the 
concentration of active protease bound to the beads was calculated as 
approximately 12.8 pg pL'1. Although this Figure is likely to be somewhat different 
from the actual concentration it was considered accurate enough to use as an
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Figure 4.9 Quantification of purified recombinant GST-HA3 by comparison 
with known amounts of pure BSA
Coomassie stained gel of various dilutions of preparations of recombinant GST-HA3 
and BSA.
Lane 1, 5 pL purified GST-HA3;
Lane 2, 2.5 pL GST-HA3;
Lane 3, 1.25 pL GST-HA3;
Lane 4, 0.625 pL GST-HA3;
Lane 5, 0.64 mg mL
Lane 6, 0.32 mg mL
Lane 7, 0.16 mg mL
Lane 8, 0.08 mg mL
Lane 9, 0.04 mg mL
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Figure 4.10 The concentration of PfSUB2 can be estimated by comparison 
with GST-HA3
Western blot of dilutions of purified PfSUB2 and GST-HA3 probed with the anti-HA 
mAb 3F10.
Lane 1, 3.2 ng GST-HA3;
lane 2, 0.64 ng GST-HA3; lane 3, 128 pg GST-HA3; lane 4, 25.6 pg GST-HA3; lane 
5, 5.12 pg GST-HA3; lane 6, 1.02 pg GST-HA3; lane 7, 0.20 pg GST-HA3; lane 8, 
10 pL PfSUB2HA beads
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estimation of the amount of ‘active’ PfSUB2 bound to the Protein G Sepharose 
beads.
Fluorogenic substrates are widely used to detect protease activity and the 
minimum amount of enzyme needed to detect activity has been calculated in many 
cases. These figures were therefore used to determine if it was feasible that PfSUB2 
activity could be detected with the purified protein, given the estimated concentration 
of 12.8 pg pL'1 of ’active' protein bound to the beads. Blackman et al. had previously 
demonstrated that > 10 ng pL'1 of recombinant PfSUBI was required to detect 
cleavage of the fluorogenic peptide pepF1-6R when used at the same concentration 
as MSP1 rho was in the previous section 4.3 [153]. Similarly concentrations of 
chymotrypsin > 0.5 pg ml_ -1 were required to detect cleavage of the fluorogenic 
substrate 7-glutarylphenylalaninamido-4-methylcoumarin [176]. Some fluorogenic 
substrates allow more sensitive detection of enzymes as it was possible to detect 
renin activity at a lower concentration, of 0.5 pg pL'1, [177],
These findings suggest that, although it is possible to detect some enzymes 
when the concentration is as low as 12.8 pg pL"1, reliable detection often requires a 
substantially higher concentration of active enzyme. As active PfSUB2 has yet to be 
expressed the precise requirements for optimal enzymatic function are unknown and 
this, combined with the relatively low amount of ‘active’ PfSUB2 bound to the Protein 
G Sepharose beads, means it is unlikely activity will be detected. As the PfSUB2 is 
present as a relatively small proportion of the total protein content of the parasite 
purification of the protein from the parasite is perhaps unrealistic [114].
Discussion
PfSUB2 is the best candidate for the enzyme responsible for the cleavage of 
both MSP1 and AMA1 from the parasite surface. However, previous attempts to 
express active recombinant PfSUB2 for functional studies have been unsuccessful. 
The work in this chapter focused on purifying PfSUB2 from the parasite by exploiting
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the C-terminal tag present in the PfSUB2HA line generated in Chapter 3. It initially 
appeared that the tag had allowed successful purification of the enzyme from the 
parasite. However, despite the use of a number of substrates it was not possible to 
detect PfSUB2 activity and a contaminating protease appeared present.
Although there were a number of potential reasons for the inability to detect 
activity with the purified PfSUB2 it seemed most likely that the concentration of 
PfSUB2 bound to the beads was too low. The amount of the 72 kDa form of 
PfSUB2, predicted to be the active form of the enzyme, purified onto the beads was 
estimated to be 12.8 pg pL'1. Comparisons with other proteases indicated that with 
this concentration of enzyme it was unlikely that activity could be detected. Given 
the relatively small amount of PfSUB2 present in the P. falciparum cell it seems 
unlikely that purification of the protein from the parasite will ever obtain the amounts 
of protein that may be required to detect activity. Further attempts to obtain active 
enzyme should focus on over-expression of PfSUB2 within the parasite (see 
Chapter 5) or preferably the use of unconventional expression systems such as T. 
gondii or Tetrahymena thermophila [178]. The A+T rich genome and corresponding 
codon usage of T. thermophilia means it is a good expression system for P. 
falciparum proteins [178],
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Chapter 5: Episomal expression of PfSUB2 within P. falciparum  
Introduction
The expression of P. falciparum proteins in heterologous expression systems 
for structure-function analysis is problematic often as a result of the high A+T 
content of the parasite genome [136, 178, 179]. A number of approaches have been 
used to overcome these difficulties including the use of Tetrahymena thermophila, 
another A+T rich protozoan, as an expression system or the re-codonisation of P. 
falciparum genes to reduce the A+T content [136, 178, 180]. Another potential 
solution to this problem is the use of P. falciparum itself to over-express parasite 
proteins that cannot be expressed in more conventional expression systems. 
Advances in P. falciparum transfection technology have enabled expression of both 
endogenous and heterogenous proteins from episomes carried by the parasite [121, 
124, 132], Proteins expressed this way fold correctly, undergo normal processing 
events and, in the case of enzyme expression, exhibit typical activity [124, 130, 
132], At present the factors controlling levels of endogenous protein that can be 
expressed within the parasite are unknown; for example expression of PfAMAI from 
an episome did not result in increased protein levels over untransfected controls, 
and the majority of protein detected was found to be encoded by the episome 
suggesting that an episome-derived gene product has dominance over endogenous 
protein [132], In T. gondii expression of myosin from an episome also resulted in 
down regulation of the endogenous protein [133], The choice of promoter for driving 
protein expression from an episome within the parasite is likely to be critical for 
correct targeting and localisation although it does not appear to affect correct folding 
or processing [151, 181].
The study of P. falciparum promoter regions has proved challenging. The 
A+T richness of intergenic regions, combined with their often highly repetitive nature 
with long homopolymeric adenosine or thymidine (poly(dA)poly(dT)) tracts, has 
made the identification of regulatory elements difficult; for example the region
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upstream of genes often contains many copies of a classical TATA box motif 
although it is unlikely most are functional [182-186], In studies investigating 
promoter structure in Plasmodium truncations of the region 5' to a gene usually 
results in a gradual reduction in promoter activity with no particular motif identifiable 
as essential for promoter activity [124, 183, 184],
Numerous attempts to express PfSUB2 in an enzymatically active, 
recombinant form in heterologous expression systems have been unsuccessful 
despite re-codonisation of the pfsub2 gene to reduce the A+T content [120, 172], 
This chapter focuses on attempts made to overcome this obstacle by over­
expression of the protease within the parasite, where correct folding and processing 
of the protease are expected to proceed efficiently. The pfsub2 promoter has not 
previously been studied although the relatively low levels of PfSUB2 found within the 
parasite suggest it is weak [114]. The aim of the study was to express active 
PfSUB2 that could then be purified from the parasite and used in enzymatic assays. 
A stronger promoter could therefore be used to attempt to express higher levels of 
PfSUB2 than if the wild-type promoter was used as - provided folding and 
processing of the protein is correct -  it is possible that mis-localisation may still 
result in active protease. The factors controlling the levels of PfSUB2 are unknown 
and as a result it was considered that it might prove impossible to achieve levels 
higher than those of wild-type parasites. However, it was also hypothesised that the 
PfSUB2 expressed from the episome might show dominance over the endogenous 
PfSUB2. Note that this work was performed before the epitope tagging of PfSUB2 
described in Chapter 3.
5.1 Expression of PfSUB2 under the control of the hsp86 promoter
Four constructs were initially designed to over-express PfSUB2 within P. 
falciparum; these were named pHHT-sub2, pHHT-sub2HA, pHHT-sub2w and 
pHHT-sub2wHA. Constructs pHHT-sub2 and pHHT-sub2HA contain pfsub2synth
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gene sequence encoding only the predicted ectodomain of PfSUB2, respectively 
with or without a single HA epitope tag at the 3' end of the gene. The full-length 
pfsub2synth gene was used in constructs pHHT-sub2w and pHHT-sub2wHA, again 
with or without a single HA tag. In all these constructs the pfsub2synth sequence was 
under the control of the P. falciparum heat shock protein 86 (hsp86) promoter which 
is commonly used in P. falciparum transfection constructs [121, 181], The hsp86 
gene is transcribed at a relatively high level throughout the erythrocytic cycle 
whereas PfSUB2 is maximally expressed at relatively low levels only at around 40- 
48 hours post-invasion [19,114]. Use of the hsp86 promoter was therefore expected 
to result in expression of higher levels of PfSUB2 than if the authentic pfsub2 
promoter was used.
Multiple attempts to obtain stable D10 transfectants harbouring the above 
constructs in episomal form failed while parallel control transfections using pHHT- 
TK, carried out under identical conditions, were always successful (data not shown) 
[127], Eventually, however, parasites apparently harbouring pHHT-sub2HA were 
detected in thin blood films after 55 days of drug selection. Plasmid was rescued 
from this line and three clones were selected for restriction digest analysis alongside 
a sample of the ‘original’ pHHT-sub2HA plasmid used for the initial transfection 
(Figure 5.1). Undigested plasmid samples were analysed in parallel to confirm 
digestion efficiency. Spe I digestion of pHHT-sub2HA should release an 887 bp 
fragment corresponding to the hsp86 promoter. This band was seen in the digest of 
the ‘original’ pHHT-sub2HA but was missing from digests of all 3 recovered clones. 
Comparison of Spe I digested and the corresponding undigested constructs made it 
clear that one of the Spe I sites remained in the recovered clones as the constructs 
were linearised by digestion. These linearised forms appeared the same size as the 
Spe I digested ‘original’ pHHT-sub2HA backbone suggesting that re-arrangements 
had taken place during replication of the plasmid in the parasite, resulting in loss of 
the majority if not the entire hsp86 promoter region. Further analysis by IFA and
155
Figure 5.1 pHHT-sub2HA undergoes re-arrangements within the parasite
Ethidium bromide stained agarose gel of restriction digests of plasmids recovered 
from D10 parasites after transfection with pHHT-sub2HA.
Lane 1, recovered pHHT-sub2HA clone 1, undigested; lane 2, recovered pHHT- 
sub2HA clone 2, undigested; lane 3, recovered pHHT-sub2HA clone 3, undigested; 
lane 4, original pHHT-sub2HA, undigested; lane 5, 1 kb markers (Amersham 
Pharmacia; sizes are indicated on the left in kb); lane 6, recovered pHHT-sub2HA 
clone 1 - Spe I digested; lane 7, recovered pHHT-sub2HA clone 2 - Spe I digested; 
lane 8, recovered pHHT-sub2HA clone 3 - Spe I digested; lane 9, original pHHT- 
sub2HA- Spe I digested.
The band representing the hsp86 promoter present in lane 9 but absent from lanes 
6-8 is indicated.
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Western blot to try and detect any HA tagged protein were unsuccessful (data not 
shown), suggesting this deletion had removed all promoter activity.
The selection of a construct that had undergone re-arrangements which 
effectively eliminated the hsp86 promoter, together with the prolonged selection 
period required to obtain a stable, drug-resistant line, suggested that the promoter 
activity was deleterious to the parasite. There are a number of possible reasons for 
this, including the following: (1) a simple increase in the levels of active PfSUB2 may 
be toxic to the parasite possibly due to it acting on proteins other than its authentic 
substrate: (2) expression of inactive and misfolded PfSUB2 may be toxic; and (3) 
constitutive expression of PfSUB2 resulting in trafficking to the ‘wrong’ location 
within the parasite may be toxic. PfSUB2 is a microneme protein (see Chapter 3) 
and these organelles are not present throughout the erythrocytic cycle [7]. As the 
hsp86 promoter is constitutively active PfSUB2 expressed under this promoter is 
likely to be trafficked to alternative sub-cellular locations during most of the 
erythrocytic cycle. The default destination for export of malaria proteins is the PV so 
it is likely that any PfSUB2 expressed after the merozoite stage is exported to this 
destination [181, 187].
5.2 Expression of inactive PfSUB2 under the control of the hsp86 promoter
The results from the previous section implied that expression of PfSUB2 
under the control of the hsp86 promoter was toxic to the parasite. However it was 
unknown whether the protein expressed was correctly folded and active, or 
unfolded. PfSUB2 is a serine protease and therefore mutation of pfsub2synth to 
replace the active site serine (Ser961) with alanine would result in inactive PfSUB2. 
This could then be placed in the plasmid backbone used before and it was reasoned 
that if transfections involving these ‘inactive’ constructs were successful it would 
imply that the PfSUB2 expressed from the previous constructs was active. On the 
other hand, if the apparent toxicity was as a result of unfolded protein or simply
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incorrect localisation of the pfSUB2 the ‘inactive’ constructs would also be toxic to 
the parasite. To test these possibilities, transfections of P. falciparum with pHHT- 
sub2j, pHHT-sub2HAj, pHHT-sub2wi and pHHT-sub2wHAi where the PfSUB2 active 
site serine (Ser961) codon had been substituted with an alanine codon were then 
performed. However, multiple attempts to obtain stable D10 transfectants 
harbouring the above ‘inactive’ constructs in episomal form failed, while parallel 
pHHT-TK transfections were always successful (data not shown). This suggested 
that constitutive expression of PfSUB2 throughout the erythrocytic cycle was toxic 
regardless of protease activity.
From these experiments it was clear that the hsp86 promoter was not 
suitable to drive expression of PfSUB2 from an episome. The apparent toxicity 
appeared to be due to the constitutive nature of the promoter and therefore the use 
of other promoters was considered for work to proceed.
5.3 Expression of PfSUB2 under the control of the amal promoter
The results described above suggested that expression of PfSUB2 under 
the control of a constitutively active erythrocytic cycle promoter is toxic to the 
parasite. Microarray data indicates that AMA1 is expressed at the same time as 
PfSUB2 but appears to be a more abundant protein [19]. It was therefore postulated 
that the use of the amal promoter to drive expression of PfSUB2 from an episome 
might prevent toxicity while resulting in the production of more protein than if the 
endogenous pfusb2 promoter was used. In order to test this notion, construct 
pAMA15'-sub2wHA was prepared. This construct contains the full-length pfsub2synth 
gene, modified with a single C-terminal HA tag, under the control of the amal 
promoter. Transfections of D10 parasites with the above construct were performed 
and parasites were detected by thin film after 18 days of drug selection. Plasmid 
was recovered from this culture and three clones analysed by restriction digest.
159
There were no rearrangements of the plasmid in any of the clones selected (data 
not shown). This parasite line was named amaf-PfSUB2HA.
Analysis by IFA using the anti-HA mAb 3F10 produced a signal in -10% of 
mature schizonts, revealing the presence of a HA tagged protein, with the intensity 
of the fluorescence varying greatly between individual schizonts (Figure. 5.2). The 
PfSUB2 expressed from the episome was named PfSUB2epi. Interestingly, the anti- 
HA signal was quite different to that seen in the PfSUB2HA line (Chapter 3) 
exhibiting a more diffuse pattern that appeared to be distributed throughout the 
daughter merozoites, perhaps suggesting a cytoplasmic location for the protein.
P. falciparum carries episomal DNA as trimeric concatamers with multiple 
concatamers per parasite and parasite replication is associated with rather 
inefficient segregation of plasmid between daughter merozoites [126, 188]. As a 
result, it has often been observed that proteins expressed from an episome can only 
be detected in a proportion of parasites [189], This is especially true of episomal 
expression of proteins labelled with GFP where only a proportion of the parasites 
fluoresce [190, 191]. The lack of detectable PfSUB2epi in the majority of parasites 
and the large variation in the intensity of the 3F10 signal in those parasites with 
detectable protein levels was therefore not unexpected, and was probably due to 
variation in plasmid copy number between individual parasites. It would be predicted 
that the more copies of plasmid carried by the individual parasite the greater the 
amount of protein produced and therefore the more intense the signal when 
detected by IFA. The high intensity of fluorescence seen in some of the amal- 
PfSUB2HA schizonts compared to clones in which the endogenous pfsub2 gene 
had been epitope-tagged (see Chapter 3) suggested that within these parasites the 
PfSUB2 levels were higher than in wild-type parasites (see Figure 5.2) and that 
these levels are not immediately toxic to the parasite. However as these ‘high 
expressers’ accounted for less than 10% of the population, the overall PfSUB2 I
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Figure 5.2 Individual parasites harbouring plasmid pAMA15'-sub2wHA 
express varying amounts of PfSUB2epi
IFA analysis of ama7-PfSUB2HA parasites using the anti-HA mAb 3F10. Parasite 
nuclei are stained with DAPI (blue). Schizont A appears to express significantly 
higher levels of PfSUB2epi than schizont B. These images were obtained from the 
same thin blood film. Magnification 100x.
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levels were thought unlikely to be significantly greater than those of a wild type 
population.
PfSUB2epi detection in the amaf-PfSUB2HA parasites was also likely 
hindered by the decision to use a single HA tag as opposed to a HA3 tag, which 
would allow more sensitive detection. The reason for using a single tag was that, at 
the point that these experiments were initiated, it was not known whether a HA3 tag 
would be deleterious to the parasite. However the work described in Chapter 3 has 
since shown that this is not the case.
Westerns blots with 3F10 were performed on schizont lysates but were 
inconclusive due to the very weak signals obtained (data not shown). This was 
probably due to the fact only a small amount of schizonts were carrying detectable 
levels of protein as discussed above, and the presence of only a single tag. The 
inability to assess whether a full length PfSUB2 was expressed from the episome 
and whether it underwent correct processing meant the amaf-PfSUB2HA line was 
of limited use. Further work on this line was abandoned until these issues could be 
resolved.
5.4 Expression of a triple HA tagged PfSUB2 under the control of the amal 
promoter
The above results indicated that episomal expression of PfSUB2 under the 
control of the amal promoter could result in expression of tagged protein but with 
both segregation and detection problems (see 5.2). Plasmid pAMA15'-sub2wHA 
was modified to rectify these problems. First, the Rep20 sequence was added as it 
has previously been shown to improve plasmid segregation between daughter 
merozoites [122, 192]. Second, as the work from Chapter 3 had in the meantime 
shown that it is possible to tag the endogenous pfsub2 with a HA3 tag without any 
deleterious effects on parasite growth, sequence encoding a HA3 tag at the 3' end
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of the pfsub2synth gene was included to improve detection of the protein within the 
parasite.
Transfections were performed with pAMA15'-sub2wHA3Rep20 and parasites 
were detected in blood smears after 17 days of drug selection. The resulting 
parasite line was named ama'/-PfSUB2HA3R. Plasmid was recovered from this line 
and three clones selected for restriction digest analysis. None of the clones selected 
showed any re-arrangements (data not shown). Disappointingly the Rep20 
sequence did not significantly reduce the time taken for parasites to appear after the 
start of drug selection (17 days vs. 18 days without Rep20) as it had previously been 
shown to [122, 190], This suggests that for this plasmid the presence of the Rep20 
sequence does not improve segregation between daughter merozoites.
IFA analysis with the anti-HA mAb 3F10 revealed the presence of a HA 
tagged protein in schizonts with a higher percentage (~30-50%) of parasites 
showing a signal compared to the ama7-PfSUB2 line. The intensity of the signal in 
individual schizonts varied greatly as before (data not shown). The protein 
expressed from this episome was named PfSUB2HA3epi. The variation in intensity 
of the 3F10 signal provided further evidence that the Rep20 sequence had not 
improved plasmid segregation as this would be expected to result in a more even 
distribution of the fluorescence signal. The increase in the proportion of parasites 
expressing detectable protein was therefore considered likely to be due to improved 
detection of the protein due to the addition of two further HA tags to the C-terminus 
of the protein. Once again the small percentage of parasites exhibiting a very 
intense signal appeared phenotypically normal suggesting that high levels of 
PfSUB2 are not immediately toxic to the parasite.
The IFA pattern seen using 3F10 in amaf-PfSUB2HA3R schizonts was the 
same as seen with the amaf-PfSUB2HA schizonts in 5.2. The signal appeared 
diffuse and spread within daughter merozoites with no apparent accumulation of 
protein at the apical end. Dual labelling of the schizonts with anti-RhopH2 and anti-
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AMA1 mAbs, markers for rhoptry and microneme organelles respectively, confirmed 
the absence of an accumulation of PfSUB2 at the apical end of the parasite as there 
was no co-localisation of either signal with that of 3F10 (see Figure. 5.3) [58, 59, 
152]. Similarly, the use of an anti-MSP1 mAb confirmed there was no PfSUB2 found 
on the parasite surface. Endogenous PfSUB2 is secreted from the micronemes onto 
the parasite surface upon merozoite release and from here is capped to the 
posterior end of the parasite (Chapter 3). In order to evaluate whether the same 
trafficking pattern could be seen with the episomally expressed PfSUB2, free 
merozoites of the a/T7a'/-PfSUB2HA3R line were then studied to determine whether 
the PfSUB2HA3epi re-localised upon merozoite release from the schizont. However, 
the signal detected in the amaf-PfSUB2HA3R free merozoites was the same as that 
seen in the schizonts, being diffuse and confined within the merozoites (Figure 5.4). 
Dual labelling with the anti-RhopH2 or anti-MSP1 mAbs again showed no co­
localisation with 3F10 in either the rhoptries or on the merozoite surface. In many of 
the schizonts and merozoites the MSP1 surface signal appeared to encircle the 
diffuse PfSUB2HA3epi signal. It was therefore concluded that the PfSUB2HA3epi 
was expressed predominantly in the cytoplasm of both schizonts and free 
merozoites. It is worth noting that previous studies have shown that AMA1 
expressed under the control of the dhfr-ts promoter is also found in the parasite 
cytoplasm and the IFA analyses carried out in that study showed a very similar 
pattern to that seen here with PfSUB2HA3epi [151].
The mis-localisation of PfSUB2HA3epi observed above was considered 
probably a result of the use of the amal promoter instead of the authentic pfsub2 
promoter. AMA1 and PfSUB2 are expressed at the same time during the RBC cycle 
and therefore it had been hoped that using the amal promoter would result in 
expression of PfSUB2 at the correct time and trafficking to the correct sub-cellular 
location [19]. However as the ultimate aim of this section of the work was to purify
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Figure 5.3 PfSUB2HA3epi expressed by schizonts harbouring plasmid 
pAMA15'-sub2wHA3Rep20does not locate to the parasite plasma membrane, 
the micronemes, or rhoptries
IFA analysis of ama7-PfSUB2HA3R schizonts. Slides were probed with the anti-HA 
mAb 3F10 and either mAb 61.3 (anti-RhopH2), mAb 4G2 (anti-AMA1) or mAb X509 
(anti-MSP1). Parasite nuclei are stained throughout with DAPI (blue). Magnification 
100x.
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Figure 5.4 PfSUB2HA3epi expressed by parasites harbouring plasmid 
pAMA15'-sub2wHA3Rep20 does not localise to the free merozoite surface or 
rhoptries
IFA analysis of free merozoites of a parasite culture stably transfected with 
pAMA15'-sub2wHA3Rep20. Slides were probed with the anti-HA mAb 3F10 and 
either mAb 61.3 (anti-RhopH2) or mAb X509 (anti-MSP1). Parasites nuclei are 
stained throughout with DAPI (blue). Magnification 100x.
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the PfSUB2HA3epi from the parasite provided the protein is active, its sub-cellular 
location was thought unimportant.
Western blots were then performed, using mAbs 3F10 and H5 (anti-Rap2), 
to probe lysates of ama'/-PfSUB2HA3R schizonts in parallel with those of 
PfSUB2HA schizonts (Figure. 5.5). The 3F10 probed blot revealed a number of 
bands in the ama 1 -PfSUB2HA3R lane, migrating with apparent masses of 150 kDa, 
72 kDa, 55 kDa, and a closely spaced triplet of 38 to 36kDa. The 150 kDa and 72 
kDa species probably correspond to the full length PfSUB2 and processed, ‘active’ 
PfSUB2 respectively, as they were exactly the same size as those bands seen in 
the PfSUB2HA line. The remaining polypeptides are detected on a western blot and 
are therefore most likely to contain the HA3 tag. In order for a PfSUB2 fragment to 
contain the C-terminal HA3 tag and the catalytic triad needed for protease activity it 
is predicted to have a mass of 67 kDa. As the bands are all smaller than this it is 
unlikely that they contain the catalytic triad and are therefore probably inactive. They 
were therefore considered likely to be breakdown products. The 55 kDa and 36 kDa 
bands were seen in the PfSUB2HA lane as well as the amaf-PfSUB2HA3R lane. 
This other two 38-36 kDa bands were unique to the a/T7af-PfSUB2HA3R lane and 
were thought possibly to be the result of differences in sample preparation and the 
action of proteases.
Cleavage of the propeptide from the catalytic domain of eukaryotic subtilases 
usually occurs in the ER or Golgi [193, 194], In the case of furin, for example, the 
propeptide is first cleaved in the ER but full activation of the protease only occurs 
after further cleavage of the propeptide in the Golgi to dissociate it from the rest of 
the protein [161]. In the presence of brefeldin A, an inhibitor of anterograde 
transport from ER to Golgi, processing of PfSUB2 to the 74 kDa species occurs but 
further cleavage to the 72 kDa terminal processing product is blocked [195], This 
indicates that, while the propeptide is cleaved within the ER the final processing 
step, potentially indicating full activation, occurs outside this compartment. PfSUB2
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Figure 5.5 PfSUB2HA3epi undergoes typical processing.
Western blots were performed on extracts of PfSUB2HA clone 2D, and of schizonts 
stably transfected with construct pAMA15'-sub2wHA3Rep20. Blots were probed with 
the anti-HA mAb 3F10 or the anti-Rap2 mAb H5. Species corresponding to the 
various processed forms of PfSUB2 are arrowed and indicated.
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is therefore likely to be fully active only after it has left the ER. PfSUB2HA3epi and 
the endogenous PfSUB2 are likely to be found together in the ER and Golgi before 
trafficking to distinct locations within the merozoite. If PfSUB2 is not fully active until 
after the ER the observed processing of PfSUB2HA3epi is unlikely to be due to the 
action of the endogenous PfSUB2 in trans, and is therefore most likely autocatalytic, 
indicating that it is catalytically active. Experimental confirmation of this could be 
achieved through the use of the ‘inactive’ active-site Ser-to-Ala p fs u b 2 s y nth mutant 
used in the above experiment (5.2) within the pAMA15' backbone. If the 
PfSUB2HA3epi is not cleaved when the active site serine has been replaced with an 
alanine the unmutated PfSUB2HA3epi must be active.
These experiments demonstrated that pfsub2synth could be transcribed and 
translated by P. falciparum to produce a full length PfSUB2. The protein undergoes 
typical processing and is therefore likely to be correctly folded and active. This 
implies that episomal expression of PfSUB2 can be used to produce active protease 
that could potentially be purified from the parasite and therefore the parasite could 
be used as an expression system. To assess relative expression levels of the 
synthetic gene product, the blot probed with the anti-Rap2 antibody (Figure 5.5) was 
used to assess the loading of the gels and to assess the relative amounts of 
PfSUB2 in the different parasite lanes. The Rap2 blot showed that more protein was 
loaded in the PfSUB2HA lane than the amaf-PfSUB2HA3R lane. This is consistent 
with the greater amount of PfSUB2 seen in the PfSUB2HA lane in the blot probed 
with 3F10 (Figure 5.5). By comparing the amount of PfSUB2 present against the 
amount of sample loaded it appeared that there is an equivalent amount of PfSUB2 
in both the a/r]a'/-PfSUB2HA3R and PfSUB2HA lines. Of course as the endogenous 
PfSUB2 in the amaf-PfSUB2HA3R line was not tagged it would not have been 
detected in these blots and the amaf-PfSUB2HA3R parasites might actually be 
expressing higher levels of PfSUB2. Alternatively, as found by Healer et al. in the a 
previous study referred to above [132], the PfSUB2HA3epi may show dominance
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over the endogenous PfSUB2 resulting in the majority of PfSUB2 originating from 
the episome.
As only a fraction of the schizonts in the amaf-PfSUB2HA3R line expressed 
detectable levels of PfSUB2HA3epi it was perhaps not surprising that the levels 
seen were equivalent to those seen in the PfSUB2HA line despite the use of the 
amal promoter to drive protein expression. It seems likely that, until the segregation 
problems seen with episomal expression can be rectified, over-expression of 
parasite proteins within P. falciparum will not be possible. As the PfSUB2HA3epi 
levels were not significantly different to the levels of PfSUB2 detected in PfSUB2HA, 
attempts to purify the protein were abandoned.
5.5 Characterisation of the pfsub2 promoter
Attempts to ‘knock-out’ the pfsub2 gene in the parasite have been 
unsuccessful suggesting the protein plays an essential function in blood-stages of 
the parasite [117]. Functional studies involving mutagenesis of the pfsub2 gene are 
therefore made difficult as any that alter the normal activity, trafficking or movement 
of the protease might be lethal to the parasite and therefore the effects would be 
impossible to detect. The expression of a mutant tagged form of PfSUB2 from an 
episome could be used to overcome these difficulties as the endogenous PfSUB2 
would remain unaltered and therefore the parasites would remain viable whatever 
manipulations were made to the episomal copy of the gene. The effect of the 
mutations on the episomally encoded protein could then be studied. However before 
such an approach can be considered possible, PfSUB2 must be expressed from an 
episome and shown to be processed and trafficked in a manner that mimics that of 
the endogenous protein. As shown above, PfSUB2 expressed from an episome 
under the control of the amal promoter is correctly processed and therefore is 
presumably correctly folded and active. However the sub-cellular localisation of the 
protein was found to be incorrect. One possible explanation for this mis-trafficking is
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the use of a heterologous promoter, and so work was initiated to characterise the 
endogenous pfsub2 promoter in order that it could be used for future studies of this 
type [128, 181].
CAT is an E. coli enzyme that acetylates chloramphenicol, inactivating the 
antibiotic and therefore conferring resistance to it. CAT is a robust and highly 
processing enzyme, readily detected using a simple assay, and the CAT reporter 
system is commonly used to identify P. falciparum intergenic regions with promoter 
activity [121, 124]; the ability of intergenic regions to drive expression of CAT can be 
quantitatively assessed by detection of CAT expression in the parasite. Six 
fragments of the region 5' to the pfsub2 gene F1 (-1459 to -1 bp), F2 (-1267 to -1 
bp), F3 (-1054 to -1 bp), F4 (-824 to -1 bp), F5 (-624 to -1 bp) and F6 (-286 to -1 
bp) were amplified from parasite DNA. This upstream sequence appears typical of 
P. falciparum intergenic regions, with an A+T content of 85% and a number of 
poly(dA)/poly(dT) tracts [182, 184, 185]. Each PCR fragment was placed upstream 
of the cat gene within the vector backbone of pHC1-CAT and the resulting 
constructs transfected into the parasite alongside the positive control pHC1-CAT 
(where the cat gene is under the control of the cam promoter) and the negative 
control plasmid pHC1-no 5'UTR (a control plasmid supplied by R. O’Donnell, which 
is identical to pHC1-CAT except that it lacks a promoter for the cat gene) [130]. 
Stable lines carrying all of the plasmids mentioned above were established and the 
ability of each 5' fragment to drive reporter gene expression was then assessed by 
CAT assay.
The results of these assays are shown in Figure 5.6. Acetylated forms of 
chloramphenicol were observed in the positive control lanes (bacterial CAT and 
pHC1-CAT) as well as the F1, F2, F3, F4 and F5 lanes. These results suggest that 
the pfsub2 5' fragments F1, F2, F3, F4 and F5 all contain elements capable of 
driving expression of CAT in the parasite and therefore exhibit promoter activity. 
However, the intensity of the acetylated chloramphenicol bands decreased as the
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Figure 5.6 The pfsub2 5' UTR displays promoter activity
CAT assay performed on extracts of P. falciparum cultures stably transfected with 
constructs pHC1-CATF1 (F1), pHC1-CATF2 (F2), pHC1-CATF3 (F3), pHC1-CATF4 
(F4), pHC1-CATF5 (F5), pHC1-CATF6 (F6), pHC1-CAT (CAT) and pHC1-no 5'UTR 
(NP). The lane marked (Neg) is the negative control. The lanes marked (Pos) are 
the positive control containing bacterial CAT. The species on the film correspond to 
(a) non-acetylated residual substrate, (b) 1-acetyl-chloramphenicol and (c) 1,3 acetyl 
chloramphenicol.
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fragments decrease in size from the F1, F2 and F3 lanes, which were equally 
intense, to the weaker bands seen in the F4 lane and the weaker still in the F5 lane. 
This suggests that the F1, F2 and F3 fragments can act as equally strong 
promoters. As the F3 fragment is 405 bp shorter than the F1 fragment this suggests 
that the region between -1459 to -1054 bp has no major promoter activity. The F6 
fragment was the only pfsub2 5' fragment to show no activity, and given its small 
size in comparison with previously characterised P. falciparum promoters this is 
unsurprising [124], Overall, the observed gradual decrease in activity as the 
fragments decrease in size is consistent with results obtained by others with other P. 
falciparum promoters [124, 183, 184],
Plasmid was recovered from all the pHC1-CATprom lines and several clones 
of each analysed by restriction digest in parallel with samples of the plasmid used 
for transfection (Figure 5.7). The results of this were surprising. All the recovered 
clones could be readily linearised, migrating with an apparent size identical to that of 
the parental plasmids. This suggested that no major deletions had occurred during 
passage in the parasite. However, further digestion of the recovered plasmid proved 
impossible. To confirm that these results were not due to experimental error, fresh 
samples of DNA were produced from all the lines and new clones of recovered 
plasmid selected and analysed by restriction digest. The results remained the same. 
The recovered control plasmids pHC1-CAT and pHC1-CATnp also failed to digest 
as expected.
The restriction digest results contradict those seen by CAT assays and 
parasite growth. Xho I and Cel II digestion of all the constructs should release a 793 
bp band, corresponding to the cat gene, and a band corresponding to the promoter 
fragment but in none of the Xho I/Cel II digests of the recovered clones were bands 
of these sizes released, suggesting re-arrangements of the plasmid. However the 
selected parasites clearly expressed a functional CAT as seen in the CAT assays. 
The fact that the parasite lines were pyrimethamine resistant also implies the
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Figure 5.7 Restriction digest analysis of recovered pHC1-CATprom plasmids 
gives unexpected results
Agarose gels stained with ethidium bromide of restriction digest analysis of 
recovered clones of pHC1-CATF1 and pHC1-no 5'UTR. Plasmids are undigested 
unless marked otherwise. Xho I/Cel II digests of pHC1-CATF1 is expected to 
produce bands of 793 bp, 1.459 kb and 6.597 kb as can be seen in the lane 
(arrowed) containing the input plasmid. Xho I/Cel II digests of pHC1-no 5'UTR is 
predicted to produce bands of 793 bp and 6.597 kb as can be seen in the lane 
containing this input plasmid (asterisked). Pst I/EcoR I digests of pHC1-no 5'UTR 
should produce bands of 361 bp, 467 bp, 1.008 kb, 1.391 kb, 1.454 kb and 2.709 kb 
as can be seen in the input plasmid (double asterisked). As can be seen, none of 
the clones isolated from recovered DNA produced the expected restriction fragment 
pattern upon digestion.
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presence in each plasmid of a functional drug resistance cassette. It seems most 
unlikely that the number of re-arrangements needed to remove all the restriction 
sites would leave an unaltered cassette. This suggested that the restriction digest 
results may not be correct and that the plasmid DNA had become in some way 
resistant to digestion after replication in the parasite. Although the analysis of the 
recovered plasmids gave unexpected results this does not invalidate the results 
obtained from the CAT assays. The aim of these experiments was to identify 
fragments of the region 5' to the pfsub2 gene that possess promoter activity. The 
results showed that the region between -1459 to -1 bp can drive protein expression 
and that this region can be reduced by 405 bp (-1054 to -1 bp) with no major drop in 
promoter activity. Further deletions of the region downstream o f-1054 bp reduced 
promoter activity. The F1, F2 or F3 fragments could therefore all be used to drive 
expression of PfSUB2 although as F3 is the smallest it would possibly be easier to 
clone in E. coli. However previous work by others has shown that reductions in the 
5' region of a gene can alter the expression profile of the respective protein [128]. It 
should be confirmed that the F3 fragment drives expression of a reporter gene at the 
time of PfSUB2 expression before being used to drive expression of pfsub2svnth from 
an episome [114, 116]. Unfortunately the stability of CAT means it cannot be used to 
study promoter activity accurately within the different stages of the RBC cycle and a 
less stable reporter protein such as luciferase is required. The half life of luciferase 
is only a few hours and can therefore be used to distinguish promoter activity during 
the different stages of the 48 hour P. falciparum RBC cycle [196]. Once the DNA 
sequences identified here are shown to express luciferase with the same temporal 
kinetics as PfSUB2 (i.e. peaking at 40-48 hours post invasion) they can be used to 
express PfSUB2 from an episome.
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Discussion
Initially the work in this chapter focused on use of P. falciparum to over­
express PfSUB2 in a bid to obtain a source of correctly folded active protein. The 
choice of promoter to drive expression of PfSUB2 is important; expression under the 
control of a constitutive promoter was found to be toxic to the parasite while use of a 
late stage promoter resulted in the production of a correctly processed and therefore 
-  it is presumed - folded and enzymatically active PfSUB2. In individual amal- 
PfSUB2HA3R parasites high levels of PfSUB2 were detected by IFA and these 
parasites appeared phenotypically normal suggesting that high levels of the 
protease are not necessarily toxic to the parasite. However within the population as 
a whole the amount of PfSUB2HA3epi produced was approximately the same as the 
amount of PfSUB2 expressed in the PfSUB2HA line, likely as result of poor 
segregation of plasmid between daughter merozoites. Until these segregation 
problems are resolved it seems unlikely that high levels of PfSUB2 can be 
expressed within the parasite.
Our results confirm previous studies that the use of alternative promoters to 
express a malarial protein from an episome can result in its mis-localisation. In order 
to develop a system for driving PfSUB2 expression from an episome whilst obtaining 
correct localisation, the pfsub2 promoter was studied. A number of fragments of the 
region 5' to the pfsub2 gene have been found which possess promoter activity. 
Once the ability of these sequences to control expression of the protein at the 
correct stages of the RBC cycle has been assessed, they can be used to continue 
the work on expression of PfSUB2 from an episome. It may then be possible to use 
this system to study the effects of mutations within the episome-encoded PfSUB2, 
and in this way assess the proteins function.
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Discussion
PfSUB2 is considered to be MESH, the protease involved in shedding MSP1 
and AMA1 from the merozoite surface, and is therefore a good candidate for future 
drug design. However, previous work on PfSUB2 has been hampered by the 
difficulties in detecting the protein within the parasite and the inability to express it in 
an active recombinant form. The work described in this thesis focused on utilising 
transfection technology to further understand the role of PfSUB2 within the parasite.
Overview
Epitope tagging of the PfSUB2 C-terminus allowed unambiguous localisation 
of the protein to the micronemes of the mature schizont. This differs from the dense 
granule location previously described but is consistent with the observation that 
PfSUB2 is released onto the parasite surface at or prior to invasion as dense 
granules are not believed to release their contents until invasion is complete [116]. 
This is not the first instance of mis-localisation of P. falciparum proteins as AMA1 
was initially localised to the rhoptries before reassignment to the micronemes [132], 
The accurate detection of PfSUB2 within the parasite has allowed the protein to be 
studied during schizogony and eventual merozoite release and has resulted in the 
following model. Initially PfSUB2 accumulates in the micronemes of the mature 
schizont. The protease undergoes processing in the ER but may remain associated 
with the propeptide to prevent the cleavage of proteins within the microneme. Upon 
merozoite release active PfSUB2 is secreted onto the parasite surface where it 
engages with an actin-based motor. It is unlikely that this interaction is via the 
PfSUB2 cytoplasmic domain as this region is unconserved amongst Plasmodium 
species, lacks the residues associated with TRAP and MIC2 interaction with actin 
and -  as shown by this study - can be modified by the addition of a tag without 
deleterious effects on parasite growth [39, 40]. It is possible that PfSUB2 may 
interact with the actinomyosin motor through ectoplasmic interactions with other
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micronemal proteins that are themselves connected to the motor. An example of this 
is seen in T. gondii where MIC2-associated protein (M2AP) remains complexed to 
MIC2 throughout secretion, translocation and release. This interaction with MIC2 
causes the capping of TgM2AP which itself lacks a transmembrane domain [197],
Once on the surface of the merozoite PfSUB2 is pulled to the posterior of the 
cell, in the process encountering and cleaving MSP1 and AMA1 from the surface of 
the parasite. However in this work this capping movement has only been studied in 
the absence of invasion. It is possible that on invading merozoites PfSUB2 
movement occurs during the parasites entry into the nascent parasitophorous 
vacuole and that the protease concentrates at the moving junction. PfSUB2 is then 
carried into the RBC on the parasite surface where it eventually appears to diffuse 
back over the parasite surface perhaps as a result of the actinomyosin motor 
stopping once invasion is complete. By a few hours post invasion PfSUB2 is no 
longer detected and this may reflect turnover of the protease following completion of 
its role during invasion.
Future work
PfSUB2 is the first example of a merozoite protein that undergoes capping 
and the protein behaves in the way predicted for MESH. However, many questions 
remain unanswered and work is still needed to further dissect the role of the protein 
during invasion. At present the precise location of PfSUB2 as the parasite invades 
the RBC is unknown. The small size of the P. falciparum merozoite makes studies of 
the moving junction, even using IEM, extremely challenging. One approach to 
overcoming this obstacle would be to fuse the reporter protein GFP to PfSUB2. This 
would allow studies in real time to determine the timing and dynamics of PfSUB2 
movement as invasion proceeds.
It would also be interesting to further investigate the interaction between 
PfSUB2 and the actinomyosin motor within the parasite, for example defining the
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regions of the protein required for movement. The episomal expression of PfSUB2 
developed in Chapter 5 could be used with the fragments of the pfsub2 5' region 
shown to have promoter activity controlling expression of the pfsub2synth gene. 
Initially it would have to be confirmed that the sub-cellular location, time of 
expression and processing of the episomally expressed PfSUB2 matched that of the 
endogenous PfSUB2. The effect of various mutations on the movement of PfSUB2 
could then be assessed. It is perhaps worthy of note that the region between the 
catalytic triad and predicted transmembrane domain of PfSUB2 is relatively large 
and extremely well conserved amongst Plasmodium species (see Figure 1.5). The 
function of this region is unknown but given the level of conservation it is likely to be 
functionally important. If this region is involved in interactions with other proteins, 
mutations of conserved residues may affect these interactions and prevent PfSUB2 
capping. This approach could also be used to mutate residues around the sites at 
which processing is predicted to occur in an attempt to prevent it. This would reveal 
the precise processing sites and allow the propeptide to be accurately defined. 
Although PfSUB2 is predicted to have a relaxed substrate specificity it is unlikely the 
enzyme can cleave every sequence and by mutating the residues at the cleavage 
site to prevent processing the sequence specificity of the enzyme could be 
examined. A similar approach has been used with some success in the case of 
PfSUBI [112].
Conclusion
While the ability to transfect P. falciparum and modify PfSUB2 has increased 
our understanding of the protein there are still many questions left to answer about 
its role during invasion. However it is clear that PfSUB2 is a good candidate for drug 
design. Protease inhibitors are used to treat infections such as Human 
Immunodeficiency Virus (HIV). However, as with P. falciparum, the emergence of 
drug resistant forms of the virus has reduced the efficacy of these drugs. This has
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been combated with the use of combination therapy involving several drugs aimed 
at different targets which reduces the rate at which resistance occurs. White et al 
discussed using a similar approach with P. falciparum infections as combination 
therapy is predicted to prolong the efficacy of antimalarials [4]. A protease inhibitor 
would be a useful addition to current pool of antimalarials and could be used in 
combination therapy.
186
1. WHO, WHO, 'Roll Back Malaria.' 
http://www.rbm.who.int/cmc upload/0/000/015/370/RBMInfosheet 3.h 
tm.
2. Snow, R.W., et al., The global distribution of clinical episodes of 
Plasmodium falciparum malaria. Nature, 2005. 434(7030): p. 214-7.
3. Gallup, J.L. and J.D. Sachs, The economic burden of malaria. Am J
Trop Med Hyg, 2001. 64(1-2 Suppl): p. 85-96.
4. White, N.J., et al., Averting a malaria disaster. Lancet, 1999. 
353(9168): p. 1965-7.
5. Breman, J.G., The ears of the hippopotamus: manifestations, 
determinants, and estimates of the malaria burden. Am J Trop Med 
Hyg, 2001. 64(1-2 Suppl): p. 1-11.
6. Blackman, M.J., Proteases involved in erythrocyte invasion by the 
malaria parasite: function and potential as chemotherapeutic targets. 
Curr Drug Targets, 2000.1(1): p. 59-83.
7. Bannister, L.H., et al., A brief illustrated guide to the ultrastructure of
Plasmodium falciparum asexual blood stages. Parasitol Today, 2000. 
16(10): p. 427-33.
8. Aikawa, M., et al., Erythrocyte entry by malarial parasites. A moving 
junction between erythrocyte and parasite. J Cell Biol, 1978. 77(1): p. 
72-82.
9. Dvorak, J.A., et al., Invasion of erythrocytes by malaria merozoites. 
Science, 1975. 187(4178): p. 748-50.
10. Carruthers, V.B. and L.D. Sibley, Sequential protein secretion from 
three distinct organelles of Toxoplasma gondii accompanies invasion 
of human fibroblasts. Eur J Cell Biol, 1997. 73(2): p. 114-23.
11. Culvenor, J.G., K.P. Day, and R.F. Anders, Plasmodium falciparum 
ring-infected erythrocyte surface antigen is released from merozoite 
dense granules after erythrocyte invasion. Infect Immun, 1991. 59(3): 
p. 1183-7.
12. Miller, L.H., et al., Interaction between cytochalasin B-treated malarial 
parasites and erythrocytes. Attachment and junction formation. J Exp 
Med, 1979. 149(1): p. 172-84.
13. Pinder, J.C., et al., Actomyosin motor in the merozoite of the malaria 
parasite, Plasmodium falciparum: implications for red cell invasion. J 
Cell Sci, 1998. 111 ( Pt 13): p. 1831-9.
14. Dobrowolski, J.M. and L.D. Sibley, Toxoplasma invasion of 
mammalian cells is powered by the actin cytoskeleton of the parasite. 
Cell, 1996. 84(6): p. 933-9.
15. Dobrowolski, J.M., V.B. Carruthers, and L.D. Sibley, Participation of 
myosin in gliding motility and host cell invasion by Toxoplasma gondii. 
Mol Microbiol, 1997. 26(1): p. 163-73.
16. Bumstead, J. and F. Tomley, Induction of secretion and surface 
capping of microneme proteins in Eimeria tenella. Mol Biochem 
Parasitol, 2000. 110(2): p. 311-21.
17. Pinder, J., et al., Motile systems in malaria merozoites: how is the red 
blood cell invaded? Parasitol Today, 2000. 16(6): p. 240-5.
18. Wesseling, J.G., M.A. Smits, and J.G. Schoenmakers, Extremely 
diverged actin proteins in Plasmodium falciparum. Mol Biochem 
Parasitol, 1988. 30(2): p. 143-53.
187
19. Le Roch, K.G., et al., Discovery of gene function by expression 
profiling of the malaria parasite life cycle. Science, 2003. 301(5639): p. 
1503-8.
20. Field, S.J., et al., Actin in the merozoite of the malaria parasite, 
Plasmodium falciparum. Cell Motil Cytoskeleton, 1993. 25(1): p. 43-8.
21. Wetzel, D. M., et al., Actin filament polymerization regulates gliding 
motility by apicomplexan parasites. Mol Biol Cell, 2003. 14(2): p. 396- 
406.
22. Dobrowolski, J.M., I.R. Niesman, and L.D. Sibley, Actin in the parasite 
Toxoplasma gondii is encoded by a single copy gene, ACT1 and 
exists primarily in a globular form. Cell Motil Cytoskeleton, 1997.
37(3): p. 253-62.
23. Schuler, H., A.K. Mueller, and K. Matuschewski, Unusual properties of 
Plasmodium falciparum actin: new insights into microfilament 
dynamics of apicomplexan parasites. FEBS Lett, 2005. 579(3): p. 655-
60.
24. Meissner, M., D. Schluter, and D. Soldati, Role of Toxoplasma gondii 
myosin A in powering parasite gliding and host cell invasion. Science, 
2002. 298(5594): p. 837-40.
25. Bergman, L.W., et al., Myosin A tail domain interacting protein (MTIP) 
localizes to the inner membrane complex of Plasmodium sporozoites.
J Cell Sci, 2003. 116(Pt 1): p. 39-49.
26. Menard, R., Gliding motility and cell invasion by Apicomplexa: insights 
from the Plasmodium sporozoite. Cell Microbiol, 2001. 3(2): p. 63-73.
27. Sultan, A.A., et al., TRAP is necessary for gliding motility and 
infectivity of plasmodium sporozoites. Cell, 1997. 90(3): p. 511-22.
28. Kappe, S., et al., Conservation of a gliding motility and cell invasion 
machinery in Apicomplexan parasites. J Cell Biol, 1999. 147(5): p. 
937-44.
29. Huynh, M.H., et al., Trans-genera reconstitution and complementation 
of an adhesion complex in Toxoplasma gondii. Cell Microbiol, 2004. 
6(8): p. 771-82.
30. Dessens, J.T., et al., CTRP is essential for mosquito infection by 
malaria ookinetes. Embo J, 1999. 18(22): p. 6221-7.
31. Robson, K.J., et al., A highly conserved amino-acid sequence in 
thrombospondin, properdin and in proteins from sporozoites and blood 
stages of a human malaria parasite. Nature, 1988. 335(6185): p. 79-
82.
32. Wan, K.L., et al., Molecular characterisation of an expressed 
sequence tag locus of Toxoplasma gondii encoding the micronemal 
protein MlC2. Mol Biochem Parasitol, 1997. 84(2): p. 203-14.
33. Robson, K.J., et al., Thrombospondin-related adhesive protein (TRAP) 
of Plasmodium falciparum: expression during sporozoite ontogeny and 
binding to human hepatocytes. Embo J, 1995.14(16): p. 3883-94.
34. Carruthers, V.B., O.K. Giddings, and L.D. Sibley, Secretion of 
micronemal proteins is associated with toxoplasma invasion of host 
cells. Cell Microbiol, 1999.1(3): p. 225-35.
35. Gantt, S., et al., Antibodies against thrombospondin-related 
anonymous protein do not inhibit Plasmodium sporozoite infectivity in 
vivo. Infect Immun, 2000. 68(6): p. 3667-73.
188
36. Carruthers, V.B. and L.D. Sibley, Mobilization of intracellular calcium 
stimulates microneme discharge in Toxoplasma gondii. Mol Microbiol, 
1999. 31(2): p. 421-8.
37. Tomley, F.M. and D.S. Soldati, Mix and match modules: structure and 
function of microneme proteins in apicomplexan parasites. Trends 
Parasitol, 2001. 17(2): p. 81-8.
38. Wang, J., D.R. Tolan, and L. Pagliaro, Metabolic compartmentation in 
living cells: structural association of aldolase. Exp Cell Res, 1997. 
237(2): p. 445-51.
39. Buscaglia, C.A., et al., Sites of interaction between aldolase and 
thrombospondin-related anonymous protein in plasmodium. Mol Biol 
Cell, 2003. 14(12): p. 4947-57.
40. Jewett, T.J. and L.D. Sibley, Aldolase forms a bridge between cell 
surface adhesins and the actin cytoskeleton in apicomplexan 
parasites. Mol Cell, 2003. 11(4): p. 885-94.
41. Brassier, F., et al., C-terminal processing of the toxoplasma protein 
MIC2 is essential for invasion into host cells. J Biol Chem, 2003.
278(8): p. 6229-34.
42. Carruthers, V.B., G.D. Sherman, and L.D. Sibley, The Toxoplasma 
adhesive protein MIC2 is proteolytically processed at multiple sites by 
two parasite-derived proteases. J Biol Chem, 2000. 275(19): p. 14346-
53.
43. Opitz, C., et al., Intramembrane cleavage of microneme proteins at the 
surface of the apicomplexan parasite Toxoplasma gondii. Embo J,
2002. 21(7): p. 1577-85.
44. Sibley, L.D., S. Hakansson, and V.B. Carruthers, Gliding motility: an 
efficient mechanism for cell penetration. CurrBiol, 1998. 8(1): p. R12-
4.
45. Russell, D.G. and R.E. Sinden, The role of the cytoskeleton in the 
motility ofcoccidian sporozoites. J Cell Sci, 1981. 50: p. 345-59.
46. Adams, J.H., et al., An expanding ebl family of Plasmodium 
falciparum. Trends Parasitol, 2001. 17(6): p. 297-9.
47. Duraisingh, M.T., et al., Erythrocyte-binding antigen 175 mediates 
invasion in Plasmodium falciparum utilizing sialic acid-dependent and - 
independent pathways. Proc Natl Acad Sci U S A ,  2003. 100(8): p. 
4796-801.
48. Sim, B.K., et al., Receptor and ligand domains for invasion of 
erythrocytes by Plasmodium falciparum. Science, 1994. 264(5167): p. 
1941-4.
49. Gilberger, T.W., et al., The cytoplasmic domain of the Plasmodium 
falciparum ligand EBA-175 is essential for invasion but not protein 
trafficking. J Cell Biol, 2 0 0 3 .162(2): p. 317-27.
50. Silvie, O., et al., A role for apical membrane antigen 1 during invasion 
of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem,
2004. 279(10): p. 9490-6.
51. Triglia, T., et al., Apical membrane antigen 1 plays a central role in 
erythrocyte invasion by Plasmodium species. Mol Microbiol, 2000. 
38(4): p. 706-18.
52. Narum, D.L., et al., Immunization with parasite-derived apical 
membrane antigen 1 or passive immunization with a specific
189
monoclonal antibody protects BALB/c mice against lethal Plasmodium 
yoeliiyoelii YM blood-stage infection. Infect Immun, 2000. 68(5): p. 
2899-906.
53. Malkin, E.M., et al., Phase 1 clinical trial of apical membrane antigen 
1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. 
Infect Immun, 2005. 73(6): p. 3677-85.
54. Saul, A., et al., A human phase 1 vaccine clinical trial of the 
Plasmodium falciparum malaria vaccine candidate apical membrane 
antigen 1 in Montanide ISA720 adjuvant. Vaccine, 2005. 23(23): p. 
3076-83.
55. Hehl, A.B., et al., Toxoplasma gondii homologue of plasmodium apical 
membrane antigen 1 is involved in invasion of host cells. Infect 
Immun, 2000. 68(12): p. 7078-86.
56. Narum, D.L. and A.W. Thomas, Differential localization of full-length 
and processed forms of PF83/AMA-1 an apical membrane antigen of 
Plasmodium falciparum merozoites. Mol Biochem Parasitol, 1994. 
67(1): p. 59-68.
57. Howell, S.A., et al., Proteolytic processing and primary structure of 
Plasmodium falciparum apical membrane antigen-1. J Biol Chem,
2001. 276(33): p. 31311-20.
58. Bannister, L.H., et al., Plasmodium falciparum apical membrane 
antigen 1 (PfAMA-1) is translocated within micronemes along 
subpellicular microtubules during merozoite development. J Cell Sci,
2003. 116(Pt 18): p. 3825-34.
59. Healer, J., et al., Independent translocation of two micronemal 
proteins in developing Plasmodium falciparum merozoites. Infect 
Immun, 2002. 70(10): p. 5751-8.
60. Howell, S.A., et al., A single malaria merozoite serine protease 
mediates shedding of multiple surface proteins by juxtamembrane 
cleavage. J Biol Chem, 2003. 278(26): p. 23890-8.
61. Hodder, A.N., et al., The disulfide bond structure of Plasmodium apical 
membrane antigen-1. J Biol Chem, 1996. 271(46): p. 29446-52.
62. Tordai, H., L. Banyai, and L. Patthy, The PAN module: the N-terminal 
domains of plasminogen and hepatocyte growth factor are 
homologous with the apple domains of the prekallikrein family and with 
a novel domain found in numerous nematode proteins. FEBS Lett, 
1999. 461(1-2): p. 63-7.
63. Pizarro, J.C., et al., Crystal structure of the malaria vaccine candidate 
apical membrane antigen 1. Science, 2005. 308(5720): p. 408-11.
64. Kato, K., et al., Domain III of Plasmodium falciparum apical membrane 
antigen 1 binds to the erythrocyte membrane protein Kx. Proc Natl 
Acad Sci U S A ,  2005. 102(15): p. 5552-7.
65. Fraser, T.S., et al., Erythrocyte-binding activity of Plasmodium yoelii 
apical membrane antigen-1 expressed on the surface of transfected 
COS-7 cells. Mol Biochem Parasitol, 2001.117(1): p. 49-59.
66. Mitchell, G.H., et al., Apical membrane antigen 1, a major malaria 
vaccine candidate, mediates the close attachment of invasive 
merozoites to host red blood cells. Infect Immun, 2004. 72(1): p. 154- 
8 .
190
67. Mital, J., et al., Conditional Expression of Toxoplasma gondii Apical 
Membrane Antigen-1 (TgAMAI) Demonstrates That TgAMAI Plays a 
Critical Role in Host Cell Invasion. Mol Biol Cell, 2005.16(9): p. 4341- 
9.
68. Herrera, S., et al., A conserved region of the MSP-1 surface protein of 
Plasmodium falciparum contains a recognition sequence for 
erythrocyte spectrin. Embo J, 1993.12(4): p. 1607-14.
69. Goel, V.K., et al., Band 3 is a host receptor binding merozoite surface 
protein 1 during the Plasmodium falciparum invasion of erythrocytes. 
Proc Natl Acad Sci U S A ,  2003. 100(9): p. 5164-9.
70. O'Donnell, R.A., et al., Functional conservation of the malaria vaccine 
antigen MSP-119across distantly related Plasmodium species. Nat 
Med, 2000. 6(1): p. 91-5.
71. Dutta, S., et al., Merozoite surface protein 1 of plasmodium vivax 
induces a protective response against Plasmodium cynomolgi 
challenge in rhesus monkeys. Infect Immun, 2005. 73(9): p. 5936-44.
72. Gerold, P., et al., Structural analysis of the glycosyl- 
phosphatidylinositol membrane anchor of the merozoite surface 
proteins-1 and -2 of Plasmodium falciparum. Mol Biochem Parasitol, 
1996. 75(2): p. 131-43.
73. Holder, A. A., et a I., Processing of the precursor to the major merozoite 
surface antigens of Plasmodium falciparum. Parasitology, 1987. 94 ( 
Pt 2): p. 199-208.
74. Blackman, M.J., et al., A single fragment of a malaria merozoite 
surface protein remains on the parasite during red cell invasion and is 
the target of invasion-inhibiting antibodies. J Exp Med, 1990.172(1): 
p. 379-82.
75. Blackman, M.J. and A.A. Holder, Secondary processing of the 
Plasmodium falciparum merozoite surface protein-1 (MSP1) by a 
calcium-dependent membrane-bound serine protease: shedding of 
MSP133 as a noncovalently associated complex with other fragments 
of the MSP1. Mol Biochem Parasitol, 1992. 50(2): p. 307-15.
76. Blackman, M.J., et al., Proteolytic processing of the Plasmodium 
falciparum merozoite surface protein-1 produces a membrane-bound 
fragment containing two epidermal growth factor-like domains. Mol 
Biochem Parasitol, 1991. 49(1): p. 29-33.
77. Morgan, W.D., et al., Solution structure of an EGF module pair from 
the Plasmodium falciparum merozoite surface protein 1. J Mol Biol, 
1999. 289(1): p. 113-22.
78. Chitarra, V., et al., The crystal structure of C-terminal merozoite 
surface protein 1 at 1.8 A resolution, a highly protective malaria 
vaccine candidate. Mol Cell, 1999. 3(4): p. 457-64.
79. Hooper, N.M., E.H. Karran, and A.J. Turner, Membrane protein 
secretases. Biochem J, 1997. 321 ( Pt 2): p. 265-79.
80. Sisodia, S.S., Beta-amyloid precursor protein cleavage by a 
membrane-bound protease. Proc Natl Acad Sci U S A ,  1992. 89(13): 
p. 6075-9.
81. Franzke, C.W., et al., Shedding of collagen XVII/BP180: structural 
motifs influence cleavage from cell surface. J Biol Chem, 2004. 
279(23): p. 24521-9.
191
82. Schwager, S.L., et al., Cleavage of disulfide-bridged stalk domains 
during shedding of angiotensin-converting enzyme occurs at multiple 
juxtamembrane sites. Biochemistry, 2001. 40(51): p. 15624-30.
83. Brakebusch, C., et al., Structural requirements for inducible shedding 
of the p55 tumor necrosis factor receptor. J Biol Chem, 1994. 269(51): 
p. 32488-96.
84. Alfalah, M., et al., A point mutation in the juxtamembrane stalk of 
human angiotensin l-converting enzyme invokes the action of a 
distinct secretase. J Biol Chem, 2001. 276(24): p. 21105-9.
85. Barrett, A.J. and N.D. Rawlings, Families and clans of serine 
peptidases. Arch Biochem Biophys, 1995. 318(2): p. 247-50.
86. Wu, Y., et al., Data-mining approaches reveal hidden families of 
proteases in the genome of malaria parasite. Genome Res, 2003. 
13(4): p. 601-16.
87. Clausen, T., C. Southan, and M. Ehrmann, The HtrA family of 
proteases: implications for protein composition and cell fate. Mol Cell,
2002. 10(3): p. 443-55.
88. Dowse, T.J. and D. Soldati, Rhomboid-like proteins in Apicomplexa: 
phytogeny and nomenclature. Trends Parasitol, 2005. 21(6): p. 254-8.
89. Freeman, M., Proteolysis within the membrane: rhomboids revealed. 
Nat Rev Mol Cell Biol, 2004. 5(3): p. 188-97.
90. Urban, S., J.R. Lee, and M. Freeman, Drosophila rhomboid-1 defines 
a family of putative intramembrane serine proteases. Cell, 2001. 
107(2): p. 173-82.
91. Urban, S. and M. Freeman, Substrate specificity of rhomboid 
intramembrane proteases is governed by helix-breaking residues in 
the substrate transmembrane domain. Mol Cell, 2003. 11(6): p. 1425-
34.
92. Brossier, F., et al., A spatially localized rhomboid protease cleaves cell 
surface adhesins essential for invasion by Toxoplasma. Proc Natl 
Acad Sci U S A ,  2005. 102(11): p. 4146-51.
93. Dowse, T.J., et al., Apicomplexan rhomboids have a potential role in 
microneme protein cleavage during host cell invasion. Int J Parasitol, 
2005. 35(7): p. 747-56.
94. Zhou, X.W., et al., Proteomic analysis of cleavage events reveals a 
dynamic two-step mechanism for proteolysis of a key parasite 
adhesive complex. Mol Cell Proteomics, 2004. 3(6): p. 565-76.
95. Carruthers, V.B. and M.J. Blackman, A new release on life: emerging 
concepts in proteolysis and parasite invasion. Mol Microbiol, 2005. 
55(6): p. 1617-30.
96. Howell, S.A., et al., Distinct mechanisms govern proteolytic shedding 
of a key invasion protein in apicomplexan pathogens. Mol Microbiol,
2005. 57(5): p. 1342-56.
97. Siezen, R.J., et al., Homology modelling and protein engineering 
strategy of subtilases, the family of subtilisin-like serine proteinases. 
Protein Eng, 1991. 4(7): p. 719-37.
98. Siezen, R.J. and J.A. Leunissen, Subtilases: the superfamily of 
subtilisin-like serine proteases. Protein Sci, 1997. 6(3): p. 501-23.
192
99. Nebes, V.L. and E.W. Jones, Activation of the proteinase B precursor 
of the yeast Saccharomyces cerevisiae by autocatalysis and by an 
internal sequence. J Biol Chem, 1991. 266(34): p. 22851-7.
100. Espenshade, P.J., et al., Autocatalytic processing of site-1 protease 
removes propeptide and permits cleavage of sterol regulatory 
element-binding proteins. J Biol Chem, 1999. 274(32): p. 22795-804.
101. Sajid, M., C. Withers-Martinez, and M.J. Blackman, Maturation and 
specificity of Plasmodium falciparum subtilisin-like protease-1, a 
malaria merozoite subtilisin-like serine protease. J Biol Chem, 2000. 
275(1): p. 631-41.
102. Kessler, E. and M. Safrin, The propeptide of Pseudomonas 
aeruginosa elastase acts an elastase inhibitor. J Biol Chem, 1994. 
269(36): p. 22726-31.
103. Fugere, M., et al., Inhibitory potency and specificity of subtilase-like 
pro-protein convertase (SPC) prodomains. J Biol Chem, 2002.
277(10): p. 7648-56.
104. Ikemura, H., H. Takagi, and M. Inouye, Requirement of pro-sequence 
for the production of active subtilisin E in Escherichia coli. J Biol 
Chem, 1987. 262(16): p. 7859-64.
105. Li, Y., et al., Functional analysis of the propeptide of subtilisin E  as an 
intramolecular chaperone for protein folding. Refolding and inhibitory 
abilities of propeptide mutants. J Biol Chem, 1995. 270(42): p. 25127-
32.
106. Yabuta, Y., et al., Folding pathway mediated by an intramolecular 
chaperone: propeptide release modulates activation precision of pro- 
subtilisin. J Biol Chem, 2001. 276(48): p. 44427-34.
107. Marie-Claire, C., et al., Folding pathway mediated by an intramolecular 
chaperone: the structural and functional characterization of the 
aqualysin I propeptide. J Mol Biol, 2001. 305(1): p. 151-65.
108. Hidaka, Y., et al., Dual function of the propeptide of prouroguanylin in 
the folding of the mature peptide: disulfide-coupled folding and 
dimerization. J Biol Chem, 2000. 275(33): p. 25155-62.
109. Blackman, M.J., et al., A subtilisin-like protein in secretory organelles 
of Plasmodium falciparum merozoites. J Biol Chem, 1998. 273(36): p. 
23398-409.
110. O'Donnell, R. and M. Blackman, Unpublished results.
111. Yeoh, S., et al., Unpublished results.
112. Withers-Martinez, C., et al., Expression of recombinant Plasmodium 
falciparum subtilisin-like protease-1 in insect cells. Characterization, 
comparison with the parasite protease, and homology modeling. J Biol 
Chem, 2002. 277(33): p. 29698-709.
113. O'Donnell, R., F. Hackett, and M. Blackman, Unpublished results.
114. Hackett, F., et al., PfSUB-2: a second subtilisin-like protein in 
Plasmodium falciparum merozoites. Mol Biochem Parasitol, 1999. 
103(2): p. 183-95.
115. Uzureau, P., et al., Gene targeting demonstrates that the Plasmodium 
berghei subtilisin PbSUB2 is essential for red cell invasion and reveals 
spontaneous genetic recombination events. Cell Microbiol, 2004. 6(1): 
p. 65-78.
193
116.
117.
118.
119.
120 . 
121 . 
122 .
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
Barale, J.C., et al., Plasmodium falciparum subtilisin-like protease 2, a 
merozoite candidate for the merozoite surface protein 1-42 maturase. 
Proc Natl Acad Sci U S A ,  1999. 96(11): p. 6445-50.
O'Donnell, R.A., M.J. Blackman, and B.S. Crabb, Unpublished results. 
Han, Y.S., et al., Molecular interactions between Anopheles stephensi 
midgut cells and Plasmodium berghei: the time bomb theory of 
ookinete invasion of mosquitoes. Embo J, 2000. 19(22): p. 6030-40. 
Florens, L., et al., A proteomic view of the Plasmodium falciparum life 
cycle. Nature, 2002. 419(6906): p. 520-6.
Harris, P.K., et al., Molecular Identification of a Malaria Merozoite 
Surface Sheddase. PLOS Pathogen, 2005. In Press.
Wu, Y., et al., Transfection of Plasmodium falciparum within human 
red blood cells. Proc Natl Acad Sci U S A ,  1995. 92(4): p. 973-7. 
O'Donnell, R.A., et al., A genetic screen for improved plasmid 
segregation reveals a role for Rep20 in the interaction of Plasmodium 
falciparum chromosomes. Embo J, 2002. 21(5): p. 1231-9.
Wu, Y., L.A. Kirkman, and T.E. Wellems, Transformation of 
Plasmodium falciparum malaria parasites by homologous integration 
of plasmids that confer resistance to pyrimethamine. Proc Natl Acad 
Sci U S A ,  1996. 93(3): p. 1130-4.
Crabb, B.S. and A.F. Cowman, Characterization of promoters and 
stable transfection by homologous and nonhomologous recombination 
in Plasmodium falciparum. Proc Natl Acad Sci U S A ,  1996. 93(14): p. 
7289-94.
Fidock, D.A. and T.E. Wellems, Transformation with human 
dihydrofolate reductase renders malaria parasites insensitive to 
WR99210 but does not affect the intrinsic activity of proguanil. Proc 
Natl Acad Sci U S A ,  1997. 94(20): p. 10931-6.
O'Donnell, R., et al., An alteration in concatameric structure is 
associated with efficient segregation of plasmids in transfected 
Plasmodium falciparum parasites. Nucleic Acids Res, 2001. 29(3): p. 
716-24.
Duraisingh, M.T., T. Triglia, and A.F. Cowman, Negative selection of 
Plasmodium falciparum reveals targeted gene deletion by double 
crossover recombination. Int J Parasitol, 2002. 32(1): p. 81-9. 
Wickham, M.E., J.K. Thompson, and A.F. Cowman, Characterisation 
of the merozoite surface protein-2 promoter using stable and transient 
transfection in Plasmodium falciparum. Mol Biochem Parasitol, 2003. 
129(2): p. 147-56.
Triglia, T., et al., Allelic exchange at the endogenous genomic locus in 
Plasmodium falciparum proves the role of dihydropteroate synthase in 
sulfadoxine-resistant malaria. Embo J, 1998.17(14): p. 3807-15. 
Crabb, B.S., et al., Stable transgene expression in Plasmodium 
falciparum. Mol Biochem Parasitol, 1997. 90(1): p. 131-44.
Crabb, B.S., et al., Targeted gene disruption shows that knobs enable 
malaria-infected red cells to cytoadhere under physiological shear 
stress. Cell, 1997. 89(2): p. 287-96.
Healer, J., et al., Allelic polymorphisms in apical membrane antigen-1 
are responsible for evasion of antibody-mediated inhibition in 
Plasmodium falciparum. Mol Microbiol, 2004. 52(1): p. 159-68.
194
133. Meissner, M., et al., Modulation of myosin A expression by a newly 
established tetracycline repressor-based inducible system in 
Toxoplasma gondii. Nucleic Acids Res, 2001. 29(22): p. E115.
134. Meissner, M., et al., Tetracycline analogue-regulated transgene 
expression in Plasmodium falciparum blood stages using Toxoplasma 
gondii transactivators. Proc Natl Acad Sci U S A ,  2005.102(8): p. 
2980-5.
135. Cowman, A.F., et al., Functional analysis of the Plasmodium 
falciparum genome using transfection. Methods in Microbiology, ed. B. 
Wren. Vol. 33. 2002: Elsevier. 383-96.
136. Withers-Martinez, C., et al., PCR-based gene synthesis as an efficient 
approach for expression of the A+T-rich malaria genome. Protein Eng,
1999. 12(12): p. 1113-20.
137. Ho, S.N., et al., Site-directed mutagenesis by overlap extension using 
the polymerase chain reaction. Gene, 1989. 77(1): p. 51-9.
138. Horton, R.M., et al., Engineering hybrid genes without the use of 
restriction enzymes: gene splicing by overlap extension. Gene, 1989. 
77(1): p. 61-8.
139. Craven, R.A., et al., Vectors for the expression of tagged proteins in 
Schizosaccharomyces pombe. Gene, 1998. 221(1): p. 59-68.
140. Miller, S.K., et al., A subset of Plasmodium falciparum SERA genes 
are expressed and appear to play an important role in the erythrocytic 
cycle. J Biol Chem, 2002. 277(49): p. 47524-32.
141. Trager, W. and J.B. Jensen, Human malaria parasites in continuous
culture. Science, 1976. 193(4254): p. 673-5.
142. Lambros, C. and J.P. Vanderberg, Synchronization of Plasmodium 
falciparum erythrocytic stages in culture. J Parasitol, 1979. 65(3): p. 
418-20.
143. Tosta, C.E., et al., Plasmodium yoelii and Plasmodium berghei: 
isolation of infected erythrocytes from blood by colloidal silica gradient 
centrifugation. Exp Parasitol, 1980. 50(1): p. 7-15.
144. Bejon, P.A., et al., A role for microtubules in Plasmodium falciparum
merozoite invasion. Parasitology, 1997.114 ( Pt 1): p. 1-6.
145. Wasserman, M., C. Alarcon, and P.M. Mendoza, Effects ofCa++  
depletion on the asexual cell cycle of Plasmodium falciparum. Am J 
Trop Med Hyg, 1982. 31(4): p. 711-7.
146. Shaw, M.K., et al., Microtubules, but not actin filaments, drive 
daughter cell budding and cell division in Toxoplasma gondii. J Cell 
Sci, 2000. 113 ( Pt 7) p. 1241-54.
147. Laine, J., et al., Differential regulation of Akt kinase isoforms by the 
members of the TCL1 oncogene family. J Biol Chem, 2002. 277(5): p. 
3743-51.
148. Neill, J.D., et al., Epitope-tagged gonadotropin-releasing hormone 
receptors heterologously-expressed in mammalian (COS-1) and insect 
(Sf9) cells. Mol Cell Endocrinol, 1997.127(2): p. 143-54.
149. Ling, I.T. and A.A. Holder, Unpublished results.
150. Blackman, M.J., H. Whittle, and A.A. Holder, Processing of the 
Plasmodium falciparum major merozoite surface protein-1: 
identification of a 33-kilodalton secondary processing product which is
195
shed prior to erythrocyte invasion. Mol Biochem Parasitol, 1991. 49(1): 
p. 35-44.
151. Kocken, C.H., et al., Precise timing of expression of a Plasmodium 
falciparum-derived transgene in Plasmodium berg he i is a critical 
determinant of subsequent subcellular localization. J Biol Chem, 1998. 
273(24): p. 15119-24.
152. Holder, A.A., et al., Isolation of a Plasmodium falciparum rhoptry 
protein. Mol Biochem Parasitol, 1985.14(3): p. 293-303.
153. Blackman, M.J., et al., Structural and biochemical characterization of a 
fluorogenic rhodamine-labeled malarial protease substrate. 
Biochemistry, 2002. 41(40): p. 12244-52.
154. Deans, J.A., et al., Biosynthesis of a putative protective Plasmodium 
knowlesi merozoite antigen. Mol Biochem Parasitol, 1984.11: p. 189- 
204.
155. Klemba, M., et al., Trafficking of plasmepsin II to the food vacuole of 
the malaria parasite Plasmodium falciparum. J Cell Biol, 2004. 164(1): 
p. 47-56.
156. Mattsson, J.G. and D. Soldati, MPS1: a small, evolutionarily 
conserved zinc finger protein from the protozoan Toxoplasma gondii. 
FEMS Microbiol Lett, 1999. 180(2): p. 235-9.
157. Khan, F., et al., Cyclin-dependent kinase TPK2 is a critical cell cycle 
regulator in Toxoplasma gondii. Mol Microbiol, 2002. 45(2): p. 321-32.
158. Sehgal, A., et al., Translocation ofribosomal protein P0 onto the 
Toxoplasma gondii tachyzoite surface. Int J Parasitol, 2003. 33(14): p. 
1589-94.
159. Yung, S., T.R. Unnasch, and N. Lang-Unnasch, Analysis of apicoplast 
targeting and transit peptide processing in Toxoplasma gondii by 
deletional and insertional mutagenesis. Mol Biochem Parasitol, 2001.
118(1): p. 11-21.
160. Field, J., et al., Purification of a RAS-responsive adenylyl cyclase 
complex from Saccharomyces cerevisiae by use of an epitope addition 
method. Mol Cell Biol, 1988. 8(5): p. 2159-65.
161. Anderson, E.D., et al., Activation of the furin endoprotease is a 
multiple-step process: requirements for acidification and internal 
propeptide cleavage. Embo J, 1997. 16(7): p. 1508-18.
162. Golightly, L.M., et al., 3' UTR elements enhance expression ofPgs28, 
an ookinete protein of Plasmodium gallinaceum. Mol Biochem 
Parasitol, 2000.105(1): p. 61-70.
163. Ward, G.E., et al., Staurosporine inhibits invasion of erythrocytes by 
malarial merozoites. Exp Parasitol, 1994. 79(3): p. 480-7.
164. Gros, P., K.H. Kalk, and W.G. Hoi, Calcium binding to thermitase. 
Crystallographic studies of thermitase at 0, 5, and 100 mM calcium. J 
Biol Chem, 1991. 266(5): p. 2953-61.
165. Coue, M., et al., Inhibition of actin polymerization by latrunculin A. 
FEBS Lett, 1987. 213(2): p. 316-8.
166. MacLean-Fletcher, S. and T.D. Pollard, Mechanism of action of 
cytochalasin B on actin. Cell, 1980. 20(2): p. 329-41.
167. Valderrama, F., et al., Actin microfilaments facilitate the retrograde 
transport from the Golgi complex to the endoplasmic reticulum in 
mammalian cells. Traffic, 2001. 2(10): p. 717-26.
196
168. Poulsen, N.C., et al., Diatom gliding is the result of an actin-myosin 
motility system. Cell Motil Cytoskeleton, 1999. 44(1): p. 23-33.
169. Makioka, A., et al., Entamoeba invadens: enhancement of excystation 
and metacystic development by cytochalasin D. Exp Parasitol, 2001. 
98(3): p. 145-51.
170. Cramer, L.P. and T.J. Mitchison, Myosin is involved in postmitotic cell 
spreading. J Cell Biol, 1995.131(1): p. 179-89.
171. Jean, L., et al., Functional characterization of the propeptide of 
Plasmodium falciparum subtilisin-like protease-1. J Biol Chem, 2003. 
278(31): p. 28572-9.
172. Yeoh, S., S. Fleck, and M.J. Blackman, Unpublished data.
173. Geoghegan, K.F., P.J. Rosner, and L.R. Hoth, Dye-pairreporter 
systems for protein-peptide molecular interactions. Bioconjug Chem,
2000. 11(1): p. 71-7.
174. Packard, B.Z., et al., Profluorescent protease substrates: 
intramolecular dimers described by the exciton model. Proc Natl Acad 
Sci U S A ,  1996. 93(21): p. 11640-5.
175. Corrie, J.E. and J.S. Craik, Synthesis and Characterisation of Pure 
Isomers of lodoacetamidotetramethylrhodamine. J Chem Soc Perkin 
Trans, 1994. 1: p. 2967-2973.
176. Zimmerman, M., G. Patel, and N.J. Patel Gay, A new fluorogenic 
substrate for chymotrypsin. Anal Biochem, 1976. 70(1): p. 258-62.
177. Wang, G.T., et al., A continuous fluorescence assay of renin activity. 
Anal Biochem, 1993. 210(2): p. 351-9.
178. Peterson, D.S., et al., The circumsporozoite protein of Plasmodium 
falciparum is expressed and localized to the cell surface in the free- 
living ciliate Tetrahymena thermophila. Mol Biochem Parasitol, 2002. 
122(2): p. 119-26.
179. Sayers, J.R., et al., AGA/AGG codon usage in parasites: implications 
for gene expression in Escherichia coli. Parasitol Today, 1995.11(9): 
p. 345-6.
180. Kocken, C.H., et al., High-level expression of the malaria blood-stage 
vaccine candidate Plasmodium falciparum apical membrane antigen 1 
and induction of antibodies that inhibit erythrocyte invasion. Infect 
Immun, 2002. 70(8): p. 4471-6.
181. Rug, M., et al., Correct promoter control is needed for trafficking of the 
ring-infected erythrocyte surface antigen to the host cytosol in 
transfected malaria parasites. Infect Immun, 2004. 72(10): p. 6095-
105.
182. Porter, M.E., The DNA polymerase delta promoter from Plasmodium 
falciparum contains an unusually long 5' untranslated region and 
intrinsic DNA curvature. Mol Biochem Parasitol, 2001. 114(2): p. 249-
55.
183. Poison, H.E. and M.J. Blackman, A role for poly(dA)poly(dT) tracts in 
directing activity of the Plasmodium falciparum calmodulin gene 
promoter. Mol Biochem Parasitol, 2005.141(2): p. 179-89.
184. Dechering, K.J., et al., Isolation and functional characterization of two 
distinct sexual-stage-specific promoters of the human malaria parasite 
Plasmodium falciparum. Mol Cell Biol, 1999. 19(2): p. 967-78.
197
185. Horrocks, P. and B.J. Kilbey, Physical and functional mapping of the 
transcriptional start sites of Plasmodium falciparum proliferating cell 
nuclear antigen. Mol Biochem Parasitol, 1996. 82(2): p. 207-15.
186. Holloway, S.P., et al., Isolation of alpha-tubulin genes from the human 
malaria parasite, Plasmodium falciparum: sequence analysis of alpha- 
tubulin. Mol Microbiol, 1989. 3(11): p. 1501-10.
187. Adisa, A., et al., The signal sequence of exported protein-1 directs the 
green fluorescent protein to the parasitophorous vacuole of 
transfected malaria parasites. J Biol Chem, 2003. 278(8): p. 6532-42.
188. van Dijk, M.R., et al., Replication, expression and segregation of 
plasmid-borne DNA in genetically transformed malaria parasites. Mol 
Biochem Parasitol, 1997. 86(2): p. 155-62.
189. O'Donnell, R.A., Personal communication.
190. Tonkin, C.J., et al., Localization of organellarproteins in Plasmodium 
falciparum using a novel set of transfection vectors and a new 
immunofluorescence fixation method. Mol Biochem Parasitol, 2004. 
137(1): p. 13-21.
191. Kadekoppala, M., et al., Rapid recombination among transfected 
plasmids, chimeric episome formation and trans gene expression in 
Plasmodium falciparum. Mol Biochem Parasitol, 2001.112(2): p. 211-
8 .
192. Sato, S. and R.J. Wilson, The use ofDsRED in single- and dual-color 
fluorescence labeling of mitochondrial and plastid organelles in 
Plasmodium falciparum. Mol Biochem Parasitol, 2004.134(1): p. 175-
9.
193. Nagahama, M., et al., Biosynthetic processing and quaternary 
interactions of proprotein convertase SPC4 (PACE4). FEBS Lett,
1998. 434(1-2): p. 155-9.
194. Zhou, A. and R.E. Mains, Endoproteolytic processing of 
proopiomelanocortin and prohormone convertases 1 and 2 in 
neuroendocrine cells overexpressing prohormone convertases 1 or 2.
J Biol Chem, 1994. 269(26): p. 17440-7.
195. Withers-Martinez, C., L. Jean, and M.J. Blackman, Subtilisin-like 
proteases of the malaria parasite. Mol Microbiol, 2004. 53(1): p. 55-63.
196. Thompson, J.F., L.S. Hayes, and D.B. Lloyd, Modulation of firefly 
luciferase stability and impact on studies of gene regulation. Gene, 
1991. 103(2): p. 171-7.
197. Rabenau, K.E., et al., TgM2APparticipates in Toxoplasma gondii 
invasion of host cells and is tightly associated with the adhesive 
protein TgMIC2. Mol Microbiol, 2001. 41(3): p. 537-47.
198
